Novel Procedure for Modeling Ligand/Receptor Induced

Journal of Medicinal Chemistry 49, 534-553

DOI: 10.1021/jm050540c

Citation Report

#	Article	IF	CITATIONS
15	Do Structurally Similar Ligands Bind in a Similar Fashion?. Journal of Medicinal Chemistry, 2006, 49, 6716-6725.	2.9	171
16	A Novel Computational Analysis of Ligand-Induced Conformational Changes in the ATP Binding Sites of Cyclin Dependent Kinases. Journal of Medicinal Chemistry, 2006, 49, 5434-5441.	2.9	29
17	Extra Precision Glide:Â Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Proteinâ°'Ligand Complexes. Journal of Medicinal Chemistry, 2006, 49, 6177-6196.	2.9	5,196
18	Scaffold-Hopping: How Far Can You Jump?. QSAR and Combinatorial Science, 2006, 25, 1162-1171.	1.5	135
19	Homology models of dipeptidyl peptidases 8 and 9 with a focus on loop predictions near the active site. Proteins: Structure, Function and Bioinformatics, 2006, 66, 160-171.	1.5	63
20	Ensemble docking of multiple protein structures: Considering protein structural variations in molecular docking. Proteins: Structure, Function and Bioinformatics, 2006, 66, 399-421.	1.5	314
21	Advances in predicting CYP-mediated drug interactions in the drug discovery setting. Expert Opinion on Drug Discovery, 2006, 1, 677-691.	2.5	10
22	Modeling and active site refinement for G protein-coupled receptors: application to the $\hat{l}^2$ -2 adrenergic receptor. Journal of Computer-Aided Molecular Design, 2006, 20, 463-470.	1.3	13
23	Protein Structure Similarity Clustering: Dynamic Treatment of PDB Structures Facilitates Clustering. Angewandte Chemie - International Edition, 2006, 45, 7766-7770.	7.2	17
25	Receptor-Based Computational Screening of Compound Databases: The Main Docking-Scoring Engines. Current Protein and Peptide Science, 2006, 7, 369-393.	0.7	47
26	Incorporating protein flexibility into docking and structure-based drug design. Expert Opinion on Drug Discovery, 2006, 1, 335-349.	2.5	30
27	Ligand efficiency indices for effective drug discovery. Expert Opinion on Drug Discovery, 2007, 2, 469-488.	2.5	253
28	Structure-Based Drug Design: Docking and Scoring. Current Protein and Peptide Science, 2007, 8, 312-328.	0.7	279
29	Structural Information and Computational Methods Used in Design of Neuraminidase Inhibitors. Current Computer-Aided Drug Design, 2007, 3, 113-132.	0.8	3
30	Chapter 12 Principles of G-Protein Coupled Receptor Modeling for Drug Discovery. Annual Reports in Computational Chemistry, 2007, 3, 209-227.	0.9	1
31	Pose Prediction Accuracy in Docking Studies and Enrichment of Actives in the Active Site of GSK-3Î <sup>2</sup> .  Journal of Chemical Information and Modeling, 2007, 47, 1446-1459.	2.5	46
32	Small Molecule Inhibitors of the MDM2-p53 Interaction Discovered by Ensemble-Based Receptor Models. Journal of the American Chemical Society, 2007, 129, 12809-12814.	6.6	133
33	Docking Ligands into Flexible and Solvated Macromolecules. 1. Development and Validation of FITTED 1.0. Journal of Chemical Information and Modeling, 2007, 47, 435-449.	2.5	182

#	Article	IF	Citations
34	Lessons in Molecular Recognition. 2. Assessing and Improving Cross-Docking Accuracy. Journal of Chemical Information and Modeling, 2007, 47, 2293-2302.	2.5	112
35	Comparative Performance of Several Flexible Docking Programs and Scoring Functions:  Enrichment Studies for a Diverse Set of Pharmaceutically Relevant Targets. Journal of Chemical Information and Modeling, 2007, 47, 1599-1608.	2.5	148
36	Multiscale Optimization of a Truncated Newton Minimization Algorithm and Application to Proteins and Proteinâ <sup>^</sup> Ligand Complexes. Journal of Chemical Theory and Computation, 2007, 3, 640-648.	2.3	29
37	A Flexible Approach to Induced Fit Docking. Journal of Medicinal Chemistry, 2007, 50, 6507-6518.	2.9	154
38	Flexible Ligand Docking with Glide., 2007, Chapter 8, Unit 8.12.		131
39	Docking and Scoring., 2007,, 255-281.		1
40	How Reliable Are Current Docking Approaches for Structure-Based Drug Design? Lessons from Aldose Reductase. Angewandte Chemie - International Edition, 2007, 46, 3575-3578.	7.2	53
42	Homology Modeling of the Serotonin Transporter: Insights into the Primary Escitalopram-binding Site. ChemMedChem, 2007, 2, 815-826.	1.6	45
43	Virtual screening strategies in drug discovery. Current Opinion in Chemical Biology, 2007, 11, 494-502.	2.8	372
44	Computational approach to site-directed ligand discovery. Proteins: Structure, Function and Bioinformatics, 2007, 68, 551-560.	1.5	3
45	FLIPDock: Docking flexible ligands into flexible receptors. Proteins: Structure, Function and Bioinformatics, 2007, 68, 726-737.	1.5	97
46	Evaluation of docking programs for predicting binding of Golgi α-mannosidase II inhibitors: A comparison with crystallography. Proteins: Structure, Function and Bioinformatics, 2007, 69, 160-176.	1.5	55
47	Prediction and assignment of function for a divergent N-succinyl amino acid racemase. Nature Chemical Biology, 2007, 3, 486-491.	3.9	98
48	Signposts of Docking and Scoring in Drug Design. Chemical Biology and Drug Design, 2007, 70, 360-365.	1.5	6
49	Novel PPARâ€gamma Agonists Identified from a Natural Product Library: A Virtual Screening, Inducedâ€Fit Docking and Biological Assay Study. Chemical Biology and Drug Design, 2008, 71, 57-70.	1.5	117
50	Synthesis, biological evaluation and molecular modeling studies of N6-benzyladenosine analogues as potential anti-toxoplasma agents. Biochemical Pharmacology, 2007, 73, 1558-1572.	2.0	35
51	Multi-dimensional QSAR in drug discovery. Drug Discovery Today, 2007, 12, 1013-1017.	3.2	141
52	Calculation of Protein-Ligand Binding Affinities. Annual Review of Biophysics and Biomolecular Structure, 2007, 36, 21-42.	18.3	807

#	Article	IF	Citations
53	Identification of a putative binding site for 5-alkyl-benzothiadiazides in the AMPA receptor dimer interface. Journal of Molecular Graphics and Modelling, 2007, 26, 213-225.	1.3	11
54	Induced-fit docking of mometasone furoate and further evidence for glucocorticoid receptor 17α pocket flexibility. Journal of Molecular Graphics and Modelling, 2008, 27, 512-521.	1.3	46
55	An improved relaxed complex scheme for receptor flexibility in computer-aided drug design. Journal of Computer-Aided Molecular Design, 2008, 22, 693-705.	1.3	283
56	Improving database enrichment through ensemble docking. Journal of Computer-Aided Molecular Design, 2008, 22, 621-627.	1.3	63
57	A new method for ligand docking to flexible receptors by dual alanine scanning and refinement (SCARE). Journal of Computer-Aided Molecular Design, 2008, 22, 311-325.	1.3	74
58	Molecular dynamics simulations of ligand-induced backbone conformational changes in the binding site of the periplasmic lysine-, arginine-, ornithine-binding protein. Journal of Computer-Aided Molecular Design, 2008, 22, 799-814.	1.3	6
59	Inhibition and induction of human cytochrome P450 enzymes: current status. Archives of Toxicology, 2008, 82, 667-715.	1.9	481
60	Exploring structural variability in X-ray crystallographic models using protein local optimization by torsion-angle sampling. Acta Crystallographica Section D: Biological Crystallography, 2008, 64, 383-396.	2.5	15
61	Conformational selection <i>in silico</i> : Loop latching motions and ligand binding in enzymes. Proteins: Structure, Function and Bioinformatics, 2008, 71, 153-164.	1.5	22
62	Flexible protein–flexible ligand docking with disrupted velocity simulated annealing. Proteins: Structure, Function and Bioinformatics, 2008, 71, 440-454.	1.5	30
63	Expanding GPCR homology model binding sites via a balloon potential: A molecular dynamics refinement approach. Proteins: Structure, Function and Bioinformatics, 2008, 71, 1919-1929.	1.5	37
64	Modeling and Selection of Flexible Proteins for Structureâ€Based Drug Design: Backbone and Side Chain Movements in p38 MAPK. ChemMedChem, 2008, 3, 336-344.	1.6	21
65	αâ€Naphthylaminopropanâ€2â€ol Derivatives as BACE1 Inhibitors. ChemMedChem, 2008, 3, 1530-1534.	1.6	26
66	Prediction of the receptor conformation for iGluR2 agonist binding: QM/MM docking to an extensive conformational ensemble generated using normal mode analysis. Journal of Molecular Graphics and Modelling, 2008, 26, 1259-1268.	1.3	23
67	Flexible ligand–flexible protein docking in protein kinase systems. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2008, 1784, 244-251.	1.1	39
68	Synthesis, induced-fit docking investigations, and in vitro aldose reductase inhibitory activity of non-carboxylic acid containing 2,4-thiazolidinedione derivatives. Bioorganic and Medicinal Chemistry, 2008, 16, 5840-5852.	1.4	58
69	Novel insights into GPCRâ€"Peptide interactions: Mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensin receptor 1. Bioorganic and Medicinal Chemistry, 2008, 16, 9359-9368.	1.4	37
70	The design and synthesis of novel α-ketoamide-based p38 MAP kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1772-1777.	1.0	20

#	ARTICLE	IF	CITATIONS
71	Novel Method for Probing the Specificity Binding Profile of Ligands: Applications to HIV Protease. Chemical Biology and Drug Design, 2008, 71, 387-407.	1.5	26
72	Driving Forces for Ligand Migration in the Leucine Transporter. Chemical Biology and Drug Design, 2008, 72, 265-272.	1.5	24
73	Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go. British Journal of Pharmacology, 2008, 153, S7-26.	2.7	416
74	Understanding the molecular basis of HBV drug resistance by molecular modeling. Antiviral Research, 2008, 80, 339-353.	1.9	34
75	Towards improving compound selection in structure-based virtual screening. Drug Discovery Today, 2008, 13, 219-226.	3.2	97
76	Flexible ligand docking to multiple receptor conformations: a practical alternative. Current Opinion in Structural Biology, 2008, 18, 178-184.	2.6	456
77	Beyond Induced-Fit Receptor-Ligand Interactions: Structural Changes that Can Significantly Extend Bond Lifetimes. Structure, 2008, 16, 1047-1058.	1.6	23
78	Knowledge Based Prediction of Ligand Binding Modes and Rational Inhibitor Design for Kinase Drug Discovery. Journal of Medicinal Chemistry, 2008, 51, 5149-5171.	2.9	148
79	Structureâ^'Activity Relationships of 7-Deaza-6-benzylthioinosine Analogues as Ligands of <i>Toxoplasma gondii</i> Adenosine Kinase. Journal of Medicinal Chemistry, 2008, 51, 3934-3945.	2.9	33
80	Hot-Spots-Guided Receptor-Based Pharmacophores (HS-Pharm): A Knowledge-Based Approach to Identify Ligand-Anchoring Atoms in Protein Cavities and Prioritize Structure-Based Pharmacophores. Journal of Chemical Information and Modeling, 2008, 48, 1396-1410.	2.5	91
81	Fingerprint Directed Scaffold Hopping for Identification of CCR2 Antagonists. Journal of Chemical Information and Modeling, 2008, 48, 1891-1902.	2.5	22
82	Fully Automated Molecular Mechanics Based Induced Fit Proteinâ^Ligand Docking Method. Journal of Chemical Information and Modeling, 2008, 48, 1965-1973.	2.5	149
83	Binding of Serotonin to the Human Serotonin Transporter. Molecular Modeling and Experimental Validation. Journal of the American Chemical Society, 2008, 130, 3853-3865.	6.6	123
85	Ensemble-Based Virtual Screening Reveals Potential Novel Antiviral Compounds for Avian Influenza Neuraminidase. Journal of Medicinal Chemistry, 2008, 51, 3878-3894.	2.9	195
86	Ligand Specificity of Constitutive Androstane Receptor as Probed by Induced-Fit Docking and Mutagenesis. Journal of Medicinal Chemistry, 2008, 51, 7119-7131.	2.9	14
87	What has virtual screening ever done for drug discovery?. Expert Opinion on Drug Discovery, 2008, 3, 841-851.	2.5	126
88	Molecular Docking for Substrate Identification: The Short-Chain Dehydrogenases/Reductases. Journal of Molecular Biology, 2008, 375, 855-874.	2.0	60
89	Involvement of the Second Extracellular Loop and Transmembrane Residues of CCR5 in Inhibitor Binding and HIV-1 Fusion: Insights into the Mechanism of Allosteric Inhibition. Journal of Molecular Biology, 2008, 381, 956-974.	2.0	59

#	Article	IF	CITATIONS
90	Target Flexibility: An Emerging Consideration in Drug Discovery and Design. Journal of Medicinal Chemistry, 2008, 51, 6237-6255.	2.9	280
91	Proteinâ^'Ligand Docking against Non-Native Protein Conformers. Journal of Chemical Information and Modeling, 2008, 48, 2214-2225.	2.5	129
92	MM-GB/SA Rescoring of Docking Poses in Structure-Based Lead Optimization. Journal of Chemical Information and Modeling, 2008, 48, 958-970.	2.5	186
93	Flexible Side Chain Models Improve Enrichment Rates in In Silico Screening. Journal of Medicinal Chemistry, 2008, 51, 5919-5931.	2.9	49
94	Multiscale Monte Carlo Sampling of Protein Sidechains: Application to Binding Pocket Flexibility. Journal of Chemical Theory and Computation, 2008, 4, 835-846.	2.3	14
95	Prediction of Protein Loop Conformations Using the AGBNP Implicit Solvent Model and Torsion Angle Sampling. Journal of Chemical Theory and Computation, 2008, 4, 855-868.	2.3	60
96	Computationally Identified Novel Diphenyl- and Phenylpyridine Androgen Receptor Antagonist Structures. Journal of Chemical Information and Modeling, 2008, 48, 1882-1890.	2.5	17
97	Optimization of High Throughput Virtual Screening by Combining Shape-Matching and Docking Methods. Journal of Chemical Information and Modeling, 2008, 48, 489-497.	2.5	46
98	Ligand-Binding Pocket Shape Differences between Sphingosine 1-Phosphate (S1P) Receptors S1P <sub>1</sub> and S1P <sub>3</sub> Determine Efficiency of Chemical Probe Identification by Ultrahigh-Throughput Screening. ACS Chemical Biology, 2008, 3, 486-498.	1.6	52
99	Novel Binding Mode of the Acidic CYP2D6 Substrates Pactimibe and Its Metabolite R-125528. Drug Metabolism and Disposition, 2008, 36, 1938-1943.	1.7	14
100	A Number of Marketed Dihydropyridine Calcium Channel Blockers Have Mineralocorticoid Receptor Antagonist Activity. Hypertension, 2008, 51, 742-748.	1.3	112
101	Identification of Plasmodium falciparum Spermidine Synthase Active Site Binders through Structure-Based Virtual Screening. Journal of Medicinal Chemistry, 2008, 51, 2777-2786.	2.9	30
102	POSE SCALING: GEOMETRICAL ASSESSMENT OF LIGAND BINDING POSES. Journal of Theoretical and Computational Chemistry, 2008, 07, 833-852.	1.8	4
103	Discovery of drug-like inhibitors of an essential RNA-editing ligase in <i>Trypanosoma brucei</i> Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17278-17283.	3.3	128
104	Cofilin is a pH sensor for actin free barbed end formation: role of phosphoinositide binding. Journal of Cell Biology, 2008, 183, 865-879.	2.3	169
105	Designing a ligand for pharmaceutical purposes. Expert Opinion on Drug Discovery, 2008, 3, 579-590.	2.5	4
106	How to Efficiently Include Receptor Flexibility During Computational Docking. Current Computer-Aided Drug Design, 2008, 4, 143-153.	0.8	19
107	Small Molecule Docking. , 2008, , 469-500.		2

#	Article	IF	CITATIONS
108	Structure Activity Relationships of Quinoxalin-2-one Derivatives as Platelet-Derived Growth Factor-BETA. Receptor (PDGF.BETA. R) Inhibitors, Derived from Molecular Modeling. Chemical and Pharmaceutical Bulletin, 2008, 56, 682-687.	0.6	11
109	Prospective Ligand- and Target-Based 3D QSAR: State of the Art 2008. Current Topics in Medicinal Chemistry, 2009, 9, 791-810.	1.0	28
110	Rational Design of $\hat{l}_{\pm}$ -Conotoxin Analogues Targeting $\hat{l}_{\pm}$ 7 Nicotinic Acetylcholine Receptors. Journal of Biological Chemistry, 2009, 284, 9498-9512.	1.6	40
111	Fluoxetine (Prozac) Binding to Serotonin Transporter Is Modulated by Chloride and Conformational Changes. Journal of Neuroscience, 2009, 29, 9635-9643.	1.7	84
112	CDC25A and B Dual-Specificity Phosphatase Inhibitors: Potential Agents for Cancer Therapy. Current Medicinal Chemistry, 2009, 16, 1831-1849.	1.2	25
113	Dual Activities of Odorants on Olfactory and Nuclear Hormone Receptors. Journal of Biological Chemistry, 2009, 284, 30547-30555.	1.6	21
114	Position 5.46 of the Serotonin 5-HT2A Receptor Contributes to a Species-Dependent Variation for the 5-HT2C Agonist (R)-9-Ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one: Impact on Selectivity and Toxicological Evaluation. Molecular Pharmacology, 2009, 76, 1211-1219.	1.0	10
115	Managing protein flexibility in docking and its applications. Drug Discovery Today, 2009, 14, 394-400.	3.2	223
116	Evaluation of the binding orientations of testosterone in the active site of homology models for CYP2C11 and CYP2C13. Biochemical Pharmacology, 2009, 78, 406-413.	2.0	19
117	Cyclostreptin and Microtubules: Is a Lowâ€Affinity Binding Site Required?. ChemBioChem, 2010, 11, 101-109.	1.3	14
118	Synthesis, SAR, and Biological Evaluation of αâ€Sulfonylphosphonic Acids as Selective Matrix Metalloproteinase Inhibitors. ChemMedChem, 2009, 4, 352-362.	1.6	31
119	Inducedâ€Fit Docking Approach Provides Insight into the Binding Mode and Mechanism of Action of HIVâ€1 Integrase Inhibitors. ChemMedChem, 2009, 4, 1446-1456.	1.6	54
120	Developing technologies in biodefense research: computational drug design. Drug Development Research, 2009, 70, 279-287.	1.4	4
121	Conformational selection of protein kinase A revealed by flexibleâ€ligand flexibleâ€protein docking. Journal of Computational Chemistry, 2009, 30, 631-644.	1.5	22
122	Insights into docking and scoring neuronal $\hat{l}\pm4\hat{l}^22$ nicotinic receptor agonists using molecular dynamics simulations and QM/MM calculations. Journal of Computational Chemistry, 2009, 30, 2443-2454.	1.5	23
123	Exploring hierarchical refinement techniques for induced fit docking with protein and ligand flexibility. Journal of Computational Chemistry, 2010, 31, 1224-1235.	1.5	50
124	Combinatorial chemistry in the agrosciences. Bioorganic and Medicinal Chemistry, 2009, 17, 4035-4046.	1.4	45
125	Induced-fit docking studies of the active and inactive states of protein tyrosine kinases. Journal of Molecular Graphics and Modelling, 2009, 28, 336-346.	1.3	91

#	Article	IF	CITATIONS
126	Effects of protein conformation in docking: improved pose prediction through protein pocket adaptation. Journal of Computer-Aided Molecular Design, 2009, 23, 355-374.	1.3	88
127	Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation. Journal of Computer-Aided Molecular Design, 2009, 23, 541-554.	1.3	147
128	Virtual fragment screening: an exploration of various docking and scoring protocols for fragments using Glide. Journal of Computer-Aided Molecular Design, 2009, 23, 527-539.	1.3	73
129	A novel conformation optimization model and algorithm for structure-based drug design. Journal of Mathematical Chemistry, 2009, 46, 182-198.	0.7	3
130	Docking and scoring with alternative sideâ€chain conformations. Proteins: Structure, Function and Bioinformatics, 2009, 74, 712-726.	1.5	38
131	In pursuit of virtual lead optimization: Pruning ensembles of receptor structures for increased efficiency and accuracy during docking. Proteins: Structure, Function and Bioinformatics, 2009, 75, 62-74.	1.5	37
132	Automated site preparation in physicsâ€based rescoring of receptor ligand complexes. Proteins: Structure, Function and Bioinformatics, 2009, 77, 52-61.	1.5	22
133	Application of a Library of Artificial Receptors Formed by Selfâ€Organization of ⟨i⟩N⟨/i⟩â€Lipidated Peptides Immobilized on Cellulose for Preliminary Studies of Binding of ⟨i⟩N⟨/i⟩â€Phenylpiperazines. QSAR and Combinatorial Science, 2009, 28, 728-736.	1.5	3
134	Molecular docking: theoretical background, practical applications and perspectives. Mendeleev Communications, 2009, 19, 237-242.	0.6	22
135	Inside the Hsp90 inhibitors binding mode through induced fit docking. Journal of Molecular Graphics and Modelling, 2009, 27, 712-722.	1.3	29
136	Discovery of Potent and Reversible Monoacylglycerol Lipase Inhibitors. Chemistry and Biology, 2009, 16, 1045-1052.	6.2	94
137	Structure-based virtual screening for novel inhibitors of the sarco/endoplasmic reticulum calcium ATPase and their experimental evaluation. Bioorganic and Medicinal Chemistry, 2009, 17, 1353-1360.	1.4	15
138	5-Arylidene-2-phenylimino-4-thiazolidinones as PTP1B and LMW-PTP inhibitors. Bioorganic and Medicinal Chemistry, 2009, 17, 1928-1937.	1.4	79
139	Synthesis, activity and molecular modeling of a new series of chromones as low molecular weight protein tyrosine phosphatase inhibitors. Bioorganic and Medicinal Chemistry, 2009, 17, 2658-2672.	1.4	44
140	Discovery and structure–activity relationship analysis of Staphylococcus aureus sortase A inhibitors. Bioorganic and Medicinal Chemistry, 2009, 17, 7174-7185.	1.4	94
141	Identification of novel agonists of the integrin CD11b/CD18. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6902-6906.	1.0	20
142	9-(Arenethenyl)purines as Dual Src/Abl Kinase Inhibitors Targeting the Inactive Conformation: Design, Synthesis, and Biological Evaluation. Journal of Medicinal Chemistry, 2009, 52, 4743-4756.	2.9	41
143	Docking Flexible Peptide to Flexible Protein by Molecular Dynamics Using Two Implicit-Solvent Models: An Evaluation in Protein Kinase and Phosphatase Systems. Journal of Physical Chemistry B, 2009, 113, 14343-14354.	1.2	31

#	Article	IF	CITATIONS
144	SHOP: Receptor-Based Scaffold HOPping by GRID-Based Similarity Searches. Journal of Chemical Information and Modeling, 2009, 49, 658-669.	2.5	19
145	Identification of Xenoestrogens in Food Additives by an Integrated in Silico and in Vitro Approach. Chemical Research in Toxicology, 2009, 22, 52-63.	1.7	74
146	Consistent Improvement of Cross-Docking Results Using Binding Site Ensembles Generated with Elastic Network Normal Modes. Journal of Chemical Information and Modeling, 2009, 49, 716-725.	2.5	106
147	The NanA Neuraminidase of <i>Streptococcus pneumoniae</i> Is Involved in Biofilm Formation. Infection and Immunity, 2009, 77, 3722-3730.	1.0	132
148	RosettaLigand Docking with Full Ligand and Receptor Flexibility. Journal of Molecular Biology, 2009, 385, 381-392.	2.0	376
149	Crystallographic and Cellular Characterisation of Two Mechanisms Stabilising the Native Fold of $\hat{l}\pm 1$ -Antitrypsin: Implications for Disease and Drug Design. Journal of Molecular Biology, 2009, 387, 857-868.	2.0	34
150	Docking Ligands into Flexible and Solvated Macromolecules. 3. Impact of Input Ligand Conformation, Protein Flexibility, and Water Molecules on the Accuracy of Docking Programs. Journal of Chemical Information and Modeling, 2009, 49, 997-1009.	2.5	101
151	Evaluation of Homology Modeling of G-Protein-Coupled Receptors in Light of the A <sub>2A</sub> Adenosine Receptor Crystallographic Structure. Journal of Medicinal Chemistry, 2009, 52, 3284-3292.	2.9	90
152	Molecular Docking of Carbohydrate Ligands to Antibodies: Structural Validation against Crystal Structures. Journal of Chemical Information and Modeling, 2009, 49, 2749-2760.	2.5	62
153	Molecular Docking Screens Using Comparative Models of Proteins. Journal of Chemical Information and Modeling, 2009, 49, 2512-2527.	2.5	132
155	Molecular Modeling for Screening Environmental Chemicals for Estrogenicity: Use of the Toxicant-Target Approach. Chemical Research in Toxicology, 2009, 22, 1594-1602.	1.7	15
156	QM/MM Simulation on P450 BM3 Enzyme Catalysis Mechanism. Journal of Chemical Theory and Computation, 2009, 5, 1421-1431.	2.3	33
157	Site-Saturation Mutagenesis of Tryptophan 116 of Saccharomyces pastorianus Old Yellow Enzyme Uncovers Stereocomplementary Variants. Journal of the American Chemical Society, 2009, 131, 3271-3280.	6.6	140
158	Advances in fragment-based drug discovery platforms. Expert Opinion on Drug Discovery, 2009, 4, 1125-1144.	2.5	28
159	Binding of Small-Molecule Ligands to Proteins: "What You See―ls Not Always "What You Get― Structure, 2009, 17, 489-498.	1.6	500
160	Novel Method for Generating Structure-Based Pharmacophores Using Energetic Analysis. Journal of Chemical Information and Modeling, 2009, 49, 2356-2368.	2.5	279
161	Chapter 12 The Use of Receptor Homology Modeling to Facilitate the Design of Selective Chemokine Receptor Antagonists. Methods in Enzymology, 2009, 461, 249-279.	0.4	21
162	Protein-Protein Interaction Inhibition (2P2I): Fewer and Fewer Undruggable Targets. Combinatorial Chemistry and High Throughput Screening, 2009, 12, 968-983.	0.6	11

#	Article	IF	CITATIONS
163	Steroid Hormone Binding Receptors: Application of Homology Modeling, Induced Fit Docking, and Molecular Dynamics to Study Structure- Function Relationships. Current Topics in Medicinal Chemistry, 2009, 9, 844-853.	1.0	15
164	G Protein Coupled Receptors - In Silico Drug Discovery and Design. Current Topics in Medicinal Chemistry, 2010, 10, 638-656.	1.0	24
166	Emerging Methods for Ensemble-Based Virtual Screening. Current Topics in Medicinal Chemistry, 2010, 10, 3-13.	1.0	99
167	Beyond Rhodopsin: G Protein-Coupled Receptor Structure and Modeling Incorporating the Î <sup>2</sup> 2-adrenergic and Adenosine A2A Crystal Structures. Methods in Molecular Biology, 2010, 672, 359-386.	0.4	13
168	Discovery of Novel Cyanodihydropyridines as Potent Mineralocorticoid Receptor Antagonists. Journal of Medicinal Chemistry, 2010, 53, 5970-5978.	2.9	41
169	Discovery of (3 <i>&gt;S</i> ,3a <i>R</i> )-2-(3-Chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2 <i>H</i> -benzo[ <i>g</i> ]in Acid (PF-3882845), an Orally Efficacious Mineralocorticoid Receptor (MR) Antagonist for Hypertension and Nephropathy, Journal of Medicinal Chemistry, 2010, 53, 5979-6002.	dazole-7-0	cagboxylic
170	Nanoscale enzyme inhibitors: Fullerenes inhibit carbonic anhydrase by occluding the active site entrance. Bioorganic and Medicinal Chemistry, 2010, 18, 2822-2828.	1.4	66
171	Docking to flexible nicotinic acetylcholine receptors: A validation study using the acetylcholine binding protein. Journal of Molecular Graphics and Modelling, 2010, 29, 415-424.	1.3	10
172	Pharmacophore modeling and 3D-QSAR analysis of phosphoinositide 3-kinase p110 $\hat{l}_{\pm}$ inhibitors. Journal of Molecular Modeling, 2010, 16, 1449-1460.	0.8	32
173	Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism. Journal of Computer-Aided Molecular Design, 2010, 24, 237-256.	1.3	34
174	Prediction of protein–ligand binding affinity by free energy simulations: assumptions, pitfalls and expectations. Journal of Computer-Aided Molecular Design, 2010, 24, 639-658.	1.3	221
175	An efficient synthesis of a rationally designed 1,5 disubstituted imidazole AT1 Angiotensin II receptor antagonist: reorientation of imidazole pharmacophore groups in losartan reserves high receptor affinity and confirms docking studies. Journal of Computer-Aided Molecular Design, 2010, 24, 749-758.	1.3	16
176	Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening. Journal of Computer-Aided Molecular Design, 2010, 24, 971-991.	1.3	85
177	The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family. European Journal of Pharmacology, 2010, 635, 49-55.	1.7	32
178	In Pursuit of Fully Flexible Proteinâ€Ligand Docking: Modeling the Bilateral Mechanism of Binding. Molecular Informatics, 2010, 29, 164-173.	1.4	19
179	IKK-β inhibitors: An analysis of drug–receptor interaction by using Molecular Docking and Pharmacophore 3D-QSAR approaches. Journal of Molecular Graphics and Modelling, 2010, 29, 72-81.	1.3	39
180	Development of accurate binding affinity predictions of novel renin inhibitors through molecular docking studies. Journal of Molecular Graphics and Modelling, 2010, 29, 425-435.	1.3	56
181	DFG-in and DFG-out homology models of TrkB kinase receptor: Induced-fit and ensemble docking. Journal of Molecular Graphics and Modelling, 2010, 29, 309-320.	1.3	3

#	Article	IF	CITATIONS
182	3D-QSAR and docking studies on transforming growth factor (TGF)- $\hat{l}^2$ receptor 1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1918-1923.	1.0	11
183	Structure–activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase. Bioorganic and Medicinal Chemistry, 2010, 18, 3403-3412.	1.4	16
184	New chloro, fluorobenzylindole derivatives as integrase strand-transfer inhibitors (INSTIs) and their mode of action. Bioorganic and Medicinal Chemistry, 2010, 18, 5510-5518.	1.4	15
185	Optimization of α-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric site. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4819-4824.	1.0	20
186	Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5690-5694.	1.0	23
187	Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology, 2010, 7, 21.	0.9	36
188	Modeling G proteinâ€coupled receptors for structureâ€based drug discovery using lowâ€frequency normal modes for refinement of homology models: Application to H3 antagonists. Proteins: Structure, Function and Bioinformatics, 2010, 78, 457-473.	1.5	25
189	DynaDock: A new molecular dynamicsâ€based algorithm for protein–peptide docking including receptor flexibility. Proteins: Structure, Function and Bioinformatics, 2010, 78, 1084-1104.	1.5	147
190	AP24163 Inhibits the Gatekeeper Mutant of BCRâ€ABL and Suppresses ⟨i⟩In vitro⟨/i⟩ Resistance. Chemical Biology and Drug Design, 2010, 75, 223-227.	1.5	19
191	Docking of Protein Kinase B Inhibitors: Implications in the Structureâ€Based Optimization of a Novel Scaffold. Chemical Biology and Drug Design, 2010, 76, 269-276.	1.5	15
192	Chemical Space Sampling in Virtual Screening by Different Crystal Structures. Chemical Biology and Drug Design, 2010, 76, 472-479.	1.5	5
195	Pharmacophore methods., 2010, , 137-150.		4
196	Binding and Orientation of Tricyclic Antidepressants within the Central Substrate Site of the Human Serotonin Transporter. Journal of Biological Chemistry, 2010, 285, 8363-8374.	1.6	85
197	Conformational Transitions upon Ligand Binding: Holo-Structure Prediction from Apo Conformations. PLoS Computational Biology, 2010, 6, e1000634.	1.5	117
198	Computational Approaches for Fragment-Based and De Novo Design. Current Topics in Medicinal Chemistry, 2010, 10, 14-32.	1.0	100
199	Molecular Recognition and Drug-Lead Identification: What Can Molecular Simulations Tell Us?. Current Medicinal Chemistry, 2010, 17, 25-41.	1.2	39
200	Molecular Modeling Approaches in the Discovery of New Drugs for Anti-Cancer Therapy: The Investigation of p53-MDM2 Interaction and its Inhibition by Small Molecules. Current Medicinal Chemistry, 2010, 17, 3142-3154.	1.2	55
201	Binding Energy Distribution Analysis Method (BEDAM) for Estimation of Proteinâ°'Ligand Binding Affinities. Journal of Chemical Theory and Computation, 2010, 6, 2961-2977.	2.3	143

#	Article	IF	Citations
202	Stereochemical Requirements for the Mineralocorticoid Receptor Antagonist Activity of Dihydropyridines. Journal of Medicinal Chemistry, 2010, 53, 4300-4304.	2.9	38
203	Structural Basis for Platelet Antiaggregation by Angiotensin II Type 1 Receptor Antagonist Losartan (DuP-753) via Glycoprotein VI. Journal of Medicinal Chemistry, 2010, 53, 2087-2093.	2.9	27
204	Docking Validation Resources: Protein Family and Ligand Flexibility Experiments. Journal of Chemical Information and Modeling, 2010, 50, 1986-2000.	2.5	153
205	Advances and Challenges in Protein-Ligand Docking. International Journal of Molecular Sciences, 2010, 11, 3016-3034.	1.8	418
206	Improved Ligand-Protein Binding Affinity Predictions Using Multiple Binding Modes. Biophysical Journal, 2010, 98, 2682-2691.	0.2	104
207	A Nonazole CYP51 Inhibitor Cures Chagas' Disease in a Mouse Model of Acute Infection. Antimicrobial Agents and Chemotherapy, 2010, 54, 2480-2488.	1.4	56
208	Characterization of Glutathione Conjugates of Duloxetine by Mass Spectrometry and Evaluation of <i>in Silico</i> Approaches to Rationalize the Site of Conjugation for Thiophene Containing Drugs. Chemical Research in Toxicology, 2010, 23, 1393-1404.	1.7	30
209	Ligand-Steered Modeling and Docking: A Benchmarking Study in Class A G-Protein-Coupled Receptors. Journal of Chemical Information and Modeling, 2010, 50, 2119-2128.	2.5	60
210	Interaction Kinetic and Structural Dynamic Analysis of Ligand Binding to Acetylcholine-Binding Protein. Biochemistry, 2010, 49, 8143-8154.	1.2	28
211	Structureâ^'Function Relationships of Estrogenic Triphenylethylenes Related to Endoxifen and 4-Hydroxytamoxifen. Journal of Medicinal Chemistry, 2010, 53, 3273-3283.	2.9	40
212	Studying Enzymeâ^'Substrate Specificity in Silico: A Case Study of the <i>Escherichia coli</i> Glycolysis Pathway. Biochemistry, 2010, 49, 4003-4005.	1.2	18
213	Understanding the Molecular Activity of Alkaline Sphingomyelinase (NPP7) by Computer Modeling. Biochemistry, 2010, 49, 9096-9105.	1.2	9
215	Protein Dynamics and Drug Design: The Role of Molecular Simulations. , 2010, , 340-385.		0
216	Bovine Chymosin: A Computational Study of Recognition and Binding of Bovine κ-Casein. Biochemistry, 2010, 49, 2563-2573.	1.2	27
217	Ensemble Docking from Homology Models. Journal of Chemical Theory and Computation, 2010, 6, 2547-2557.	2.3	65
218	Class I Phospho-inositide-3-kinases (PI3Ks) Isoform-Specific Inhibition Study by the Combination of Docking and Molecular Dynamics Simulation. Journal of Chemical Information and Modeling, 2010, 50, 136-145.	2.5	30
219	Discovery of 3-[2-(Imidazo[1,2- <i>b</i> )]pyridazin-3-yl)ethynyl]-4-methyl- <i>N</i> -{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluo (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant. Journal of Medicinal Chemistry, 2010, 53, 4701-4719.	oromethyl 2.9	)phenyl}benz
220	Ensemble Docking into Multiple Crystallographically Derived Protein Structures: An Evaluation Based on the Statistical Analysis of Enrichments. Journal of Chemical Information and Modeling, 2010, 50, 511-524.	2.5	126

#	ARTICLE	IF	CITATIONS
221	Expression, purification and functional characterization of $\hat{I}^{\Omega}$ B kinase-2 (IKK-2) mutants. Protein Expression and Purification, 2010, 72, 254-261.	0.6	4
222	Rational design of CCR2 antagonists: a survey of computational studies. Expert Opinion on Drug Discovery, 2010, 5, 543-557.	2.5	12
223	Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review. Expert Opinion on Therapeutic Patents, 2010, 20, 405-425.	2.4	61
224	Targeting the BH3 Domain Mediated Proteinâ^'Protein Interaction of Bcl-xL through Virtual Screening. Journal of Chemical Information and Modeling, 2010, 50, 906-923.	2.5	30
225	Manipulating the Stereoselectivity of Limonene Epoxide Hydrolase by Directed Evolution Based on Iterative Saturation Mutagenesis. Journal of the American Chemical Society, 2010, 132, 15744-15751.	6.6	90
226	The Two Enantiomers of Citalopram Bind to the Human Serotonin Transporter in Reversed Orientations. Journal of the American Chemical Society, 2010, 132, 1311-1322.	6.6	79
227	Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 4891-4905.	2.9	199
228	<i>In silico</i> fragment-based drug design. Expert Opinion on Drug Discovery, 2010, 5, 1047-1065.	2.5	24
229	Rapid Flexible Docking Using a Stochastic Rotamer Library of Ligands. Journal of Chemical Information and Modeling, 2010, 50, 1623-1632.	2.5	80
230	Binding of a Small Molecule at a Protein–Protein Interface Regulates the Chaperone Activity of Hsp70–Hsp40. ACS Chemical Biology, 2010, 5, 611-622.	1.6	149
231	Tackling the challenges posed by target flexibility in drug design. Expert Opinion on Drug Discovery, 2010, 5, 347-359.	2.5	38
232	Transplantâ^'Insertâ^'Constrainâ^'Relaxâ^'Assemble (TICRA): Proteinâ^'Ligand Complex Structure Modeling and Application to Kinases. Journal of Chemical Information and Modeling, 2011, 51, 52-60.	2.5	1
233	Catalytic Mechanism and Three-Dimensional Structure of Adenine Deaminase <sup>,</sup> . Biochemistry, 2011, 50, 1917-1927.	1.2	42
234	Synthesis of butyl-isobutyl-phthalate and its interaction with Â-glucosidase in vitro. Journal of Biochemistry, 2011, 149, 27-33.	0.9	36
235	Direct Detection of Structurally Resolved Dynamics in a Multiconformation Receptorâ°'Ligand Complex. Journal of the American Chemical Society, 2011, 133, 6422-6428.	6.6	20
236	Significant Enhancement of Docking Sensitivity Using Implicit Ligand Sampling. Journal of Chemical Information and Modeling, 2011, 51, 693-706.	2.5	24
237	The Enzyme Function Initiative. Biochemistry, 2011, 50, 9950-9962.	1.2	169
238	An Extended î <sup>2</sup> 7î±7 Substrate-Binding Loop Is Essential for Efficient Catalysis by 3-Deoxy- <scp>d</scp> - <i>manno</i> -Octulosonate 8-Phosphate Synthase. Biochemistry, 2011, 50, 9318-9327.	1.2	5

#	Article	IF	CITATIONS
239	Rational Design of New Class of BH3-Mimetics As Inhibitors of the Bcl-x <sub>L</sub> Protein. Journal of Chemical Information and Modeling, 2011, 51, 1249-1258.	2.5	22
240	Approximating Protein Flexibility through Dynamic Pharmacophore Models: Application to Fatty Acid Amide Hydrolase (FAAH). Journal of Chemical Information and Modeling, 2011, 51, 3247-3253.	2.5	20
241	Enzymatic Deamination of the Epigenetic Base $\langle i \rangle N \langle  i \rangle$ -6-Methyladenine. Journal of the American Chemical Society, 2011, 133, 2080-2083.	6.6	24
242	Structure-Based Design of Potent Aromatase Inhibitors by High-Throughput Docking. Journal of Medicinal Chemistry, 2011, 54, 4006-4017.	2.9	83
243	Allosteric inhibition of the hepatitis C virus NS5B polymerase: <i>in silico</i> strategies for drug discovery and development. Future Medicinal Chemistry, 2011, 3, 1027-1055.	1.1	39
244	The Mouse Eugenol Odorant Receptor: Structural and Functional Plasticity of a Broadly Tuned Odorant Binding Pocket. Biochemistry, 2011, 50, 843-853.	1.2	81
245	<i>AADS</i> - An Automated Active Site Identification, Docking, and Scoring Protocol for Protein Targets Based on Physicochemical Descriptors. Journal of Chemical Information and Modeling, 2011, 51, 2515-2527.	2.5	113
246	Chaxamycins A–D, Bioactive Ansamycins from a Hyper-arid Desert <i>Streptomyces</i> sp Journal of Natural Products, 2011, 74, 1491-1499.	1.5	116
249	Toward a Robust Search Method for the Protein-Drug Docking Problem. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2011, 8, 1120-1133.	1.9	12
250	Discovery of a Cytokinin Deaminase. ACS Chemical Biology, 2011, 6, 1036-1040.	1.6	15
251	Chemoinformatics and Computational Chemical Biology. Methods in Molecular Biology, 2011, , .	0.4	10
252	A Molecular Mechanics Approach to Modeling Protein–Ligand Interactions: Relative Binding Affinities in Congeneric Series. Journal of Chemical Information and Modeling, 2011, 51, 2082-2089.	2.5	50
253	Protein Phosphorylation and Prevention of Cytochrome Oxidase Inhibition by ATP: Coupled Mechanisms of Energy Metabolism Regulation. Cell Metabolism, 2011, 13, 712-719.	7.2	173
254	Combined Receptor and Ligand-Based Approach to the Universal Pharmacophore Model Development for Studies of Drug Blockade to the hERG1 Pore Domain. Journal of Chemical Information and Modeling, 2011, 51, 463-474.	2.5	88
255	Rapid Shape-Based Ligand Alignment and Virtual Screening Method Based on Atom/Feature-Pair Similarities and Volume Overlap Scoring. Journal of Chemical Information and Modeling, 2011, 51, 2455-2466.	2.5	190
256	Chapter 18. Structure-based Virtual Screening for Ligands of G Protein-coupled Receptors. RSC Drug Discovery Series, 2011, , 359-374.	0.2	4
257	The binding sites for benztropines and dopamine in the dopamine transporter overlap. Neuropharmacology, 2011, 60, 182-190.	2.0	57
258	Application of NMR and Molecular Docking in Structure-Based Drug Discovery. Topics in Current Chemistry, 2011, 326, 1-34.	4.0	39

#	Article	IF	CITATIONS
259	Synthesis and α-Glucosidase Inhibitory Mechanisms of Bis(2,3-dibromo-4,5-dihydroxybenzyl) Ether, a Potential Marine Bromophenol α-Glucosidase Inhibitor. Marine Drugs, 2011, 9, 1554-1565.	2.2	66
260	Statistical Potential for Modeling and Ranking of Protein–Ligand Interactions. Journal of Chemical Information and Modeling, 2011, 51, 3078-3092.	2.5	69
262	Virtual screening strategies in drug design – methods and applications. Biotechnologia, 2011, 3, 249-264.	0.3	36
263	Basic Principles and Practices of Computer-Aided Drug Design. , 0, , 259-278.		0
264	Homology Models in Docking and High-Throughput Docking. Current Topics in Medicinal Chemistry, 2011, 11, 1528-1534.	1.0	46
265	Molecular Recognition in the Case of Flexible Targets. Current Pharmaceutical Design, 2011, 17, 1663-1671.	0.9	47
267	Lycium barbarum (Goji Berry) extracts and its taurine component inhibit PPAR- $\hat{I}^3$ -dependent gene transcription in human retinal pigment epithelial cells: Possible implications for diabetic retinopathy treatment. Biochemical Pharmacology, 2011, 82, 1209-1218.	2.0	53
268	A novel steroidal antiandrogen targeting wild type and mutant androgen receptors. Biochemical Pharmacology, 2011, 82, 1651-1662.	2.0	12
269	Comparison of Common Homology Modeling Algorithms: Application of User-Defined Alignments. Methods in Molecular Biology, 2011, 857, 399-414.	0.4	28
270	Protein-ligand docking. Frontiers in Bioscience - Landmark, 2011, 16, 2289.	3.0	17
271	Outstanding challenges in protein–ligand docking and structureâ€based virtual screening. Wiley Interdisciplinary Reviews: Computational Molecular Science, 2011, 1, 229-259.	6.2	94
272	Receptor flexibility in smallâ€molecule docking calculations. Wiley Interdisciplinary Reviews: Computational Molecular Science, 2011, 1, 298-314.	6.2	48
273	Computational screening of novel thiamine-catalyzed decarboxylation reactions of 2-keto acids. Bioprocess and Biosystems Engineering, 2011, 34, 375-388.	1.7	8
274	Predicting binding energies of CDK6 inhibitors in the hit-to-lead process. Theoretical Chemistry Accounts, 2011, 128, 807-823.	0.5	6
275	Aminopyridinecarboxamide-based inhaled IKK-2 inhibitors for asthma and COPD: Structure–activity relationship. Bioorganic and Medicinal Chemistry, 2011, 19, 1242-1255.	1.4	13
276	Kinetics, <i>in silico</i> docking, molecular dynamics, and MMâ€GBSA binding studies on prototype indirubins, KT5720, and staurosporine as phosphorylase kinase ATPâ€binding site inhibitors: The role of water molecules examined. Proteins: Structure, Function and Bioinformatics, 2011, 79, 703-719.	1.5	82
277	New insights into the GABA <sub>A</sub> receptor structure and orthosteric ligand binding: Receptor modeling guided by experimental data. Proteins: Structure, Function and Bioinformatics, 2011, 79, 1458-1477.	1.5	41
278	Challenges and advances in computational docking: 2009 in review. Journal of Molecular Recognition, 2011, 24, 149-164.	1.1	273

#	Article	IF	CITATIONS
279	Structural Bioinformatics Approach of Cyclinâ€Dependent Kinases 1 and 3 Complexed with Inhibitors. Molecular Informatics, 2011, 30, 219-231.	1.4	0
280	Evaluation of 1â€arylpiperazine derivative of hydroxybenzamides as 5â€HT <sub>1A</sub> and 5â€HT <sub>7</sub> serotonin receptor ligands: An experimental and molecular modeling approach. Journal of Heterocyclic Chemistry, 2011, 48, 192-198.	1.4	29
281	Thiazolidinedioneâ€Based PI3Kα Inhibitors: An Analysis of Biochemical and Virtual Screening Methods. ChemMedChem, 2011, 6, 514-522.	1.6	15
282	Discovering Smallâ€Molecule Estrogen Receptor α/Coactivator Binding Inhibitors: Highâ€Throughput Screening, Ligand Development, and Models for Enhanced Potency. ChemMedChem, 2011, 6, 654-666.	1.6	33
283	Role of protein flexibility in the discovery of new drugs. Drug Development Research, 2011, 72, 26-35.	1.4	14
284	Molecular modeling study of checkpoint kinase 1 inhibitors by multiple docking strategies and prime/MM–GBSA calculation. Journal of Computational Chemistry, 2011, 32, 2800-2809.	1.5	133
285	Kinetic and docking studies of phenol-based inhibitors of carbonic anhydrase isoforms I, II, IX and XII evidence a new binding mode within the enzyme active site. Bioorganic and Medicinal Chemistry, 2011, 19, 1381-1389.	1.4	97
286	Docking and SAR studies of d- and l-isofagomine isomers as human $\hat{l}^2$ -glucocerebrosidase inhibitors. Bioorganic and Medicinal Chemistry, 2011, 19, 3558-3568.	1.4	24
287	Block of the hERG channel by bupivacaine: Electrophysiological and modeling insights towards stereochemical optimization. European Journal of Medicinal Chemistry, 2011, 46, 3486-3498.	2.6	11
288	Docking-based virtual screening for ligands of G protein-coupled receptors: Not only crystal structures but also in silico models. Journal of Molecular Graphics and Modelling, 2011, 29, 614-623.	1.3	67
289	In silico analysis of the binding of agonists and blockers to the $\hat{I}^2$ 2-adrenergic receptor. Journal of Molecular Graphics and Modelling, 2011, 29, 809-817.	1.3	49
290	Accounting for Induced-Fit Effects in Docking: What is Possible and What is Not?. Current Topics in Medicinal Chemistry, 2011, 11, 179-191.	1.0	56
291	Molecular Docking: A Powerful Approach for Structure-Based Drug Discovery. Current Computer-Aided Drug Design, 2011, 7, 146-157.	0.8	1,955
292	Atomistic Models for Free Energy Evaluation of Drug Binding to Membrane Proteins. Current Medicinal Chemistry, 2011, 18, 2601-2611.	1.2	18
293	Pharmacophore Modelling: A Forty Year Old Approach and its Modern Synergies. Current Medicinal Chemistry, 2011, 18, 2543-2553.	1.2	69
294	MDpocket: open-source cavity detection and characterization on molecular dynamics trajectories. Bioinformatics, 2011, 27, 3276-3285.	1.8	265
295	Unbiased Simulations Reveal the Inward-Facing Conformation of the Human Serotonin Transporter and Na+ Ion Release. PLoS Computational Biology, 2011, 7, e1002246.	1.5	54
296	Predicting Binding to P-Glycoprotein by Flexible Receptor Docking. PLoS Computational Biology, 2011, 7, e1002083.	1.5	90

#	Article	IF	CITATIONS
297	Targeting Serpins in High-Throughput and Structure-Based Drug Design. Methods in Enzymology, 2011, 501, 139-175.	0.4	15
298	Ligand-Dependent Conformations and Dynamics of the Serotonin 5-HT2A Receptor Determine Its Activation and Membrane-Driven Oligomerization Properties. PLoS Computational Biology, 2012, 8, e1002473.	1.5	96
299	Introduction to Molecular Dynamics: Theory and Applications in Biomolecular Modeling. Biological and Medical Physics Series, 2012, , 3-30.	0.3	4
300	Approaches to Target Profiling of Natural Products. Current Medicinal Chemistry, 2012, 19, 3841-3855.	1.2	23
301	Towards the Chemoinformatic-Based Identification of DNA Methyltransferase Inhibitors: 2D- and 3D-Similarity Profile of Screening Libraries. Current Computer-Aided Drug Design, 2012, 8, 317-329.	0.8	10
302	Multi-scale optimization model and algorithm for computer-aided molecular docking. , 2012, , .		1
303	Steric Hindrance Mutagenesis in the Conserved Extracellular Vestibule Impedes Allosteric Binding of Antidepressants to the Serotonin Transporter. Journal of Biological Chemistry, 2012, 287, 39316-39326.	1.6	80
304	Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. Biochemical Journal, 2012, 448, 417-423.	1.7	228
305	Prediction of Ligand Binding Affinity Using a Multiple-Conformations-Multiple-Protonation Scheme: Application to Estrogen Receptor .ALPHA Chemical and Pharmaceutical Bulletin, 2012, 60, 183-194.	0.6	4
306	Mimicking the Intramolecular Hydrogen Bond: Synthesis, Biological Evaluation, and Molecular Modeling of Benzoxazines and Quinazolines as Potential Antimalarial Agents. Journal of Medicinal Chemistry, 2012, 55, 10387-10404.	2.9	58
307	α-1- <i>C</i> -Butyl-1,4-dideoxy-1,4-imino- <scp> </scp> -arabinitol as a Second-Generation Iminosugar-Based Oral α-Glucosidase Inhibitor for Improving Postprandial Hyperglycemia. Journal of Medicinal Chemistry, 2012, 55, 10347-10362.	2.9	72
308	GalaxyDock: Protein–Ligand Docking with Flexible Protein Side-chains. Journal of Chemical Information and Modeling, 2012, 52, 3225-3232.	2.5	59
309	Docking Simulation Study and Kinase Selectivity of f152A1 and Its Analogs. Journal of Chemical Information and Modeling, 2012, 52, 2059-2068.	2.5	10
310	Dioxygenase fromAspergillus fumigatusMC8: molecular modelling andin silicostudies on enzyme–substrate interactions. Molecular Simulation, 2012, 38, 144-151.	0.9	2
311	Identification of Non-Macrocyclic Small Molecule Inhibitors against the NS3/4A Serine Protease of Hepatitis C Virus through in Silico Screening. Journal of Chemical Information and Modeling, 2012, 52, 2245-2256.	2.5	12
312	Crystal Structure of a Lipid G Protein–Coupled Receptor. Science, 2012, 335, 851-855.	6.0	600
313	Insights from ligand and structure based methods in virtual screening of selective Ni-peptide deformylase inhibitors. Journal of Molecular Modeling, 2012, 18, 693-708.	0.8	5
314	A synthetic decursin analog with increased in vivo stability suppresses androgen receptor signaling in vitro and in vivo. Investigational New Drugs, 2012, 30, 1820-1829.	1.2	14

#	Article	IF	CITATIONS
315	Current Assessment of Docking into GPCR Crystal Structures and Homology Models: Successes, Challenges, and Guidelines. Journal of Chemical Information and Modeling, 2012, 52, 3263-3277.	2.5	86
316	A comparison of crystallographic and DFT optimized geometries on two taxane diterpenoids and docking studies with phospholipase A2. Medicinal Chemistry Research, 2012, 21, 2162-2168.	1.1	19
317	Insights from comprehensive multiple receptor docking to HDAC8. Journal of Molecular Modeling, 2012, 18, 3927-3939.	0.8	17
318	Consensus Induced Fit Docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors. Journal of Computer-Aided Molecular Design, 2012, 26, 1217-1228.	1.3	62
319	Modeling, Substrate Docking, and Mutational Analysis Identify Residues Essential for the Function and Specificity of a Eukaryotic Purine-Cytosine NCS1 Transporter. Journal of Biological Chemistry, 2012, 287, 36792-36803.	1.6	39
320	Inhibition of human carbonic anhydrase isozymes I, II and VI with a series of bisphenol, methoxy and bromophenol compounds. Journal of Enzyme Inhibition and Medicinal Chemistry, 2012, 27, 467-475.	2.5	39
321	Structure-Guided Topographic Mapping and Mutagenesis to Elucidate Binding Sites for the Human Ether-a-Go-Go-Related Gene 1 Potassium Channel (KCNH2) Activator NS1643. Journal of Pharmacology and Experimental Therapeutics, 2012, 342, 441-452.	1.3	29
322	Modeling Androgen Receptor Flexibility: A Binding Mode Hypothesis of CYP17 Inhibitors/Antiandrogens for Prostate Cancer Therapy. Journal of Chemical Information and Modeling, 2012, 52, 2670-2683.	2.5	9
324	Binding of the Amphetamine-like 1-Phenyl-piperazine to Monoamine Transporters. ACS Chemical Neuroscience, 2012, 3, 693-705.	1.7	28
325	Molecular Modeling to Provide Insight into the Substrate Binding and Catalytic Mechanism of Human Biliverdin-IXα Reductase. Journal of Physical Chemistry B, 2012, 116, 9580-9594.	1.2	26
326	Experimental-Like Affinity Constants and Enantioselectivity Estimates from Flexible Docking. Journal of Chemical Information and Modeling, 2012, 52, 2754-2759.	2.5	13
327	Identification of High-Affinity P2Y <sub>12</sub> Antagonists Based on a Phenylpyrazole Glutamic Acid Piperazine Backbone. Journal of Medicinal Chemistry, 2012, 55, 8615-8629.	2.9	28
328	Fluorescence polarization assay for inhibitors of the kinase domain of receptor interacting protein 1. Analytical Biochemistry, 2012, 427, 164-174.	1.1	8
329	Identification of novel drug-resistant EGFR mutant inhibitors by in silico screening using comprehensive assessments of protein structures. Bioorganic and Medicinal Chemistry, 2012, 20, 3756-3767.	1.4	11
330	Rational Design of Conformationally Constrained Cyclopentapeptide Antagonists for C-X-C Chemokine Receptor 4 (CXCR4). Journal of Medicinal Chemistry, 2012, 55, 10287-10291.	2.9	24
331	Discovery of a Novel and Potent Class of F. tularensis Enoyl-Reductase (Fabl) Inhibitors by Molecular Shape and Electrostatic Matching. Journal of Medicinal Chemistry, 2012, 55, 268-279.	2.9	57
332	Bisabolangelone, a gastric H+/K+-ATPase inhibitor: homology modeling and docking study. Medicinal Chemistry Research, 2012, 21, 2476-2479.	1.1	3
333	Modeling of Open, Closed, and Open-Inactivated States of the hERG1 Channel: Structural Mechanisms of the State-Dependent Drug Binding. Journal of Chemical Information and Modeling, 2012, 52, 2760-2774.	2.5	68

#	Article	IF	Citations
334	Unlocking the Binding and Reaction Mechanism of Hydroxyurea Substrates as Biological Nitric Oxide Donors. Journal of Chemical Information and Modeling, 2012, 52, 1288-1297.	2.5	15
335	R-Modafinil (Armodafinil): A Unique Dopamine Uptake Inhibitor and Potential Medication for Psychostimulant Abuse. Biological Psychiatry, 2012, 72, 405-413.	0.7	121
336	N-Phenyl-4-hydroxy-2-quinolone-3-carboxamides as selective inhibitors of mutant H1047R phosphoinositide-3-kinase (PI3K $\hat{l}$ ±). Bioorganic and Medicinal Chemistry, 2012, 20, 7175-7183.	1.4	25
337	The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: A concise synthesis, molecular docking studies and biological evaluation ofÂN-substituted 5-butylimidazole derivatives. European Journal of Medicinal Chemistry, 2012, 55, 358-374.	2.6	31
338	Impact of protein binding cavity volume (PCV) and ligand volume (LV) in rigid and flexible docking of protein–ligand complexes. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7593-7597.	1.0	2
339	Computational tools and resources for metabolism-related property predictions. 1. Overview of publicly available (free and commercial) databases and software. Future Medicinal Chemistry, 2012, 4, 1907-1932.	1.1	54
340	Computational Drug Discovery and Design. Methods in Molecular Biology, 2012, , .	0.4	30
341	Sanjeevini: a freely accessible web-server for target directed lead molecule discovery. BMC Bioinformatics, 2012, 13, S7.	1.2	169
342	9.7 Molecular Modeling and Simulations of Transporter Proteins – The Transmembrane Allosteric Machinery. , 2012, , 105-122.		2
343	Non-Traditional Antibacterial Screening Approaches for the Identification of Novel Inhibitors of the Glyoxylate Shunt in Gram-Negative Pathogens. PLoS ONE, 2012, 7, e51732.	1.1	45
344	Molecular Modeling and Simulation of Membrane Transport Proteins. , 0, , .		0
345	Structure prediction of Bestrophin for the induced - fit docking of anthocyanins. Bioinformation, 2012, 8, 742-748.	0.2	2
346	Farnesyl pyrophosphate is an endogenous antagonist to ADP-stimulated P2Y12 receptor-mediated platelet aggregation. Thrombosis and Haemostasis, 2012, 108, 119-132.	1.8	10
347	The linear interaction energy method for the prediction of protein stability changes upon mutation. Proteins: Structure, Function and Bioinformatics, 2012, 80, 111-125.	1.5	27
348	Protein flexibility in docking and surface mapping. Quarterly Reviews of Biophysics, 2012, 45, 301-343.	2.4	108
349	On achieving high accuracy and reliability in the calculation of relative protein–ligand binding affinities. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 1937-1942.	3.3	204
350	The fundamental role of flexibility on the strength of molecular binding. Soft Matter, 2012, 8, 6385.	1.2	56
351	New Structure–Activity Relationships of A- and D-Ring Modified Steroidal Aromatase Inhibitors: Design, Synthesis, and Biochemical Evaluation. Journal of Medicinal Chemistry, 2012, 55, 3992-4002.	2.9	60

#	Article	IF	CITATIONS
352	On the Use of Molecular Dynamics Receptor Conformations for Virtual Screening. Methods in Molecular Biology, 2012, 819, 93-103.	0.4	20
353	Rational Approaches to Improving Selectivity in Drug Design. Journal of Medicinal Chemistry, 2012, 55, 1424-1444.	2.9	248
354	Potential and Limitations of Ensemble Docking. Journal of Chemical Information and Modeling, 2012, 52, 1262-1274.	2.5	149
355	Optimization of 4-Aminoquinoline/Clotrimazole-Based Hybrid Antimalarials: Further Structure–Activity Relationships, in Vivo Studies, and Preliminary Toxicity Profiling. Journal of Medicinal Chemistry, 2012, 55, 6948-6967.	2.9	43
356	Chapter 9. Accounting for Target Flexibility During Ligand–Receptor Docking. RSC Drug Discovery Series, 2012, , 223-243.	0.2	1
357	<i>In Silico</i> Lead Generation Approaches in Multi-Target Drug Discovery. RSC Drug Discovery Series, 2012, , 130-140.	0.2	2
358	The statistical significance of selected sense–antisense peptide interactions. Journal of Computational Chemistry, 2012, 33, 1440-1447.	1.5	5
359	Molecular Determinants of Selectivity and Efficacy at the Dopamine D3 Receptor. Journal of Medicinal Chemistry, 2012, 55, 6689-6699.	2.9	153
360	Structure-Guided Design of A <sub>3</sub> Adenosine Receptor-Selective Nucleosides: Combination of 2-Arylethynyl and Bicyclo[3.1.0]hexane Substitutions. Journal of Medicinal Chemistry, 2012, 55, 4847-4860.	2.9	76
361	Conformational Transitions and Convergence of Absolute Binding Free Energy Calculations. Journal of Chemical Theory and Computation, 2012, 8, 47-60.	2.3	60
362	Novel Inhibitor Discovery through Virtual Screening against Multiple Protein Conformations Generated via Ligand-Directed Modeling: A Maternal Embryonic Leucine Zipper Kinase Example. Journal of Chemical Information and Modeling, 2012, 52, 1345-1355.	2.5	22
363	Receptor-guided 3D-QSAR approach for the discovery of c-kit tyrosine kinase inhibitors. Journal of Molecular Modeling, 2012, 18, 2885-2895.	0.8	23
364	Pose prediction and virtual screening performance of GOLD scoring functions in a standardized test. Journal of Computer-Aided Molecular Design, 2012, 26, 737-748.	1.3	138
365	Life Beyond Kinases: Structure-Based Discovery of Sorafenib as Nanomolar Antagonist of 5-HT Receptors. Journal of Medicinal Chemistry, 2012, 55, 5749-5759.	2.9	68
366	Induced fit binding of aldose reductase inhibitors to AKR1B10. Medicinal Chemistry Research, 2012, 21, 1245-1252.	1.1	3
367	Homology modeling, molecular dynamics, and molecular docking studies of Trichomonas vaginalis carbamate kinase. Medicinal Chemistry Research, 2012, 21, 2105-2116.	1.1	9
368	Docking performance of the glide program as evaluated on the Astex and DUD datasets: a complete set of glide SP results and selected results for a new scoring function integrating WaterMap and glide. Journal of Computer-Aided Molecular Design, 2012, 26, 787-799.	1.3	119
369	Lifting the lid on GPCRs: the role of extracellular loops. British Journal of Pharmacology, 2012, 165, 1688-1703.	2.7	242

#	Article	IF	CITATIONS
370	Molecular mechanism of serotonin transporter inhibition elucidated by a new flexible docking protocol. European Journal of Medicinal Chemistry, 2012, 47, 24-37.	2.6	26
371	Dibasic biphenyl H3 receptor antagonists: Steric tolerance for a lipophilic side chain. European Journal of Medicinal Chemistry, 2012, 48, 214-230.	2.6	11
372	Structure–activity relationships for the interaction of 5,10-dihydroindeno[1,2-b]indole derivatives with human and bovine carbonic anhydrase isoforms I, II, III, IV and VI. European Journal of Medicinal Chemistry, 2012, 49, 68-73.	2.6	54
373	Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B. European Journal of Medicinal Chemistry, 2012, 48, 284-295.	2.6	33
374	4-Aminoethylpiperazinyl aryl ketones with 5-HT1A/5-HT7 selectivity. Bioorganic and Medicinal Chemistry, 2012, 20, 1139-1148.	1.4	10
375	In vitro and in silico studies of polycondensed diazine systems as anti-parasitic agents. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1000-1004.	1.0	12
376	Generation of Receptor Structural Ensembles for Virtual Screening Using Binding Site Shape Analysis and Clustering. Chemical Biology and Drug Design, 2012, 80, 182-193.	1.5	71
377	Identification of Novel Poloâ€like Kinase 1 Inhibitors by a Hybrid Virtual Screening. Chemical Biology and Drug Design, 2012, 80, 328-339.	1.5	0
378	Novel Cruzain Inhibitors for the Treatment of Chagas' Disease. Chemical Biology and Drug Design, 2012, 80, 398-405.	1.5	33
379	<i>In Silico</i> screening for agonists and blockers of the $\hat{l}^2$ <sub>2</sub> adrenergic receptor: Implications of inactive and activated state structures. Journal of Computational Chemistry, 2012, 33, 561-572.	1.5	27
380	Galbanic acid decreases androgen receptor abundance and signaling and induces G $<$ sub $>$ 1 $<$ /sub $>$ arrest in prostate cancer cells. International Journal of Cancer, 2012, 130, 200-212.	2.3	30
381	A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton. Investigational New Drugs, 2012, 30, 490-507.	1.2	11
382	Pyrazolo[3,4-d]pyrimidines as inhibitor of anti-coagulation and inflammation activities of phospholipase A 2: insight from molecular docking studies. Journal of Biological Physics, 2013, 39, 419-438.	0.7	33
383	Ligand-Optimized Homology Models of D <sub>1</sub> and D <sub>2</sub> Dopamine Receptors: Application for Virtual Screening. Journal of Chemical Information and Modeling, 2013, 53, 638-648.	2.5	59
384	Improved Docking of Polypeptides with Glide. Journal of Chemical Information and Modeling, 2013, 53, 1689-1699.	2.5	1,407
385	Molecular design and synthesis of HCV inhibitors based on thiazolone scaffold. European Journal of Medicinal Chemistry, 2013, 68, 19-32.	2.6	30
386	Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan. Hypertension Research, 2013, 36, 134-139.	1.5	47
387	Induced-fit docking and binding free energy calculation on furostanol saponins from Tupistra chinensis as epidermal growth factor receptor inhibitors. Medicinal Chemistry Research, 2013, 22, 4970-4979.	1.1	16

#	Article	IF	Citations
389	Synthesis of 1,4-bis(indolin-1-ylmethyl)benzene derivatives and their structure–activity relationships for the interaction of human carbonic anhydrase isoforms I and II. Bioorganic and Medicinal Chemistry, 2013, 21, 1477-1482.	1.4	12
390	Structure-Based Virtual Screening of MT <sub>2</sub> Melatonin Receptor: Influence of Template Choice and Structural Refinement. Journal of Chemical Information and Modeling, 2013, 53, 821-835.	2.5	32
391	Could MM-GBSA be accurate enough for calculation of absolute protein/ligand binding free energies?. Journal of Molecular Graphics and Modelling, 2013, 46, 41-51.	1.3	53
392	Computational methods for drug design and discovery: focus on China. Trends in Pharmacological Sciences, 2013, 34, 549-559.	4.0	70
393	Deamination of 6-Aminodeoxyfutalosine in Menaquinone Biosynthesis by Distantly Related Enzymes. Biochemistry, 2013, 52, 6525-6536.	1.2	12
394	Structure-Guided Discovery of New Deaminase Enzymes. Journal of the American Chemical Society, 2013, 135, 13927-13933.	6.6	16
395	The Impact of Molecular Dynamics Sampling on the Performance of Virtual Screening against GPCRs. Journal of Chemical Information and Modeling, 2013, 53, 2990-2999.	2.5	52
396	Assessing Molecular Docking Tools for Relative Biological Activity Prediction: A Case Study of Triazole HIV-1 NNRTIs. Journal of Chemical Information and Modeling, 2013, 53, 3326-3342.	2.5	29
397	Nonlinear Scoring Functions for Similarity-Based Ligand Docking and Binding Affinity Prediction. Journal of Chemical Information and Modeling, 2013, 53, 3097-3112.	2.5	45
398	Fragment-based Shape Signatures: a new tool for virtual screening and drug discovery. Journal of Computer-Aided Molecular Design, 2013, 27, 1009-1036.	1.3	16
399	Murine mPGES-1 3D Structure Elucidation and Inhibitors Binding Mode Predictions by Homology Modeling and Site-Directed Mutagenesis. Journal of Chemical Information and Modeling, 2013, 53, 1804-1817.	2.5	10
400	Assignment of Pterin Deaminase Activity to an Enzyme of Unknown Function Guided by Homology Modeling and Docking. Journal of the American Chemical Society, 2013, 135, 795-803.	6.6	32
401	Kinetic and in silico analysis of thiazolidin-based inhibitors of $\hat{l}_{\pm}$ -carbonic anhydrase isoenzymes. Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, 28, 370-374.	2.5	14
402	Comparative Modeling of the Human Monoamine Transporters: Similarities in Substrate Binding. ACS Chemical Neuroscience, 2013, 4, 295-309.	1.7	59
403	Molecular and structural insight into plasmodium falciparum RIO2 kinase. Journal of Molecular Modeling, 2013, 19, 485-496.	0.8	3
404	New in silico and conventional in vitro approaches to advance HIV drug discovery and design. Expert Opinion on Drug Discovery, 2013, 8, 83-92.	2.5	5
405	Modeling G protein-coupled receptors and their interactions with ligands. Current Opinion in Structural Biology, 2013, 23, 185-190.	2.6	34
406	Molecular interaction of PCB153 to human serum albumin: Insights from spectroscopic and molecular modeling studies. Journal of Hazardous Materials, 2013, 248-249, 313-321.	6.5	31

#	Article	IF	Citations
407	Inhibition of gastric tumor growth by a novel Hsp90 inhibitor. Biochemical Pharmacology, 2013, 85, 1246-1256.	2.0	24
408	The multi-target capabilities of the compounds in a TCM used to treat sepsis and their in silico pharmacology. Complementary Therapies in Medicine, 2013, 21, 35-41.	1.3	23
409	Novel Mps1 kinase inhibitors: From purine to pyrrolopyrimidine and quinazoline leads. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6829-6833.	1.0	12
410	Accounting for Receptor Flexibility and Enhanced Sampling Methods in Computerâ€Aided Drug Design. Chemical Biology and Drug Design, 2013, 81, 41-49.	1.5	100
411	Systematic and efficient side chain optimization for molecular docking using a cheapestâ€path procedure. Journal of Computational Chemistry, 2013, 34, 1258-1269.	1.5	8
412	Assessment of new anti-HER2 ligands using combined docking, QM/MM scoring and MD simulation. Journal of Molecular Graphics and Modelling, 2013, 40, 91-98.	1.3	18
413	Flexible Backbone Sampling Methods to Model and Design Protein Alternative Conformations. Methods in Enzymology, 2013, 523, 61-85.	0.4	44
414	Automated Ligand- and Structure-Based Protocol for <i>in Silico</i> Prediction of Human Serum Albumin Binding. Journal of Chemical Information and Modeling, 2013, 53, 907-922.	2.5	47
415	Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. Journal of Computer-Aided Molecular Design, 2013, 27, 221-234.	1.3	3,989
416	Accounting for Conformational Variability in Protein–Ligand Docking with NMR-Guided Rescoring. Journal of the American Chemical Society, 2013, 135, 5819-5827.	6.6	22
417	Novel Mannich Bases, 5â∈Arylimidazolidineâ∈2,4â∈dione Derivatives with Dual 5â∈HT <sub>1A</sub> Receptor and Serotonin Transporter Affinity. Archiv Der Pharmazie, 2013, 346, 98-109.	2.1	15
418	Sulfated Polysaccharide, Curdlan Sulfate, Efficiently Prevents Entry/Fusion and Restricts Antibody-Dependent Enhancement of Dengue Virus Infection In Vitro: A Possible Candidate for Clinical Application. PLoS Neglected Tropical Diseases, 2013, 7, e2188.	1.3	61
419	Type II Kinase Inhibitors Show an Unexpected Inhibition Mode against Parkinson's Disease-Linked LRRK2 Mutant G2019S. Biochemistry, 2013, 52, 1725-1736.	1.2	54
420	Discovery of <i><scp>S</scp>taphylococcus aureus</i> Sortase <scp>A</scp> Inhibitors Using Virtual Screening and the Relaxed Complex Scheme. Chemical Biology and Drug Design, 2013, 82, 418-428.	1.5	48
421	Rational design, efficient syntheses and biological evaluation of N , N $\hat{a}\in^2$ -symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers. European Journal of Medicinal Chemistry, 2013, 62, 352-370.	2.6	28
422	Development and Binding Mode Assessment of <i>N</i> -[4-[2-Propyn-1-yl[(6 <i>S</i> )-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3 <i>H</i> -cyclopenta[ <i>g</i> Acid (BGC 945), a Novel Thymidylate Synthase Inhibitor That Targets Tumor Cells. Journal of Medicinal Chemistry, 2013, 56, 5446-5455.	·]quinazo	in-6-yl]amin
423	Boosting Virtual Screening Enrichments with Data Fusion: Coalescing Hits from Two-Dimensional Fingerprints, Shape, and Docking. Journal of Chemical Information and Modeling, 2013, 53, 1531-1542.	2.5	67
424	Analogs design, synthesis and biological evaluation of peptidomimetics with potential anti-HCV activity. Bioorganic and Medicinal Chemistry, 2013, 21, 2742-2755.	1.4	7

#	Article	IF	CITATIONS
425	Glutamine: fructose-6-phosphate amidotransferase (GFAT): homology modelling and designing of new inhibitors using pharmacophore and docking based hierarchical virtual screening protocol. SAR and QSAR in Environmental Research, 2013, 24, 733-752.	1.0	22
426	Molecular docking guided structure based design of symmetrical N,N′-disubstituted urea/thiourea as HIV-1 gp120–CD4 binding inhibitors. Bioorganic and Medicinal Chemistry, 2013, 21, 4591-4599.	1.4	20
427	Large Scale Affinity Calculations of Cyclodextrin Host–Guest Complexes: Understanding the Role of Reorganization in the Molecular Recognition Process. Journal of Chemical Theory and Computation, 2013, 9, 3136-3150.	2.3	77
428	How Does Catalase Release Nitric Oxide? A Computational Structure–Activity Relationship Study. Journal of Chemical Information and Modeling, 2013, 53, 2951-2961.	2.5	7
429	Distinct CCK-2 Receptor Conformations Associated with $\hat{l}^2$ -Arrestin-2 Recruitment or Phospholipase-C Activation Revealed by a Biased Antagonist. Journal of the American Chemical Society, 2013, 135, 2560-2573.	6.6	29
430	Mutagenesis and Computational Modeling of Human G-Protein-Coupled Receptor Y2 for Neuropeptide Y and Peptide YY. Biochemistry, 2013, 52, 7987-7998.	1.2	23
431	Skeletal hybridization and PfRIO-2 kinase modeling for synthesis of $\hat{l}_{\pm}$ -pyrone analogs as anti-malarial agent. European Journal of Medicinal Chemistry, 2013, 70, 607-612.	2.6	8
432	A Single Glycine in Extracellular Loop 1 Is the Critical Determinant for Pharmacological Specificity of Dopamine D2 and D3 Receptors. Molecular Pharmacology, 2013, 84, 854-864.	1.0	58
433	Computational methods for the design of potent aromatase inhibitors. Expert Opinion on Drug Discovery, 2013, 8, 395-409.	2.5	28
434	Computational Studies on the Resistance of Penicillinâ€Binding Protein 2B (PBP2B) of Wildâ€type and Mutant Strains of <i>Streptococcus pneumoniae</i> Against βâ€Lactam Antibiotics. Chemical Biology and Drug Design, 2013, 82, 275-289.	1.5	6
435	Discovery of the Novel mTOR Inhibitor and Its Antitumor Activities <i>In Vitro</i> and <i>In Vivo</i> Molecular Cancer Therapeutics, 2013, 12, 950-958.	1.9	19
436	Overcoming AC220 resistance of FLT3-ITD by SAR302503. Blood Cancer Journal, 2013, 3, e138-e138.	2.8	16
437	Chemical–biological characterization of a cruzain inhibitor reveals a second target and a mammalian off-target. Beilstein Journal of Organic Chemistry, 2013, 9, 15-25.	1.3	34
438	A Fluorescence-Based Thermal Shift Assay Identifies Inhibitors of Mitogen Activated Protein Kinase Kinase 4. PLoS ONE, 2013, 8, e81504.	1.1	38
439	A Unified Model of the GABAA Receptor Comprising Agonist and Benzodiazepine Binding Sites. PLoS ONE, 2013, 8, e52323.	1.1	105
440	Ligand Induced Conformational Changes of the Human Serotonin Transporter Revealed by Molecular Dynamics Simulations. PLoS ONE, 2013, 8, e63635.	1.1	49
441	Assessment and Challenges of Ligand Docking into Comparative Models of G-Protein Coupled Receptors. PLoS ONE, 2013, 8, e67302.	1.1	32
442	Advances in Binding Free Energies Calculations: QM/MM-Based Free Energy Perturbation Method for Drug Design. Current Pharmaceutical Design, 2013, 19, 4674-4686.	0.9	29

#	Article	IF	CITATIONS
443	Facile and Efficient Syntheses of a Series of N-Benzyl and N-Biphenylmethyl Substituted Imidazole Derivatives Based on (E)-Urocanic acid, as Angiotensin II AT1 Receptor Blockers. Molecules, 2013, 18, 7510-7532.	1.7	7
444	Virtual Screening Strategies in Drug Discovery: A Critical Review. Current Medicinal Chemistry, 2013, 20, 2839-2860.	1.2	511
445	Inhibition of Human Dyskerin as a New Approach to Target Ribosome Biogenesis. PLoS ONE, 2014, 9, e101971.	1.1	27
446	Transforming Growth Factor $\hat{I}^2$ Signaling Overcomes Dasatinib Resistance in Lung Cancer. PLoS ONE, 2014, 9, e114131.	1.1	8
447	Discovery of Novel Inhibitors for Nek6 Protein through Homology Model Assisted Structure Based Virtual Screening and Molecular Docking Approaches. Scientific World Journal, The, 2014, 2014, 1-9.	0.8	19
448	Inhibition and Biochemical Characterization of Methicillin-Resistant Staphylococcus aureus Shikimate Dehydrogenase: An in Silico and Kinetic Study. Molecules, 2014, 19, 4491-4509.	1.7	12
449	Combination of 2D/3D Ligand-Based Similarity Search in Rapid Virtual Screening from Multimillion Compound Repositories. Selection and Biological Evaluation of Potential PDE4 and PDE5 Inhibitors. Molecules, 2014, 19, 7008-7039.	1.7	22
450	Molecular docking study of active phytocompounds from the methanolic leaf extract of <i>vitex negundo</i> against cyclooxygenase-2. Bangladesh Journal of Pharmacology, 2014, 9, .	0.1	3
451	The Parkinson Disease-linked LRRK2 Protein Mutation I2020T Stabilizes an Active State Conformation Leading to Increased Kinase Activity. Journal of Biological Chemistry, 2014, 289, 13042-13053.	1.6	37
452	Docking Applied to the Prediction of the Affinity of Compounds to P-Glycoprotein. BioMed Research International, 2014, 2014, 1-10.	0.9	25
453	Rationalization of Activity Cliffs of a Sulfonamide Inhibitor of DNA Methyltransferases with Induced-Fit Docking. International Journal of Molecular Sciences, 2014, 15, 3253-3261.	1.8	25
454	Structure-Based Druggability Assessment of the Mammalian Structural Proteome with Inclusion of Light Protein Flexibility. PLoS Computational Biology, 2014, 10, e1003741.	1.5	29
455	A force fields-based multi-scale docking method in drug molecular design. , 2014, , .		0
456	Insight into the Interactions between Novel Coumarin Derivatives and Human A <sub>3</sub> Adenosine Receptors. ChemMedChem, 2014, 9, 2245-2253.	1.6	13
457	Na <sup>+</sup> ,K <sup>+</sup> -ATPase Isoform Selectivity for Digitalis-Like Compounds Is Determined by Two Amino Acids in the First Extracellular Loop. Chemical Research in Toxicology, 2014, 27, 2082-2092.	1.7	18
459	Binding of Mazindol and Analogs to the Human Serotonin and Dopamine Transporters. Molecular Pharmacology, 2014, 85, 208-217.	1.0	22
460	Identification of Novel Inhibitors of <i>Daboia russelli</i> Phospholipase A <sub>2</sub> Using the Combined Pharmacophore Modeling Approach. Chemical Biology and Drug Design, 2014, 84, 379-392.	1.5	7
461	Development and application of site mapping methods for the design of glycosaminoglycans. Glycobiology, 2014, 24, 840-851.	1.3	24

#	Article	IF	CITATIONS
462	Novel ATP-Competitive MEK Inhibitor E6201 Is Effective against Vemurafenib-Resistant Melanoma Harboring the MEK1-C121S Mutation in a Preclinical Model. Molecular Cancer Therapeutics, 2014, 13, 823-832.	1.9	27
463	Inhibition of dihydroceramide desaturase activity by the sphingosine kinase inhibitor SKI II. Journal of Lipid Research, 2014, 55, 1711-1720.	2.0	66
464	Crystal structure and in silico studies of dihydrodipicolinate synthase (DHDPS) from Aquifex aeolicus. Extremophiles, 2014, 18, 973-985.	0.9	5
465	Structural Biology of the S1P1 Receptor. Current Topics in Microbiology and Immunology, 2014, 378, 23-53.	0.7	6
466	Predicting the Functions and Specificity of Triterpenoid Synthases: A Mechanism-Based Multi-intermediate Docking Approach. PLoS Computational Biology, 2014, 10, e1003874.	1.5	23
467	A fluorescence-based assay suitable for quantitative analysis of deadenylase enzyme activity. Nucleic Acids Research, 2014, 42, e30-e30.	6.5	25
468	Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 1909-1915.	1.4	15
469	Characterization of pomiferin triacetate as a novel mTOR and translation inhibitor. Biochemical Pharmacology, 2014, 88, 313-321.	2.0	17
470	Functional characterization of rare variants in human dopamine receptor D4 gene by genotype–phenotype correlations. Neuroscience, 2014, 262, 176-189.	1.1	4
471	Modeling of Membrane Proteins. Springer Series in Bio-/neuroinformatics, 2014, , 357-431.	0.1	0
472	Molecular docking studies on N-hydroxyindole derivatives as potent inhibitors of human lactate dehydrogenase isoform 5 against cancer cell proliferation. Medicinal Chemistry Research, 2014, 23, 3200-3206.	1.1	1
473	MAP Kinase-Interacting Kinases—Emerging Targets against Cancer. Chemistry and Biology, 2014, 21, 441-452.	6.2	83
474	Docking and SAR studies of calystegines: Binding orientation and influence on pharmacological chaperone effects for Gaucher's disease. Bioorganic and Medicinal Chemistry, 2014, 22, 2435-2441.	1.4	13
475	Virtual fragment screening on GPCRs: A case study on dopamine D3 and histamine H4 receptors. European Journal of Medicinal Chemistry, 2014, 77, 38-46.	2.6	49
476	Prospective virtual screening for novel p53–MDM2 inhibitors using ultrafast shape recognition. Journal of Computer-Aided Molecular Design, 2014, 28, 89-97.	1.3	19
477	Structural elucidation of SrtA enzyme in Enterococcus faecalis: an emphasis on screening of potential inhibitors against the biofilm formation. Molecular BioSystems, 2014, 10, 1775-1789.	2.9	24
478	The Marine Cyanobacterial Metabolite Gallinamide A Is a Potent and Selective Inhibitor of Human Cathepsin L. Journal of Natural Products, 2014, 77, 92-99.	1.5	57
479	Computer-aided identification of novel 3,5-substituted rhodanine derivatives with activity against Staphylococcus aureus DNA gyrase. Bioorganic and Medicinal Chemistry, 2014, 22, 2176-2187.	1.4	15

#	Article	IF	CITATIONS
480	Hybrid molecules inhibiting myeloperoxidase activity and serotonin reuptake: a possible new approach of major depressive disorders with inflammatory syndrome. Journal of Pharmacy and Pharmacology, 2014, 66, 1122-1132.	1.2	17
481	Imidazo[1,2-a]pyrazine inhibitors of phosphoinositide 3-kinase alpha (PI3Kα): 3D-QSAR analysis utilizing the Hybrid Monte Carlo algorithm to refine receptor-ligand complexes for molecular alignment. SAR and QSAR in Environmental Research, 2014, 25, 221-247.	1.0	2
482	Designing of multi-targeted molecules using combination of molecular screening and in silico drug cardiotoxicity prediction approaches. Journal of Molecular Graphics and Modelling, 2014, 50, 16-34.	1.3	4
483	Towards the development of 5-HT7 ligands combining serotonin-like and arylpiperazine moieties. European Journal of Medicinal Chemistry, 2014, 80, 8-35.	2.6	8
484	Toward activated homology models of the human M1 muscarinic acetylcholine receptor. Journal of Molecular Graphics and Modelling, 2014, 49, 91-98.	1.3	13
485	The P110 subunit of PI3-K is a therapeutic target of acacetin in skin cancer. Carcinogenesis, 2014, 35, 123-130.	1.3	33
486	Identification of new 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines as highly potent EGFR-TK inhibitors with Src-family activity. European Journal of Pharmaceutical Sciences, 2014, 59, 69-82.	1.9	23
487	Aryl ethynyl anthraquinones: a useful platform for targeting telomeric G-quadruplex structures. Organic and Biomolecular Chemistry, 2014, 12, 3744-3754.	1.5	31
488	Modeling G protein-coupled receptors in complex with biased agonists. Trends in Pharmacological Sciences, 2014, 35, 277-283.	4.0	7
489	PeptiSite: A structural database of peptide binding sites in 4D. Biochemical and Biophysical Research Communications, 2014, 445, 717-723.	1.0	13
490	The Versatile Nature of the 6-Aminoquinolone Scaffold: Identification of Submicromolar Hepatitis C Virus NS5B Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 1952-1963.	2.9	43
491	The Two Na+ Sites in the Human Serotonin Transporter Play Distinct Roles in the Ion Coupling and Electrogenicity of Transport. Journal of Biological Chemistry, 2014, 289, 1825-1840.	1.6	37
492	BP-Dock: A Flexible Docking Scheme for Exploring Protein–Ligand Interactions Based on Unbound Structures. Journal of Chemical Information and Modeling, 2014, 54, 913-925.	2.5	35
493	Understanding the evolutionary relationship of hemagglutinin protein from influenza viruses using phylogenetic and molecular modeling studies. Journal of Biomolecular Structure and Dynamics, 2014, 32, 816-830.	2.0	6
494	Binding of pyrazole-based inhibitors to Mycobacterium tuberculosis pantothenate synthetase: docking and MM-GB(PB)SA analysis. Molecular BioSystems, 2014, 10, 223-239.	2.9	30
495	Receptor–ligand molecular docking. Biophysical Reviews, 2014, 6, 75-87.	1.5	324
496	Characterization of Two Distinct Modes of Drug Binding to Human Intestinal Fatty Acid Binding Protein. ACS Chemical Biology, 2014, 9, 2526-2534.	1.6	24
497	Curcumin Suppresses Proliferation of Colon Cancer Cells by Targeting CDK2. Cancer Prevention Research, 2014, 7, 466-474.	0.7	86

#	Article	IF	CITATIONS
498	Identification of novel thiadiazoloacrylamide analogues as inhibitors of dengue-2 virus NS2B/NS3 protease. Bioorganic and Medicinal Chemistry, 2014, 22, 6344-6352.	1.4	29
499	Extreme Synergistic Mutational Effects in the Directed Evolution of a Baeyer–Villiger Monooxygenase as Catalyst for Asymmetric Sulfoxidation. Journal of the American Chemical Society, 2014, 136, 17262-17272.	6.6	66
500	Computational and Biochemical Docking of the Irreversible Cocaine Analog RTI 82 Directly Demonstrates Ligand Positioning in the Dopamine Transporter Central Substrate-binding Site. Journal of Biological Chemistry, 2014, 289, 29712-29727.	1.6	24
501	Molecular Basis for Selective Serotonin Reuptake Inhibition by the Antidepressant Agent Fluoxetine (Prozac). Molecular Pharmacology, 2014, 85, 703-714.	1.0	54
502	Probing the determinants of phosphorylated sugar-substrate binding for human sialic acid synthase. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 2257-2264.	1.1	4
503	A new mechanism of allostery in a G protein–coupled receptor dimer. Nature Chemical Biology, 2014, 10, 745-752.	3.9	108
504	Leveraging structure for enzyme function prediction: methods, opportunities, and challenges. Trends in Biochemical Sciences, 2014, 39, 363-371.	3.7	31
505	Homology Modeling of Human Muscarinic Acetylcholine Receptors. Journal of Chemical Information and Modeling, 2014, 54, 243-253.	2.5	22
506	Elucidating Substrate Promiscuity in the Human Cytochrome 3A4. Journal of Chemical Information and Modeling, 2014, 54, 857-869.	2.5	18
507	Design, synthesis, antimicrobial evaluation and molecular docking studies of some new thiophene, pyrazole and pyridone derivatives bearing sulfisoxazole moiety. European Journal of Medicinal Chemistry, 2014, 84, 491-504.	2.6	104
508	Dual Histamine H <sub>3</sub> R/Serotonin 5-HT <sub>4</sub> R Ligands with Antiamnesic Properties: Pharmacophore-Based Virtual Screening and Polypharmacology. Journal of Chemical Information and Modeling, 2014, 54, 1773-1784.	2.5	27
509	Structure–activity relationships and molecular modeling studies of novel arylpiperazinylalkyl 2-benzoxazolones and 2-benzothiazolones as 5-HT7 and 5-HT1A receptor ligands. European Journal of Medicinal Chemistry, 2014, 85, 716-726.	2.6	33
510	Design, Synthesis, and Structure–Activity Relationship Studies of a Series of [4-(4-Carboxamidobutyl)]-1-arylpiperazines: Insights into Structural Features Contributing to Dopamine D3 versus D2 Receptor Subtype Selectivity. Journal of Medicinal Chemistry, 2014, 57, 7042-7060.	2.9	35
511	A Computational Approach to Enzyme Design: Predicting i‰-Aminotransferase Catalytic Activity Using Docking and MM-GBSA Scoring. Journal of Chemical Information and Modeling, 2014, 54, 2334-2346.	2.5	78
512	Characterization of the Active Site Properties of CYP4F12. Drug Metabolism and Disposition, 2014, 42, 1698-1707.	1.7	14
513	Binding-Induced Fluorescence of Serotonin Transporter Ligands: A Spectroscopic and Structural Study of 4-(4-(Dimethylamino)phenyl)-1-methylpyridinium (APP <sup>+</sup> ) and APP <sup>+</sup> Analogues. ACS Chemical Neuroscience, 2014, 5, 296-304.	1.7	21
514	Improving Docking Results via Reranking of Ensembles of Ligand Poses in Multiple X-ray Protein Conformations with MM-GBSA. Journal of Chemical Information and Modeling, 2014, 54, 2697-2717.	2.5	72
515	Molecular interaction of PCB180 to human serum albumin: insights from spectroscopic and molecular modelling studies. Journal of Molecular Modeling, 2014, 20, 2098.	0.8	19

#	Article	IF	CITATIONS
516	Molecular dynamics, dynamic site mapping, and highthroughput virtual screening on leptin and the Ob receptor as anti-obesity target. Journal of Molecular Modeling, 2014, 20, 2247.	0.8	14
517	Identification and Validation of Modulators of Exchange Protein Activated by cAMP (Epac) Activity. Journal of Biological Chemistry, 2014, 289, 8217-8230.	1.6	16
518	New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. Journal of Antimicrobial Chemotherapy, 2014, 69, 2118-2122.	1.3	50
519	A Derivative of Chrysin Suppresses Two-Stage Skin Carcinogenesis by Inhibiting Mitogen- and Stress-Activated Kinase 1. Cancer Prevention Research, 2014, 7, 74-85.	0.7	20
520	Dynamics of hERG Closure Allow Novel Insights into hERG Blocking by Small Molecules. Journal of Chemical Information and Modeling, 2014, 54, 2320-2333.	2.5	17
521	Communication of γ Phage Lysin plyG Enzymes Binding toward SrtA for Inhibition of <i>Bacillus Anthracis</i> : Protein–Protein Interaction and Molecular Dynamics Study. Cell Communication and Adhesion, 2014, 21, 257-265.	1.0	5
522	Pharmacophore Modeling, Ensemble Docking, Virtual Screening, and Biological Evaluation on Glycogen Synthase Kinaseâ€3β. Molecular Informatics, 2014, 33, 610-626.	1.4	15
523	Aminorex, a metabolite of the cocaine adulterant levamisole, exerts amphetamine like actions at monoamine transporters. Neurochemistry International, 2014, 73, 32-41.	1.9	95
524	Substrate Activity Screening with Kinases: Discovery of Smallâ€Molecule Substrateâ€Competitive câ€Src Inhibitors. Angewandte Chemie - International Edition, 2014, 53, 7010-7013.	7.2	17
525	Novel Arylsulfonamide Derivatives with 5-HT <sub>6</sub> /5-HT <sub>7</sub> Receptor Antagonism Targeting Behavioral and Psychological Symptoms of Dementia. Journal of Medicinal Chemistry, 2014, 57, 4543-4557.	2.9	58
526	Ensemble-Based Docking Using Biased Molecular Dynamics. Journal of Chemical Information and Modeling, 2014, 54, 2127-2138.	2.5	53
527	Structure-based design of small-molecule protein–protein interaction modulators: the story so far. Future Medicinal Chemistry, 2014, 6, 343-357.	1.1	46
528	Setting the stage for electron transfer: Molecular basis of ABTS-binding to four laccases from Trametes versicolor at variable pH and protein oxidation state. Journal of Molecular Catalysis B: Enzymatic, 2014, 100, 68-77.	1.8	29
529	Aminopurine derivatives as putative SopE inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, 29, 137-145.	2.5	2
530	- Pharmacophore Modeling and Pharmacophore-Based Virtual Screening. , 2015, , 140-171.		1
531	- Fragment-Based Methods in Drug Design. , 2015, , 370-407.		3
532	<i>In silico</i> ADME/T modelling for rational drug design. Quarterly Reviews of Biophysics, 2015, 48, 488-515.	2.4	250
533	<sup>18</sup> F-RB390: Innovative ligand for imaging the T877A androgen receptor mutant in prostate cancer via positron emission tomography (PET). Prostate, 2015, 75, 348-359.	1.2	3

#	Article	IF	CITATIONS
534	Analysis of conserved <scp>NCS</scp> 2 motifs in the <scp><i>E</i></scp> <i>scherichia coli</i> xanthine permease <scp>XanQ</scp> . Molecular Microbiology, 2015, 98, 502-517.	1.2	9
535	Recent Progress in FKBP Ligand Development. Current Molecular Pharmacology, 2015, 9, 27-36.	0.7	22
536	S4MPLEâ€"Sampler for Multiple Protein-Ligand Entities: Methodology and Rigid-Site Docking Benchmarking. Molecules, 2015, 20, 8997-9028.	1.7	25
537	Computational Approaches for Decoding Select Odorant-Olfactory Receptor Interactions Using Mini-Virtual Screening. PLoS ONE, 2015, 10, e0131077.	1.1	19
538	Progressive Hemorrhage and Myotoxicity Induced by Echis carinatus Venom in Murine Model: Neutralization by Inhibitor Cocktail of N,N,N',N'-Tetrakis (2-Pyridylmethyl) Ethane-1,2-Diamine and Silymarin. PLoS ONE, 2015, 10, e0135843.	1.1	16
539	Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors. Memorias Do Instituto Oswaldo Cruz, 2015, 110, 847-864.	0.8	23
540	Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases. Journal of Medicinal Chemistry, 2015, 58, 4964-4975.	2.9	52
541	Origin, diversification and substrate specificity in the family of <scp>NCS</scp> 1/ <scp>FUR</scp> transporters. Molecular Microbiology, 2015, 96, 927-950.	1.2	56
542	The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2015, 59, 4446-4452.	1.4	85
543	Synthesis of 8-hydroxy-2-iminochromene derivatives as selective and potent inhibitors of human carbonyl reductase 1. Organic and Biomolecular Chemistry, 2015, 13, 7487-7499.	1.5	15
544	Insights into the interaction of negative allosteric modulators with the metabotropic glutamate receptor 5: Discovery and computational modeling of a new series of ligands with nanomolar affinity. Bioorganic and Medicinal Chemistry, 2015, 23, 3040-3058.	1.4	16
545	Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure–activity relationship analysis and biological evaluation. European Journal of Medicinal Chemistry, 2015, 95, 116-126.	2.6	31
546	A diastereoselective P450-catalyzed epoxidation reaction: anti versus syn reactivity. Tetrahedron Letters, 2015, 56, 3435-3437.	0.7	10
547	Three Homology Models of PAR2 Derived from Different Templates: Application to Antagonist Discovery. Journal of Chemical Information and Modeling, 2015, 55, 1181-1191.	2.5	16
548	Design of selective TACE inhibitors using molecular docking studies: Synthesis and preliminary evaluation of anti-inflammatory and TACE inhibitory activity. SAR and QSAR in Environmental Research, 2015, 26, 905-923.	1.0	19
549	Free fatty acid receptors: structural models and elucidation of ligand binding interactions. BMC Structural Biology, 2015, 15, 16.	2.3	34
550	Phytochemical Indicaxanthin Inhibits Colon Cancer Cell Growth and Affects the DNA Methylation Status by Influencing Epigenetically Modifying Enzyme Expression and Activity. Journal of Nutrigenetics and Nutrigenomics, 2015, 8, 114-127.	1.8	25
551	Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia. European Journal of Medicinal Chemistry, 2015, 92, 221-235.	2.6	26

#	ARTICLE	IF	CITATIONS
552	Molecular decodification of gymnemic acids from Gymnema sylvestre. Discovery of a new class of liver X receptor antagonists. Steroids, 2015, 96, 121-131.	0.8	19
553	Modeling and protein engineering studies of active and inactive states of human dopamine D2 receptor (D2R) and investigation of drug/receptor interactions. Molecular Diversity, 2015, 19, 321-332.	2.1	29
554	Computational Polypharmacology Analysis of the Heat Shock Protein 90 Interactome. Journal of Chemical Information and Modeling, 2015, 55, 676-686.	2.5	31
555	Exploring the binding properties of agonists interacting with human TGR5 using structural modeling, molecular docking and dynamics simulations. RSC Advances, 2015, 5, 14202-14213.	1.7	35
556	Distinguishing Binders from False Positives by Free Energy Calculations: Fragment Screening Against the Flap Site of HIV Protease. Journal of Physical Chemistry B, 2015, 119, 976-988.	1.2	54
557	Methoxyflavones fromStachys glutinosawith Binding Affinity to Opioid Receptors: In Silico, in Vitro, and in Vivo Studies. Journal of Natural Products, 2015, 78, 69-76.	1.5	21
558	Context-Dependent GluN2B-Selective Inhibitors of NMDA Receptor Function Are Neuroprotective with Minimal Side Effects. Neuron, 2015, 85, 1305-1318.	3.8	57
559	Identification of a Second Substrate-binding Site in Solute-Sodium Symporters. Journal of Biological Chemistry, 2015, 290, 127-141.	1.6	18
560	Docking and binding free energy calculations of sirtuin inhibitors. European Journal of Medicinal Chemistry, 2015, 93, 584-598.	2.6	23
561	The Aspergillus nidulans Proline Permease as a Model for Understanding the Factors Determining Substrate Binding and Specificity of Fungal Amino Acid Transporters. Journal of Biological Chemistry, 2015, 290, 6141-6155.	1.6	16
562	Exploring Multiple Binding Modes Using Confined Replica Exchange Molecular Dynamics. Journal of Chemical Theory and Computation, 2015, 11, 3906-3918.	2.3	6
563	Virtual Screening for UDP-Galactopyranose Mutase Ligands Identifies a New Class of Antimycobacterial Agents. ACS Chemical Biology, 2015, 10, 2209-2218.	1.6	34
564	Groove binding mediated structural modulation and DNA cleavage by quinoline appended chalcone derivative. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2015, 151, 605-615.	2.0	16
565	Cardamonin induces apoptosis by suppressing STAT3 signaling pathway in glioblastoma stem cells. Tumor Biology, 2015, 36, 9667-9676.	0.8	41
566	Expanding the horizons of G protein-coupled receptor structure-based ligand discovery and optimization using homology models. Chemical Communications, 2015, 51, 13576-13594.	2.2	40
567	Carbohydrate scaffolds as glycosyltransferase inhibitors with in vivo antibacterial activity. Nature Communications, 2015, 6, 7719.	5.8	34
568	Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information. Journal of Computer-Aided Molecular Design, 2015, 29, 737-756.	1.3	42
569	Antihypertensive activity of a quinoline appended chalcone derivative and its site specific binding interaction with a relevant target carrier protein. RSC Advances, 2015, 5, 65496-65513.	1.7	69

#	Article	IF	CITATIONS
570	Design and synthesis of VEGFR-2 tyrosine kinase inhibitors as potential anticancer agents by virtual based screening. RSC Advances, 2015, 5, 56724-56771.	1.7	24
571	Discovery of potent carbonic anhydrase and acetylcholine esterase inhibitors: Novel sulfamoylcarbamates and sulfamides derived from acetophenones. Bioorganic and Medicinal Chemistry, 2015, 23, 3592-3602.	1.4	137
572	Structure-Based Predictions of Activity Cliffs. Journal of Chemical Information and Modeling, 2015, 55, 1062-1076.	2.5	34
573	Stabilization of Microtubules by Taxane Diterpenoids: Insight from Docking and MD simulations. Journal of Biological Physics, 2015, 41, 117-133.	0.7	40
574	Novel spirohydantoin derivative as a potent multireceptor-active antipsychotic and antidepressant agent. Bioorganic and Medicinal Chemistry, 2015, 23, 3436-3447.	1.4	32
575	Protein Flexibility in Drug Discovery: From Theory to Computation. ChemMedChem, 2015, 10, 1141-1148.	1.6	57
576	Structure–activity relationships and molecular studies of novel arylpiperazinylalkyl purine-2,4-diones and purine-2,4,8-triones with antidepressant and anxiolytic-like activity. European Journal of Medicinal Chemistry, 2015, 97, 142-154.	2.6	27
577	Truncated structures used in search for new lead compounds and in a retrospective analysis of thienopyrimidine-based EGFR inhibitors. European Journal of Medicinal Chemistry, 2015, 94, 175-194.	2.6	15
578	9 <i>H</i> -Purine Scaffold Reveals Induced-Fit Pocket Plasticity of the BRD9 Bromodomain. Journal of Medicinal Chemistry, 2015, 58, 2718-2736.	2.9	63
579	Dynamical insights of Mnk2 kinase activation by phosphorylation to facilitate inhibitor discovery. Future Medicinal Chemistry, 2015, 7, 91-102.	1.1	6
580	Structural predictions of neurobiologically relevant G-protein coupled receptors and intrinsically disordered proteins. Archives of Biochemistry and Biophysics, 2015, 582, 91-100.	1.4	4
581	Directed evolution of phenylacetone monooxygenase as an active catalyst for the baeyer–villiger conversion of cyclohexanone to caprolactone. Biotechnology and Bioengineering, 2015, 112, 1354-1364.	1.7	31
582	Structural Mechanism of the Interaction of Alzheimer Disease AÎ <sup>2</sup> Fibrils with the Non-steroidal Anti-inflammatory Drug (NSAID) Sulindac Sulfide. Journal of Biological Chemistry, 2015, 290, 28737-28745.	1.6	26
583	Understanding the challenges of protein flexibility in drug design. Expert Opinion on Drug Discovery, 2015, 10, 1301-1313.	2.5	94
584	Reduction of $\hat{l}\pm,\hat{l}^2$ -Unsaturated Ketones by Old Yellow Enzymes: Mechanistic Insights from Quantum Mechanics/Molecular Mechanics Calculations. Journal of the American Chemical Society, 2015, 137, 14733-14742.	6.6	41
585	Pharmacophore modeling and molecular docking studies of acridines as potential DPP-IV inhibitors. Canadian Journal of Chemistry, 2015, 93, 721-729.	0.6	6
586	Illicit Transport via Dipeptide Transporter Dpp is Irrelevant to the Efficacy of Negamycin in Mouse Thigh Models of Escherichia coliInfection. ACS Infectious Diseases, 2015, 1, 222-230.	1.8	9
587	Small-Molecule Allosteric Modulators of the Protein Kinase PDK1 from Structure-Based Docking. Journal of Medicinal Chemistry, 2015, 58, 8285-8291.	2.9	32

#	Article	IF	CITATIONS
588	Pyrazolo [3,4-d] pyrimidines as the inhibitors of mycobacterial $\hat{l}^2$ -oxidation trifunctional enzyme. Medicinal Chemistry Research, 2015, 24, 4002-4015.	1.1	5
589	Towards predictive docking at aminergic G-protein coupled receptors. Journal of Molecular Modeling, 2015, 21, 284.	0.8	25
590	Ligand similarity guided receptor selection enhances docking accuracy and recall for non-nucleoside HIV reverse transcriptase inhibitors. Journal of Molecular Modeling, 2015, 21, 282.	0.8	5
591	G Protein-Coupled Receptors in Drug Discovery. Methods in Molecular Biology, 2015, 1335, v.	0.4	7
592	Open challenges in structure-based virtual screening: Receptor modeling, target flexibility consideration and active site water molecules description. Archives of Biochemistry and Biophysics, 2015, 583, 105-119.	1.4	101
593	Comparison of templates for homology model of ĩł GABA C receptors: More insights to the orthosteric binding site's structure and functionality. Journal of Molecular Graphics and Modelling, 2015, 62, 43-55.	1.3	10
594	Design and synthesis of N-[6-(Substituted Aminoethylideneamino)-2-Hydroxyindan-1-yl]arylamides as selective and potent muscarinic M1 agonists. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4158-4163.	1.0	4
595	Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines. Bioorganic and Medicinal Chemistry, 2015, 23, 6125-6137.	1.4	16
596	Docking and Virtual Screening Strategies for GPCR Drug Discovery. Methods in Molecular Biology, 2015, 1335, 251-276.	0.4	17
597	Sampling of conformational ensemble for virtual screening using molecular dynamics simulations and normal mode analysis. Future Medicinal Chemistry, 2015, 7, 2317-2331.	1.1	22
598	Interaction of carbonic anhydrase isozymes I, II, and IX with some pyridine and phenol hydrazinecarbothioamide derivatives. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5636-5641.	1.0	41
599	Mechanistic insights of SrtA–LPXTG blockers targeting the transpeptidase mechanism in Streptococcus mutans. RSC Advances, 2015, 5, 100498-100510.	1.7	15
600	Derivatives Form Better Lipoxygenase Inhibitors than Piperine: <i>In Vitro</i> and <i>In Silico</i> Study. Chemical Biology and Drug Design, 2015, 85, 715-721.	1.5	18
601	Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT1A receptor functional profile. Bioorganic and Medicinal Chemistry, 2015, 23, 212-221.	1.4	31
602	Protease activated receptor-2 (PAR2): possible target of phytochemicals. Journal of Biomolecular Structure and Dynamics, 2015, 33, 2003-2022.	2.0	12
603	Discovery and development of DNA methyltransferase inhibitors using in silico approaches. Drug Discovery Today, 2015, 20, 569-577.	3.2	53
604	Inhibitory potential of three zinc chelating agents against the proteolytic, hemorrhagic, and myotoxic activities of Echis carinatus venom. Toxicon, 2015, 93, 68-78.	0.8	23
605	Structure and dynamics of DRD4 bound to an agonist and an antagonist using <i>in silico </i> i) approaches. Proteins: Structure, Function and Bioinformatics, 2015, 83, 867-880.	1.5	11

#	Article	IF	CITATIONS
606	Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study. Journal of Computer-Aided Molecular Design, 2015, 29, 155-163.	1.3	29
607	Comparative Analysis of Various Electrostatic Potentials on Docking Precision Against Cyclinâ€Dependent Kinase 2 Protein: A Multiple Docking Approach. Chemical Biology and Drug Design, 2015, 85, 107-118.	1.5	9
608	Strategies for the Development of Small Molecule Inhibitors of Ebola Viral Infection. , 2016, , .		1
609	<i>In Vitro</i> Effects of the Endocrine Disruptor <i>p,p</i> '-DDT on Human Follitropin Receptor. Environmental Health Perspectives, 2016, 124, 991-999.	2.8	28
610	Virtual Screening Approaches towards the Discovery of Toll-Like Receptor Modulators. International Journal of Molecular Sciences, 2016, 17, 1508.	1.8	32
611	Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells. Molecules, 2016, 21, 1236.	1.7	37
612	IN SILICO DOCKING ANALYSIS OF THE COMPOUNDS OF ORTHOSIPHON STAMINEUS FOR THE ANTICANCER ACTIVITY. International Research Journal of Pharmacy, 2016, 7, 17-23.	0.0	1
613	Insight on Mutation-Induced Resistance from Molecular Dynamics Simulations of the Native and Mutated CSF-1R and KIT. PLoS ONE, 2016, 11, e0160165.	1.1	8
614	Current Status of Computer-Aided Drug Design for Type 2 Diabetes. Current Computer-Aided Drug Design, 2016, 12, 167-177.	0.8	26
615	Computational methods in drug discovery. Beilstein Journal of Organic Chemistry, 2016, 12, 2694-2718.	1.3	418
616	Enhancing backbone sampling in Monte Carlo simulations using internal coordinates normal mode analysis. Bioorganic and Medicinal Chemistry, 2016, 24, 4855-4866.	1.4	1
617	Structureâ€Based Virtual Screening for Dopamine D <sub>2</sub> Receptor Ligands as Potential Antipsychotics. ChemMedChem, 2016, 11, 718-729.	1.6	51
618	Discovery of Novel Allosteric Eg5 Inhibitors Through Structureâ€Based Virtual Screening. Chemical Biology and Drug Design, 2016, 88, 178-187.	1.5	7
619	Studies on Cycloheptathiopheneâ€3â€carboxamide Derivatives as Allosteric HIVâ€1 Ribonucleaseâ€H Inhibitors. ChemMedChem, 2016, 11, 1709-1720.	1.6	15
620	Early-onset epileptic encephalopathy caused by a reduced sensitivity of Kv7.2 potassium channels to phosphatidylinositol 4,5-bisphosphate. Scientific Reports, 2016, 6, 38167.	1.6	40
621	On the role of water density fluctuations in the inhibition of a proton channel. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E8359-E8368.	3.3	33
622	CA-1H, a novel oxazole bearing analogue of combretastatin A-4, disrupts the tumor vasculatures and inhibits the tumor growth via inhibiting tubulin polymerization. Biomedicine and Pharmacotherapy, 2016, 80, 151-161.	2.5	9
623	Exploring the inhibitory potential of bioactive compound from Luffa acutangula against NF-κB—A molecular docking and dynamics approach. Computational Biology and Chemistry, 2016, 62, 29-35.	1.1	26

#	Article	IF	Citations
624	Exploring new chemical functionalities to improve aromatase inhibition of steroids. Bioorganic and Medicinal Chemistry, 2016, 24, 2823-2831.	1.4	13
625	Synthesis and inhibitory evaluation of 3-linked imipramines for the exploration of the S2 site of the human serotonin transporter. Bioorganic and Medicinal Chemistry, 2016, 24, 2725-2738.	1.4	16
626	Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase. Glycobiology, 2016, 26, 640-654.	1.3	58
627	Acetylcholinesterase and carbonic anhydrase inhibitory properties of novel urea and sulfamide derivatives incorporating dopaminergic 2-aminotetralin scaffolds. Bioorganic and Medicinal Chemistry, 2016, 24, 2318-2329.	1.4	131
628	Pharmacophore modeling and structure-based virtual screening to identify potent inhibitors targeting LuxP of <i>Vibrio harveyi</i> . Journal of Receptor and Signal Transduction Research, 2016, 36, 617-632.	1.3	12
629	WScore: A Flexible and Accurate Treatment of Explicit Water Molecules in Ligand–Receptor Docking. Journal of Medicinal Chemistry, 2016, 59, 4364-4384.	2.9	75
630	Discovery of a novel inhibitor of kinesin-like protein KIFC1. Biochemical Journal, 2016, 473, 1027-1035.	1.7	32
631	Computational analysis of EBNA1 "druggability―suggests novel insights for Epstein-Barr virus inhibitor design. Journal of Computer-Aided Molecular Design, 2016, 30, 285-303.	1.3	27
632	Development of Potent and Selective Inhibitors for Group VIA Calcium-Independent Phospholipase A <sub>2</sub> Guided by Molecular Dynamics and Structure–Activity Relationships. Journal of Medicinal Chemistry, 2016, 59, 4403-4414.	2.9	39
633	Prediction of Protein–Ligand Binding Poses via a Combination of Induced Fit Docking and Metadynamics Simulations. Journal of Chemical Theory and Computation, 2016, 12, 2990-2998.	2.3	184
634	Chiral 6-aryl-furo[2,3-d]pyrimidin-4-amines as EGFR inhibitors. European Journal of Medicinal Chemistry, 2016, 119, 278-299.	2.6	22
635	Investigation of inhibition of human glucose 6-phosphate dehydrogenase by some 99mTc chelators by <i>in silico</i> and <i>in vitro</i> methods. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 141-147.	2.5	9
636	Advanced molecular dynamics simulation methods for kinase drug discovery. Future Medicinal Chemistry, 2016, 8, 545-566.	1.1	21
637	Computer-aided drug design guided by hydrogen/deuterium exchange mass spectrometry: A powerful combination for the development of potent and selective inhibitors of Group VIA calcium-independent phospholipase A2. Bioorganic and Medicinal Chemistry, 2016, 24, 4801-4811.	1.4	21
638	Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening. Journal of Medicinal Chemistry, 2016, 59, 5542-5554.	2.9	24
639	Overview of Computer-Aided Drug Design for Epigenetic Targets. , 2016, , 21-52.		9
640	The triterpene echinocystic acid and its 3-O-glucoside derivative are revealed as potent and selective glucocorticoid receptor agonists. International Journal of Biochemistry and Cell Biology, 2016, 79, 277-287.	1.2	13
641	Balancing potency, metabolic stability and permeability in pyrrolopyrimidine-based EGFR inhibitors. European Journal of Medicinal Chemistry, 2016, 124, 583-607.	2.6	17

#	Article	IF	CITATIONS
642	Incorporation of side chain flexibility into protein binding pockets using MTflex. Bioorganic and Medicinal Chemistry, 2016, 24, 4978-4987.	1.4	7
643	Anti-inflammatory trends of new benzimidazole derivatives. Future Medicinal Chemistry, 2016, 8, 1953-1967.	1.1	32
644	Design and synthesis of purine analogues as highly specific ligands for FcyB, a ubiquitous fungal nucleobase transporter. Bioorganic and Medicinal Chemistry, 2016, 24, 5941-5952.	1.4	16
645	Molecular dynamics techniques for modeling G protein-coupled receptors. Current Opinion in Pharmacology, 2016, 30, 69-75.	1.7	26
646	Identification of Limonol Derivatives as Heat Shock Proteinâ€90 (Hsp90) Inhibitors through a Multidisciplinary Approach. Chemistry - A European Journal, 2016, 22, 13236-13250.	1.7	31
647	The dopamine D2 receptor dimer and its interaction with homobivalent antagonists: homology modeling, docking and molecular dynamics. Journal of Molecular Modeling, 2016, 22, 203.	0.8	28
648	Challenges of docking in large, flexible and promiscuous binding sites. Bioorganic and Medicinal Chemistry, 2016, 24, 4961-4969.	1.4	19
649	Binding-affinity predictions of HSP90 in the D3R Grand Challenge 2015 with docking, MM/GBSA, QM/MM, and free-energy simulations. Journal of Computer-Aided Molecular Design, 2016, 30, 707-730.	1.3	40
650	New dihydropyrimidin-2(1H)-one based Hsp90 C-terminal inhibitors. RSC Advances, 2016, 6, 82330-82340.	1.7	17
651	A simple and efficient synthesis of novel inhibitors of alpha-glucosidase based on benzimidazole skeleton and molecular docking studies. Bioorganic Chemistry, 2016, 68, 226-235.	2.0	39
652	Site-Directed Chemical Mutations on Abzymes: Large Rate Accelerations in the Catalysis by Exchanging the Functionalized Small Nonprotein Components. ACS Chemical Biology, 2016, 11, 2803-2811.	1.6	2
653	Molecular docking studies and synthesis of novel bisbenzimidazole derivatives as inhibitors of α-glucosidase. Bioorganic and Medicinal Chemistry, 2016, 24, 5103-5114.	1.4	39
654	MOLS 2.0: software package for peptide modeling and protein–ligand docking. Journal of Molecular Modeling, 2016, 22, 239.	0.8	18
655	Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacological Research, 2016, 111, 784-803.	3.1	279
657	Discovery of HIV Typeâ€1 Aspartic Protease Hit Compounds through Combined Computational Approaches. ChemMedChem, 2016, 11, 1646-1652.	1.6	3
658	Bacterial versus human sphingosine-1-phosphate lyase (S1PL) in the design of potential S1PL inhibitors. Bioorganic and Medicinal Chemistry, 2016, 24, 4381-4389.	1.4	3
659	The binding mode of picrotoxinin in GABAA-ϕreceptors: Insight into the subunit's selectivity in the transmembrane domain. Computational Biology and Chemistry, 2016, 64, 202-209.	1.1	3
660	Comparison of the ligand binding site of CYP2C8 with CYP26A1 and CYP26B1: a structural basis for the identification of new inhibitors of the retinoic acid hydroxylases. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 148-161.	2.5	9

#	Article	IF	CITATIONS
661	Identification of the key structural elements of a dihydropyrimidinone core driving toward more potent Hsp90 C-terminal inhibitors. Chemical Communications, 2016, 52, 12857-12860.	2.2	20
662	Plasma Protein Binding of Anisomelic Acid: Spectroscopy and Molecular Dynamic Simulations. Journal of Chemical Information and Modeling, 2016, 56, 2401-2412.	2.5	25
663	Relative Binding Free Energy Calculations Applied to Protein Homology Models. Journal of Chemical Information and Modeling, 2016, 56, 2388-2400.	2.5	60
664	Molecular Mechanism and Energy Basis of Conformational Diversity of Antibody SPE7 Revealed by Molecular Dynamics Simulation and Principal Component Analysis. Scientific Reports, 2016, 6, 36900.	1.6	23
665	Mechanism of Paroxetine (Paxil) Inhibition of the Serotonin Transporter. Scientific Reports, 2016, 6, 23789.	1.6	43
666	Crystal Structure of the Human Cannabinoid Receptor CB1. Cell, 2016, 167, 750-762.e14.	13.5	468
667	Computational modelling of the binding of arachidonic acid to the human monooxygenase CYP2J2. Journal of Molecular Modeling, 2016, 22, 279.	0.8	10
668	Effects of Geranyloxycinnamic Acids on COXâ€2 and <i>i</i> iNOS Functionalities in LPSâ€6timulated U937 Mononuclear Cells. ChemistrySelect, 2016, 1, 5479-5486.	0.7	O
669	Synthesis and Pharmacological Activity of a New Series of 1â€(1 <i>H</i> à€Indolâ€4â€yloxy)â€3â€(2â€(2â€methoxyphenoxy)ethylamino)propanâ€2â€ol Analogs. Archiv D 2016, 349, 211-223.	e <b>:2Pi</b> harma	∃Zi@,
670	HQSAR and molecular docking studies of furanyl derivatives as adenosine A2A receptor antagonists. Medicinal Chemistry Research, 2016, 25, 1316-1328.	1.1	4
671	Synthesis of Some Novel Norborneneâ€Fused Pyridazines as Potent Inhibitors of Carbonic Anhydrase and Acetylcholinesterase. Journal of Heterocyclic Chemistry, 2016, 53, 2049-2056.	1.4	39
672	Synthesis and biological evaluation of 2-fluoro and 3-trifluoromethyl-phenyl-piperazinylalkyl derivatives of $1 < i > H <  i > 1$ inidazo[2,1- $< i > f <  i > 1$ ] purine-2,4(3 $< i > H <  i > 1$ ,8 $< i > H <  i > 1$ )-dione as potential antidepressant agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 10-24.	2.5	21
673	Structural insights on identification of potential lead compounds targeting WbpP in Vibrio vulnificus through structure-based approaches. Journal of Receptor and Signal Transduction Research, 2016, 36, 515-530.	1.3	5
674	Computational insights into the interaction mechanism of triazolyl substituted tetrahydrobenzofuran derivatives with H+,K+-ATPase at different pH. Journal of Computer-Aided Molecular Design, 2016, 30, 27-37.	1.3	2
675	Molecular docking and structure-based virtual screening studies of potential drug target, CAAX prenyl proteases, of <i>Leishmania donovani</i> Journal of Biomolecular Structure and Dynamics, 2016, 34, 2367-2386.	2.0	26
676	Docking study and biological evaluation of pyrrolidine-based iminosugars as pharmacological chaperones for Gaucher disease. Organic and Biomolecular Chemistry, 2016, 14, 1039-1048.	1.5	46
677	Design, synthesis and biological evaluation of bisabolangelone oxime derivatives as potassium-competitive acid blockers (P-CABs). Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2268-2272.	1.0	5
678	Structural Insights into the Transport Mechanism of the Human Sodium-dependent Lysophosphatidylcholine Transporter MFSD2A. Journal of Biological Chemistry, 2016, 291, 9383-9394.	1.6	61

#	Article	IF	CITATIONS
679	A Novel Allosteric Mechanism of NF-κB Dimerization and DNA Binding Targeted by an Anti-Inflammatory Drug. Molecular and Cellular Biology, 2016, 36, 1237-1247.	1.1	19
680	Interruptin B induces brown adipocyte differentiation and glucose consumption in adipose-derived stem cells. Molecular Medicine Reports, 2016, 13, 2078-2086.	1.1	6
681	Three-dimensional homology model of GlcNAc-TV glycosyltransferase. Glycobiology, 2016, 26, 757-771.	1.3	4
682	Binding Mode and Induced Fit Predictions for Prospective Computational Drug Design. Journal of Chemical Information and Modeling, 2016, 56, 774-787.	2.5	25
683	Structural insights of a PI3K/mTOR dual inhibitor with the morpholino-triazine scaffold. Journal of Computer-Aided Molecular Design, 2016, 30, 323-330.	1.3	11
684	Adaptive BP-Dock: An Induced Fit Docking Approach for Full Receptor Flexibility. Journal of Chemical Information and Modeling, 2016, 56, 734-746.	2.5	25
685	Structural signatures of DRD4 mutants revealed using molecular dynamics simulations: Implications for drug targeting. Journal of Molecular Modeling, 2016, 22, 14.	0.8	6
686	Drug design, synthesis, inÂvitro and in silico evaluation of selective monoaminoxidase B inhibitors based on 3-acetyl-2-dichlorophenyl-5-aryl-2,3-dihydro-1,3,4-oxadiazole chemical scaffold. European Journal of Medicinal Chemistry, 2016, 108, 542-552.	2.6	34
687	Effects of protein flexibility and active site water molecules on the prediction of sites of metabolism for cytochrome P450 2C19 substrates. Molecular BioSystems, 2016, 12, 868-878.	2.9	14
688	A systematic methodology for large scale compound screening: A case study on the discovery of novel S1PL inhibitors. Journal of Molecular Graphics and Modelling, 2016, 63, 110-124.	1.3	23
689	Identification of potential inhibitors for AIRS from <i>de novo</i> purine biosynthesis pathway through molecular modeling studies – a computational approach. Journal of Biomolecular Structure and Dynamics, 2016, 34, 2199-2213.	2.0	16
690	Extended structure–activity study of thienopyrimidine-based EGFR inhibitors with evaluation of drug-like properties. European Journal of Medicinal Chemistry, 2016, 107, 255-274.	2.6	38
691	Arylpiperazinylalkyl derivatives of 8-amino-1,3-dimethylpurine-2,6-dione as novel multitarget 5-HT/D receptor agents with potential antipsychotic activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 1048-1062.	2.5	10
692	OpenGrowth: An Automated and Rational Algorithm for Finding New Protein Ligands. Journal of Medicinal Chemistry, 2016, 59, 4171-4188.	2.9	53
693	Modeling of dexmedetomidine conformers and their interactions with alpha2 adrenergic receptor subtypes. Structural Chemistry, 2016, 27, 871-881.	1.0	2
694	Homology Modeling and Docking Evaluation of Human Muscarinic Acetylcholine Receptors. Neuromethods, 2016, , 15-35.	0.2	1
695	Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation. European Journal of Medicinal Chemistry, 2016, 121, 864-879.	2.6	80
696	Identification of novel natural inhibitor for NorM $\hat{a}\in$ a multidrug and toxic compound extrusion transporter $\hat{a}\in$ an <i>insilico</i> molecular modeling and simulation studies. Journal of Biomolecular Structure and Dynamics, 2017, 35, 58-77.	2.0	22

#	Article	IF	CITATIONS
697	Identification of potential glutaminyl cyclase inhibitors from lead-like libraries by in silico and in vitro fragment-based screening. Molecular Diversity, 2017, 21, 175-186.	2.1	13
698	2â€methoxyestradiol impacts on amino acidsâ€mediated metabolic reprogramming in osteosarcoma cells by its interaction with NMDA receptor. Journal of Cellular Physiology, 2017, 232, 3030-3049.	2.0	15
699	Novel anti-tubulin agents from plant and marine origins: insight from a molecular modeling and dynamics study. RSC Advances, 2017, 7, 15917-15925.	1.7	16
700	Molecular requirements involving the human platelet protease-activated receptor-4 mechanism of activation by peptide analogues of its tethered-ligand. Platelets, 2017, 28, 812-821.	1.1	13
701	Investigating Protein–Peptide Interactions Using the Schrödinger Computational Suite. Methods in Molecular Biology, 2017, 1561, 235-254.	0.4	79
702	Crystal structure of a bicupin protein HutD involved in histidine utilization in <i>Pseudomonas</i> Proteins: Structure, Function and Bioinformatics, 2017, 85, 1580-1588.	1.5	2
703	Are induced fit protein conformational changes caused by ligandâ€binding predictable? A molecular dynamics investigation. Journal of Computational Chemistry, 2017, 38, 1229-1237.	1.5	10
704	Using Ligand-Induced Protein Chemical Shift Perturbations To Determine Protein–Ligand Structures. Biochemistry, 2017, 56, 2349-2362.	1.2	21
705	Targeting the Hsp90 C-terminal domain to induce allosteric inhibition and selective client downregulation. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 1992-2006.	1.1	23
706	Accurate Prediction of Complex Structure and Affinity for a Flexible Protein Receptor and Its Inhibitor. Journal of Chemical Theory and Computation, 2017, 13, 2389-2399.	2.3	43
707	ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. Pharmacological Research, 2017, 121, 202-212.	3.1	93
708	Real-Time Imaging of the Azole Class of Antifungal Drugs in Live Candida Cells. ACS Chemical Biology, 2017, 12, 1769-1777.	1.6	57
709	Mapping Ryanodine Binding Sites in the Pore Cavity of Ryanodine Receptors. Biophysical Journal, 2017, 112, 1645-1653.	0.2	7
710	Understanding the conformational flexibility and electrostatic properties of curcumin in the active site of rhAChE via molecular docking, molecular dynamics, and charge density analysis. Journal of Biomolecular Structure and Dynamics, 2017, 35, 3627-3647.	2.0	26
711	Modeling Binding with Large Conformational Changes: Key Points in Ensemble-Docking Approaches. Journal of Chemical Information and Modeling, 2017, 57, 1563-1578.	2.5	21
712	Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity. Bioorganic and Medicinal Chemistry, 2017, 25, 4424-4432.	1.4	48
713	Identification of new BACE1 inhibitors using Pharmacophore and Molecular dynamics simulations approach. Journal of Molecular Graphics and Modelling, 2017, 76, 56-69.	1.3	19
714	Development of efficient docking strategies and structure-activity relationship study of the c-Met type II inhibitors. Journal of Molecular Graphics and Modelling, 2017, 75, 241-249.	1.3	11

#	Article	IF	Citations
715	Improving the physicochemical properties of bicalutamide by complex formation with bovine serum albumin. European Journal of Pharmaceutical Sciences, 2017, 106, 381-392.	1.9	8
716	Sphingosine kinase 1 (SK1) allosteric inhibitors that target the dimerization site. Computational Biology and Chemistry, 2017, 69, 64-76.	1.1	6
717	Characterization of the binding mode of the PET tracer [18F]ASEM to a chimera structure of the $\hat{l}\pm7$ nicotinic acetylcholine receptor. RSC Advances, 2017, 7, 19787-19793.	1.7	4
718	Identification of a putative binding site critical for general anesthetic activation of TRPA1.  Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3762-3767.	3.3	44
719	Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle. Bioorganic and Medicinal Chemistry, 2017, 25, 2713-2723.	1.4	32
720	Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas. Pharmacological Research, 2017, 120, 116-132.	3.1	184
721	Cosolvent-Based Molecular Dynamics for Ensemble Docking: Practical Method for Generating Druggable Protein Conformations. Journal of Chemical Information and Modeling, 2017, 57, 742-756.	2.5	26
722	Structure–Activity Relationships on Cinnamoyl Derivatives as Inhibitors of p300 Histone Acetyltransferase. ChemMedChem, 2017, 12, 1359-1368.	1.6	11
723	Evaluation of the novel algorithm of flexible ligand docking with moveable target-protein atoms. Computational and Structural Biotechnology Journal, 2017, 15, 275-285.	1.9	17
724	Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: InÂvitro and inÂvivo study. Cancer Letters, 2017, 396, 145-154.	3.2	56
725	Development of Potent and Selective Antagonists for the UTP-Activated P2Y <sub>4</sub> Receptor. Journal of Medicinal Chemistry, 2017, 60, 3020-3038.	2.9	33
726	Building a More Predictive Protein Force Field: A Systematic and Reproducible Route to AMBER-FB15. Journal of Physical Chemistry B, 2017, 121, 4023-4039.	1.2	192
727	Exploring the binding mechanism of Heteroaryldihydropyrimidines and Hepatitis B Virus capsid combined 3D-QSAR and molecular dynamics. Antiviral Research, 2017, 137, 151-164.	1.9	22
728	Diverse arrestin-recruiting and endocytic profiles of tricyclic antipsychotics acting as direct $\hat{l}\pm 2A$ adrenergic receptor ligands. Neuropharmacology, 2017, 116, 38-49.	2.0	3
729	Allosteric MEK $1/2$ inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas. Pharmacological Research, 2017, 117, 20-31.	3.1	78
730	Indole-3-carbinol (I3C) analogues are potent small molecule inhibitors of NEDD4-1 ubiquitin ligase activity that disrupt proliferation of human melanoma cells. Biochemical Pharmacology, 2017, 127, 13-27.	2.0	59
731	Identification of a Different Agonist-Binding Site and Activation Mechanism of the Human P2Y1 Receptor. Scientific Reports, 2017, 7, 13764.	1.6	10
732	Synthesis and antibacterial activity of new symmetric polyoxygenated dibenzofurans. European Journal of Medicinal Chemistry, 2017, 141, 178-187.	2.6	6

#	Article	IF	CITATIONS
733	Selective Homogeneous Assay for Circulating Endopeptidase Fibroblast Activation Protein (FAP). Scientific Reports, 2017, 7, 12524.	1.6	28
734	Novel HDAC8 inhibitors: A multi-computational approach. SAR and QSAR in Environmental Research, 2017, 28, 707-733.	1.0	7
735	Diminazene Is a Slow Pore Blocker of Acid-Sensing Ion Channel 1a (ASIC1a). Molecular Pharmacology, 2017, 92, 665-675.	1.0	42
736	Exploring the Stability of Ligand Binding Modes to Proteins by Molecular Dynamics Simulations: A Cross-docking Study. Journal of Chemical Information and Modeling, 2017, 57, 2514-2522.	2.5	96
737	Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y <sub>2</sub> Receptor. Journal of Medicinal Chemistry, 2017, 60, 8425-8440.	2.9	27
738	Rational design and structure–activity relationship studies of quercetin–amino acid hybrids targeting the anti-apoptotic protein Bcl-xL. Organic and Biomolecular Chemistry, 2017, 15, 7956-7976.	1.5	24
739	Inhibitor mechanisms in the S1 binding site of the dopamine transporter defined by multi-site molecular tethering of photoactive cocaine analogs. Biochemical Pharmacology, 2017, 142, 204-215.	2.0	4
740	Probing the Hydrophobic Binding Pocket of G-Protein-Coupled Lysophosphatidylserine Receptor GPR34/LPS <sub>1</sub> by Docking-Aided Structure–Activity Analysis. Journal of Medicinal Chemistry, 2017, 60, 6384-6399.	2.9	17
741	Investigation of novel pharmacological chaperones for Gaucher Disease. Journal of Molecular Graphics and Modelling, 2017, 76, 364-378.	1.3	10
742	Structure–Affinity Relationships and Structure–Kinetics Relationships of Pyrido[2,1- <i>f</i> ]purine-2,4-dione Derivatives as Human Adenosine A <sub>3</sub> Receptor Antagonists. Journal of Medicinal Chemistry, 2017, 60, 7555-7568.	2.9	26
743	New molecular target insights about protein kinases of the <i>Plasmodium falciparum</i> . Using molecular docking and DFT-based reactivity descriptors. Journal of Theoretical and Computational Chemistry, 2017, 16, 1750076.	1.8	1
744	Is the Sudlow site I of human serum albumin more generous to adopt prospective anti-cancer bioorganic compound than that of bovine: A combined spectroscopic and docking simulation approach. Bioorganic Chemistry, 2017, 75, 332-346.	2.0	21
745	Gyrl-like proteins catalyze cyclopropanoid hydrolysis to confer cellular protection. Nature Communications, 2017, 8, 1485.	5.8	12
746	Structure–Affinity Relationships and Structure–Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide Derivatives as Human Cannabinoid 1 Receptor Antagonists. Journal of Medicinal Chemistry, 2017, 60, 9545-9564.	2.9	6
747	Design, synthesis, and biological evaluation of 2,4-dihydropyrano [2,3-c] pyrazole derivatives as autotaxin inhibitors. European Journal of Pharmaceutical Sciences, 2017, 107, 97-111.	1.9	11
748	Structure–function relationship of Chikungunya nsP2 protease: A comparative study with papain. Chemical Biology and Drug Design, 2017, 89, 772-782.	1.5	11
749	Cryptic purine transporters in <i>Aspergillus nidulans</i> reveal the role of specific residues in the evolution of specificity in the NCS1 family. Molecular Microbiology, 2017, 103, 319-332.	1.2	22
750	Probing an Allosteric Pocket of CDK2 with Small Molecules. ChemMedChem, 2017, 12, 33-41.	1.6	21

#	ARTICLE	IF	CITATIONS
751	Identification, functional gastrointestinal stability and molecular docking studies of lentil peptides with dual antioxidant and angiotensin I converting enzyme inhibitory activities. Food Chemistry, 2017, 221, 464-472.	4.2	114
752	Discovery of Klotho peptide antagonists against Wnt3 and Wnt3a target proteins using combination of protein engineering, protein–protein docking, peptide docking and molecular dynamics simulations. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 84-98.	2.5	11
753	Synthesis and evaluation of N-substituted 2-amino-4,5-diarylpyrimidines as selective adenosine A1 receptor antagonists. European Journal of Medicinal Chemistry, 2017, 125, 586-602.	2.6	9
754	Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects. ACS Chemical Neuroscience, 2017, 8, 165-177.	1.7	17
755	Antiâ€inflammatory and analgesic activity of carnosol and carnosic acid ⟨i⟩in vivo⟨ i⟩ and ⟨i⟩in vitro⟨ i⟩ and ⟨i⟩in silico⟨ i⟩ analysis of their target interactions. British Journal of Pharmacology, 2017, 174, 1497-1508.	2.7	50
756	Molecular docking and molecular dynamics simulations of fumarate hydratase and its mutant H235N complexed with pyromellitic acid and citrate. Journal of Bioinformatics and Computational Biology, 2017, 15, 1750026.	0.3	3
757	Three classes of ligands each bind to distinct sites on the orphan G protein-coupled receptor GPR84. Scientific Reports, 2017, 7, 17953.	1.6	50
758	Molecular modeling studies of quinoline derivatives as VEGFR-2 tyrosine kinase inhibitors using pharmacophore based 3D QSAR and docking approach. Arabian Journal of Chemistry, 2017, 10, S1980-S2003.	2.3	15
759	COX Inhibition Profile and Molecular Docking Studies of Some 2-(Trimethoxyphenyl)-Thiazoles. Molecules, 2017, 22, 1507.	1.7	42
760	Prenylflavonoid Isoxanthohumol Sensitizes MCF-7/ADR Cells to Doxorubicin Cytotoxicity via Acting as a Substrate of ABCB1. Toxins, 2017, 9, 208.	1.5	6
761	Interaction of Cholesterol with Perfringolysin O: What Have We Learned from Functional Analysis?. Toxins, 2017, 9, 381.	1.5	30
762	Combined Virtual and Experimental Screening for CK1 Inhibitors Identifies a Modulator of p53 and Reveals Important Aspects of in Silico Screening Performance. International Journal of Molecular Sciences, 2017, 18, 2102.	1.8	8
763	Interaction of Cocaine Analogue RTI82 With the Dopamine Transporter., 2017,, 527-535.		0
764	Ligand-guided homology modelling of the GABAB2 subunit of the GABAB receptor. PLoS ONE, 2017, 12, e0173889.	1.1	19
765	Homology Modeling of Human Concentrative Nucleoside Transporters (hCNTs) and Validation by Virtual Screening and Experimental Testing to Identify Novel hCNT1 Inhibitors. Drug Designing: Open Access, 2017, 06, .	0.2	4
766	MOLECULAR DOCKING AND PHARMACOKINETIC PREDICTION OF HERBAL DERIVATIVES AS MALTASE-GLUCOAMYLASE INHIBITOR. Asian Journal of Pharmaceutical and Clinical Research, 2017, 10, 392.	0.3	5
767	Zirconium catalyzed synthesis of 2-arylidene Indan-1,3-diones and evaluation of their inhibitory activity against NS2B-NS3 WNV protease. European Journal of Medicinal Chemistry, 2018, 149, 98-109.	2.6	22
768	In Vitro and in Vivo Evaluation of <sup>11</sup> C-Labeled Azetidinecarboxylates for Imaging Monoacylglycerol Lipase by PET Imaging Studies. Journal of Medicinal Chemistry, 2018, 61, 2278-2291.	2.9	41

#	Article	IF	CITATIONS
769	Molecular modeling and in vitro approaches towards cholinesterase inhibitory effect of some natural xanthohumol, naringenin, and acyl phloroglucinol derivatives. Phytomedicine, 2018, 42, 25-33.	2.3	29
770	Discovery of Trifluoromethyl Glycol Carbamates as Potent and Selective Covalent Monoacylglycerol Lipase (MAGL) Inhibitors for Treatment of Neuroinflammation. Journal of Medicinal Chemistry, 2018, 61, 3008-3026.	2.9	58
771	Prediction of Accurate Binding Modes Using Combination of Classical and Accelerated Molecular Dynamics and Free-Energy Perturbation Calculations: An Application to Toxicity Studies. ACS Omega, 2018, 3, 4357-4371.	1.6	22
772	Activity and selectivity cliffs for DPPâ€N inhibitors: Lessons we can learn from SAR studies and their application to virtual screening. Medicinal Research Reviews, 2018, 38, 1874-1915.	5.0	32
773	Characterization and engineering of a plastic-degrading aromatic polyesterase. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E4350-E4357.	3.3	632
774	Structure of the NDH-2 – HQNO inhibited complex provides molecular insight into quinone-binding site inhibitors. Biochimica Et Biophysica Acta - Bioenergetics, 2018, 1859, 482-490.	0.5	20
775	Integrating in vitro and in silico approaches to evaluate the "dual functionality―of palmatine chloride in inhibiting and disassembling Tau-derived VQIVYK peptide fibrils. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 1565-1575.	1.1	27
776	Discovery of new molecular entities able to strongly interfere with Hsp90 C-terminal domain. Scientific Reports, 2018, 8, 1709.	1.6	29
777	Insight on specificity of uracil permeases of the NAT/NCS2 family from analysis of the transporter encoded in the pyrimidine utilization operon of <i>Escherichia coli</i> . Molecular Microbiology, 2018, 108, 204-219.	1.2	16
778	Pharmacological profiling of sigma 1 receptor ligands by novel receptor homomer assays. Neuropharmacology, 2018, 133, 264-275.	2.0	50
779	The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders. Pharmacological Research, 2018, 129, 65-83.	3.1	117
780	Dopamine D3 receptor antagonist reveals a cryptic pocket in aminergic GPCRs. Scientific Reports, 2018, 8, 897.	1.6	39
781	Elucidation of the Binding Mode of the Carboxyterminal Region of Peptide YY to the Human Y <sub>2</sub> Receptor. Molecular Pharmacology, 2018, 93, 323-334.	1.0	28
782	Importance of protein flexibility in molecular recognition: a case study on Type-I1/2 inhibitors of ALK. Physical Chemistry Chemical Physics, 2018, 20, 4851-4863.	1.3	22
783	The action of a negative allosteric modulator at the dopamine D2 receptor is dependent upon sodium ions. Scientific Reports, 2018, 8, 1208.	1.6	16
784	Importance of protein flexibility on molecular recognition: modeling binding mechanisms of aminopyrazine inhibitors to Nek2. Physical Chemistry Chemical Physics, 2018, 20, 5591-5605.	1.3	15
785	Molecular determinants of loperamide and N-desmethyl loperamide binding in the hERG cardiac K+channel. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 446-451.	1.0	16
786	Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers. Pharmacological Research, 2018, 128, 1-17.	3.1	91

#	ARTICLE	IF	CITATIONS
787	The structural determinants of the bitopic binding mode of a negative allosteric modulator of the dopamine D 2 receptor. Biochemical Pharmacology, 2018, 148, 315-328.	2.0	26
788	Activity-based classification circumvents affinity prediction problems for pyrrolidine carboxamide inhibitors of InhA. Journal of Molecular Graphics and Modelling, 2018, 80, 76-84.	1.3	0
789	Synthesis, molecular docking and biological evaluation of some benzimidazole derivatives as potent pancreatic lipase inhibitors. Bioorganic Chemistry, 2018, 76, 478-486.	2.0	50
790	Assessing GPCR homology models constructed from templates of various transmembrane sequence identities: Binding mode prediction and docking enrichment. Journal of Molecular Graphics and Modelling, 2018, 80, 38-47.	1.3	19
791	Evidence for Novel Action at the Cellâ€Binding Site of Human Angiogenin Revealed by Heteronuclear NMR Spectroscopy, inâ€silico and inâ€vivo Studies. ChemMedChem, 2018, 13, 259-269.	1.6	22
792	Fiprole insecticide resistance of <scp><i>Laodelphax striatellus</i></scp> : electrophysiological and molecular docking characterization of A2′N RDL GABA receptors. Pest Management Science, 2018, 74, 2645-2651.	1.7	19
793	Structural dynamics and quantum mechanical aspects of shikonin derivatives as CREBBP bromodomain inhibitors. Journal of Molecular Graphics and Modelling, 2018, 83, 42-52.	1.3	39
794	High-performance virtual screening by targeting a high-resolution RNA dynamic ensemble. Nature Structural and Molecular Biology, 2018, 25, 425-434.	3.6	69
795	The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders. Pharmacological Research, 2018, 133, 35-52.	3.1	66
796	Computational structureâ€based drug design: Predicting target flexibility. Wiley Interdisciplinary Reviews: Computational Molecular Science, 2018, 8, e1367.	6.2	13
797	Synthesis, X-ray crystal structure studies and molecular docking analysis of 2-(3,4-dimethoxyphenyl)-4,5-diphenyl-1H-imidazole. Chemical Data Collections, 2018, 15-16, 67-74.	1.1	2
798	RosettaLigandEnsemble: A Small-Molecule Ensemble-Driven Docking Approach. ACS Omega, 2018, 3, 3655-3664.	1.6	21
799	Structural Investigation of the Dopamine-2 Receptor Agonist Bromocriptine Binding to Dimeric D2HighR and D2LowR States. Journal of Chemical Information and Modeling, 2018, 58, 826-836.	2.5	3
800	Docking-based inverse virtual screening: methods, applications, and challenges. Biophysics Reports, 2018, 4, 1-16.	0.2	99
801	Unveiling the Potential of Unfused Bichromophoric Naphthalimide To Induce Cytotoxicity by Binding to Tubulin: Breaks Monotony of Naphthalimides as Conventional Intercalators. Journal of Physical Chemistry B, 2018, 122, 3680-3695.	1.2	5
802	Analysis of Species-Selectivity of Human, Mouse and Rat Cytochrome P450 1A and 2B Subfamily Enzymes using Molecular Modeling, Docking and Dynamics Simulations. Cell Biochemistry and Biophysics, 2018, 76, 91-110.	0.9	1
803	Design, synthesis, and biological evaluation of a new class of benzo[ <i>b</i> ]furan derivatives as antiproliferative agents, with in silico predicted antitubulin activity. Chemical Biology and Drug Design, 2018, 91, 39-49.	1.5	5
804	Identification of novel Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitors using computational approaches. Journal of Biomolecular Structure and Dynamics, 2018, 36, 1306-1328.	2.0	2

#	Article	IF	CITATIONS
805	N-tert-butyloxycarbonyl-Phe-Leu-Phe-Leu-Phe (BOC2) inhibits the angiogenic activity of heparin-binding growth factors. Angiogenesis, 2018, 21, 47-59.	3.7	27
806	Presence of a consensus DNA motif at nearby DNA sequence of the mutation susceptible CG nucleotides. Gene, 2018, 639, 85-95.	1.0	12
807	Phytochemical analysis, molecular docking and antiamnesic effects of methanolic extract of Silybum marianum (L.) Gaertn seeds in scopolamine induced memory impairment in mice. Journal of Ethnopharmacology, 2018, 210, 198-208.	2.0	31
808	Selective Cannabinoid 2 Receptor Stimulation Reduces Tubular Epithelial Cell Damage after Renal Ischemia-Reperfusion Injury. Journal of Pharmacology and Experimental Therapeutics, 2018, 364, 287-299.	1.3	27
809	Kinetics of human cannabinoid 1 (CB1) receptor antagonists: Structure-kinetics relationships (SKR) and implications for insurmountable antagonism. Biochemical Pharmacology, 2018, 151, 166-179.	2.0	9
810	Structural model of the full-length Ser/Thr protein kinase StkP from S. pneumoniae and its recognition of peptidoglycan fragments. Journal of Biomolecular Structure and Dynamics, 2018, 36, 3666-3679.	2.0	9
811	Performance of multiple docking and refinement methods in the pose prediction D3R prospective Grand Challenge 2016. Journal of Computer-Aided Molecular Design, 2018, 32, 113-127.	1.3	7
812	Using physics-based pose predictions and free energy perturbation calculations to predict binding poses and relative binding affinities for FXR ligands in the D3R Grand Challenge 2. Journal of Computer-Aided Molecular Design, 2018, 32, 21-44.	1.3	23
813	Lessons learned in induced fit docking and metadynamics in the Drug Design Data Resource Grand Challenge 2. Journal of Computer-Aided Molecular Design, 2018, 32, 45-58.	1.3	18
814	A QM protein–ligand investigation of antipsychotic drugs with the dopamine D2 Receptor (D2R). Journal of Biomolecular Structure and Dynamics, 2018, 36, 2668-2677.	2.0	6
815	Development of a selective and highly sensitive fluorescence assay for nucleoside triphosphate diphosphohydrolase1 (NTPDase1, CD39). Analyst, The, 2018, 143, 5417-5430.	1.7	12
817	Exploring the Ligand Efficacy of Cannabinoid Receptor 1 (CB1) using Molecular Dynamics Simulations. Scientific Reports, 2018, 8, 13787.	1.6	25
819	A femtomolar-range suicide germination stimulant for the parasitic plant <i>Striga hermonthica</i> Science, 2018, 362, 1301-1305.	6.0	101
820	Inhibitor binding mode and allosteric regulation of Na+-glucose symporters. Nature Communications, 2018, 9, 5245.	5.8	35
821	Investigating the Selectivity of Allosteric Inhibitors for Mutant T790M EGFR over Wild Type Using Molecular Dynamics and Binding Free Energy Calculations. ACS Omega, 2018, 3, 16556-16562.	1.6	8
822	Computer-Aided Studies for Novel Arylhydantoin 1,3,5-Triazine Derivatives as 5-HT6 Serotonin Receptor Ligands with Antidepressive-Like, Anxiolytic and Antiobesity Action In Vivo. Molecules, 2018, 23, 2529.	1.7	18
823	Rescuing the CFTR protein function: Introducing 1,3,4-oxadiazoles as translational readthrough inducing drugs. European Journal of Medicinal Chemistry, 2018, 159, 126-142.	2.6	28
824	Pyrrolone Derivatives as Intracellular Allosteric Modulators for Chemokine Receptors: Selective and Dual-Targeting Inhibitors of CC Chemokine Receptors 1 and 2. Journal of Medicinal Chemistry, 2018, 61, 9146-9161.	2.9	21

#	Article	IF	Citations
825	$\mbox{}\mbox{ }\mbox{ }$	1.5	20
826	Modeling and Mutational Analysis of the Binding Mode for the Multimodal Antidepressant Drug Vortioxetine to the Human 5-HT <sub>3A</sub> Receptor. Molecular Pharmacology, 2018, 94, 1421-1434.	1.0	14
827	In vitro antioxidant activities of black cumin seeds oil and computational evaluation of thymoquinone and thymohydroquinone as inhibitors of EGFR tyrosine kinase., 2018,, 173-192.		1
828	Inhibitory effects of ascorbic acid toward snake venom metalloproteinase (SVMP) from Indian Echis carinatus venom: Insights from molecular modeling and binding studies. Journal of Biochemical and Molecular Toxicology, 2018, 32, e22224.	1.4	1
829	The trypanocidal benzoxaborole AN7973 inhibits trypanosome mRNA processing. PLoS Pathogens, 2018, 14, e1007315.	2.1	53
830	Structural Basis for (S)-3,4-Dicarboxyphenylglycine (DCPG) As a Potent and Subtype Selective Agonist of the mGlu8 Receptor. Journal of Medicinal Chemistry, 2018, 61, 10040-10052.	2.9	8
831	Probing the molecular basis for affinity/potency- and efficacy-based subtype-selectivity exhibited by benzodiazepine-site modulators at GABAA receptors. Biochemical Pharmacology, 2018, 158, 339-358.	2.0	6
832	Experimentally Validated Pharmacoinformatics Approach to Predict hERG Inhibition Potential of New Chemical Entities. Frontiers in Pharmacology, 2018, 9, 1035.	1.6	38
833	Design of a New α-1-C-Alkyl-DAB Derivative Acting as a Pharmacological Chaperone for β-Glucocerebrosidase Using Ligand Docking and Molecular Dynamics Simulation. Molecules, 2018, 23, 2683.	1.7	10
834	Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors. European Journal of Medicinal Chemistry, 2018, 158, 781-800.	2.6	58
835	4-Hydroxy-1,2,3-triazole moiety as bioisostere of the carboxylic acid function: a novel scaffold to probe the orthosteric $\hat{l}^3$ -aminobutyric acid receptor binding site. European Journal of Medicinal Chemistry, 2018, 158, 311-321.	2.6	27
836	A Chalcone-Based Potential Therapeutic Small Molecule That Binds to Subdomain IIA in HSA Precisely Controls the Rotamerization of Trp-214. ACS Omega, 2018, 3, 10114-10128.	1.6	7
837	Do new N-substituted 3-amino-4-phenyl-5-oxo-pyrazolinecarboxamide derivatives exhibit antitubercular potential?. European Journal of Pharmaceutical Sciences, 2018, 121, 155-165.	1.9	1
838	Identification of small-molecule EGFR allosteric inhibitors by high-throughput docking. Future Medicinal Chemistry, 2018, 10, 1545-1553.	1.1	21
839	Salvianolic acids from antithrombotic Traditional Chinese Medicine Danshen are antagonists of human P2Y1 and P2Y12 receptors. Scientific Reports, 2018, 8, 8084.	1.6	20
840	Exploring Substrate Binding in the Extracellular Vestibule of MhsT by Atomistic Simulations and Markov Models. Journal of Chemical Information and Modeling, 2018, 58, 1244-1252.	2.5	4
841	Structure-activity relationships in fungal nucleobases transporters as dissected by the inhibitory effects of novel purine analogues. European Journal of Medicinal Chemistry, 2018, 156, 240-251.	2.6	4
842	Identification of a Potent Tryptophan-Based TRPM8 Antagonist With in Vivo Analgesic Activity. Journal of Medicinal Chemistry, 2018, 61, 6140-6152.	2.9	31

#	Article	IF	CITATIONS
843	Exploration of Benzothiazole Rhodacyanines as Allosteric Inhibitors of Protein–Protein Interactions with Heat Shock Protein 70 (Hsp70). Journal of Medicinal Chemistry, 2018, 61, 6163-6177.	2.9	84
844	Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human $\hat{l}^2$ -Cell Proliferation. Journal of Medicinal Chemistry, 2018, 61, 7687-7699.	2.9	58
845	Structural Changes Due to Antagonist Binding in Ligand Binding Pocket of Androgen Receptor Elucidated Through Molecular Dynamics Simulations. Frontiers in Pharmacology, 2018, 9, 492.	1.6	28
846	The Use of Dynamic Pharmacophore in Computer-Aided Hit Discovery: A Case Study. Methods in Molecular Biology, 2018, 1824, 317-333.	0.4	1
847	A Computational workflow for the identification of the potent inhibitor of type II secretion system traffic ATPase of Pseudomonas aeruginosa. Computational Biology and Chemistry, 2018, 76, 191-201.	1.1	10
848	Identification, structure modification, and characterization of potential small-molecule SGK3 inhibitors with novel scaffolds. Acta Pharmacologica Sinica, 2018, 39, 1902-1912.	2.8	9
849	3-(2-Carboxyethyl)indole-2-carboxylic Acid Derivatives: Structural Requirements and Properties of Potent Agonists of the Orphan G Protein-Coupled Receptor GPR17. Journal of Medicinal Chemistry, 2018, 61, 8136-8154.	2.9	19
850	Application of Virtual Screening Approaches for the Identification of Small Molecule Inhibitors of the Methyllysine Reader Protein Spindlin1. Methods in Molecular Biology, 2018, 1824, 347-370.	0.4	5
851	Angiotensin II Type 1 Receptor Homology Models: A Comparison Between In Silico and the Crystal Structures. Methods in Molecular Biology, 2018, 1824, 449-460.	0.4	1
852	Evolutionary Analysis Provides Insight Into the Origin and Adaptation of HCV. Frontiers in Microbiology, 2018, 9, 854.	1.5	15
853	Discovery of Mcl-1 inhibitors from integrated high throughput and virtual screening. Scientific Reports, 2018, 8, 10210.	1.6	13
854	Synthesis, Design, and Structure–Activity Relationship of the Pyrimidone Derivatives as Novel Selective Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase. Molecules, 2018, 23, 1254.	1.7	11
855	In Silico Screening of Isocitrate Lyase for Novel Anti-Buruli Ulcer Natural Products Originating from Africa. Molecules, 2018, 23, 1550.	1.7	29
856	Selectivity Challenges in Docking Screens for GPCR Targets and Antitargets. Journal of Medicinal Chemistry, 2018, 61, 6830-6845.	2.9	31
857	Structural Flexibility in HCV NS5B Polymerase and Molecular Modelling of Anti-HCV Drugs. Current Chemical Biology, 2018, 12, 65-87.	0.2	2
858	Reverse screening on indicaxanthin from Opuntia ficus-indica as natural chemoactive and chemopreventive agent. Journal of Theoretical Biology, 2018, 455, 147-160.	0.8	26
859	Flexibility of Important HIV-1 Targets and in silico Design of anti- HIV Drugs. Current Chemical Biology, 2018, 12, 23-39.	0.2	1
860	Structure Based Virtual Screening Studies to Identify Novel Potential Compounds for GPR142 and Their Relative Dynamic Analysis for Study of Type 2 Diabetes. Frontiers in Chemistry, 2018, 6, 23.	1.8	40

#	Article	IF	CITATIONS
861	Quantum Chemical Approaches in Structure-Based Virtual Screening and Lead Optimization. Frontiers in Chemistry, 2018, 6, 188.	1.8	61
862	Antimetastatic effect of the pharmacological inhibition of serine/arginine-rich protein kinases (SRPK) in murine melanoma. Toxicology and Applied Pharmacology, 2018, 356, 214-223.	1.3	17
863	The LeuT-fold neurotransmitter:sodium symporter MhsT has two substrate sites. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7924-E7931.	3.3	21
864	Selection of protein conformations for structure-based polypharmacology studies. Drug Discovery Today, 2018, 23, 1889-1896.	3.2	22
865	Protein–small molecule docking with receptor flexibility in iMOLSDOCK. Journal of Computer-Aided Molecular Design, 2018, 32, 889-900.	1.3	3
866	Identification of Compounds That Decrease Glioblastoma Growth and Glucose Uptake <i>in Vitro</i> ACS Chemical Biology, 2018, 13, 2048-2057.	1.6	24
867	Computational Approaches to Studying Voltage-Gated Ion Channel Modulation by General Anesthetics. Methods in Enzymology, 2018, 602, 25-59.	0.4	3
868	Probing the "fingers―domain binding pocket of Hepatitis C virus NS5B RdRp and D559G resistance mutation via molecular docking, molecular dynamics simulation and binding free energy calculations. Journal of Biomolecular Structure and Dynamics, 2019, 37, 2440-2456.	2.0	11
869	Design of novel quinoline-aminopiperidine derivatives as <i>Mycobacterium tuberculosis</i> (MTB) GyrB inhibitors: an <i>in silico</i> study. Journal of Biomolecular Structure and Dynamics, 2019, 37, 2913-2925.	2.0	7
870	Molecular modeling of neurological membrane proteins â^ from binding sites to synapses. Neuroscience Letters, 2019, 700, 38-49.	1.0	3
871	Mathematical deep learning for pose and binding affinity prediction and ranking in D3R Grand Challenges. Journal of Computer-Aided Molecular Design, 2019, 33, 71-82.	1.3	106
872	Understanding the binding of quinoline amines with human serum albumin by spectroscopic and induced fit docking methods. Journal of Biomolecular Structure and Dynamics, 2019, 37, 2753-2765.	2.0	7
873	Discovery and development of substituted thiadiazoles as inhibitors of Staphylococcus aureus Sortase A. Bioorganic and Medicinal Chemistry, 2019, 27, 115043.	1.4	13
874	Characteristics of flavonoids as potent MERSâ€CoV 3Câ€like protease inhibitors. Chemical Biology and Drug Design, 2019, 94, 2023-2030.	1.5	191
875	New amide linked dimeric 1,2,3-triazoles bearing aryloxy scaffolds as a potent antiproliferative agents and EGFR tyrosine kinase phosphorylation inhibitors. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 126618.	1.0	23
876	In Silico Repositioning of Cannabigerol as a Novel Inhibitor of the Enoyl Acyl Carrier Protein (ACP) Reductase (InhA). Molecules, 2019, 24, 2567.	1.7	22
877	Long-Lasting Anti-Inflammatory and Antinociceptive Effects of Acute Ammonium Glycyrrhizinate Administration: Pharmacological, Biochemical, and Docking Studies. Molecules, 2019, 24, 2453.	1.7	26
878	Strategies to develop selective CB2 receptor agonists from indole carboxamide synthetic cannabinoids. European Journal of Medicinal Chemistry, 2019, 180, 291-309.	2.6	19

#	Article	IF	CITATIONS
879	Molecular Docking Guided Grid-Independent Descriptor Analysis to Probe the Impact of Water Molecules on Conformational Changes of hERG Inhibitors in Drug Trapping Phenomenon. International Journal of Molecular Sciences, 2019, 20, 3385.	1.8	15
880	Discovery of Novel Naphthylphenylketone and Naphthylphenylamine Derivatives as Cell Division Cycle 25B (CDC25B) Phosphatase Inhibitors: Design, Synthesis, Inhibition Mechanism, and in Vitro Efficacy against Melanoma Cell Lines. Journal of Medicinal Chemistry, 2019, 62, 7089-7110.	2.9	15
881	Isoform-specific Inhibition of N-methyl-D-aspartate Receptors by Bile Salts. Scientific Reports, 2019, 9, 10068.	1.6	9
882	NU-6027 Inhibits Growth of Mycobacterium tuberculosis by Targeting Protein Kinase D and Protein Kinase G. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	34
883	Novel multitarget 5-arylidenehydantoins with arylpiperazinealkyl fragment: Pharmacological evaluation and investigation of cytotoxicity and metabolic stability. Bioorganic and Medicinal Chemistry, 2019, 27, 4163-4173.	1.4	8
884	Molecular Informatics Studies of the Iron-Dependent Regulator (ideR) Reveal Potential Novel Anti-Mycobacterium ulcerans Natural Product-Derived Compounds. Molecules, 2019, 24, 2299.	1.7	7
885	Computational aided mechanistic understanding of Camellia sinensis bioactive compounds against coâ€chaperone p23 as potential anticancer agent. Journal of Cellular Biochemistry, 2019, 120, 19064-19075.	1.2	15
886	The Route to  Chemobrain' - Computational probing of neuronal LTP pathway. Scientific Reports, 2019, 9, 9630.	1.6	6
887	In Silico Insights towards the Identification of NLRP3 Druggable Hot Spots. International Journal of Molecular Sciences, 2019, 20, 4974.	1.8	18
888	Design and Selection of Novel C1s Inhibitors by In Silico and In Vitro Approaches. Molecules, 2019, 24, 3641.	1.7	11
889	Novel influenza polymerase PB2 inhibitors for the treatment of influenza A infection. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 126639.	1.0	8
890	DRUDIT: web-based DRUgs Discovery Tools to design small molecules as modulators of biological targets. Bioinformatics, 2019, 36, 1562-1569.	1.8	20
891	Discovery of Novel Pim-1 Kinase Inhibitors with a Flexible-Receptor Docking Protocol. Journal of Chemical Information and Modeling, 2019, 59, 4116-4119.	2.5	15
892	High-potency ligands for DREADD imaging and activation in rodents and monkeys. Nature Communications, 2019, 10, 4627.	5.8	128
893	Paeoniflorigenone purified from Paeonia daurica roots potently inhibits viral and bacterial DNA polymerases: investigation by experimental validation and docking simulation. Medicinal Chemistry Research, 2019, 28, 2232-2245.	1.1	8
894	Accelerated Structural Prediction of Flexible Protein–Ligand Complexes: The SLICE Method. Journal of Chemical Information and Modeling, 2019, 59, 5263-5275.	2.5	3
895	Synthesis, biology, computational studies and <i>in vitro</i> controlled release of new isoniazid-based adamantane derivatives. Future Medicinal Chemistry, 2019, 11, 2779-2802.	1.1	4
896	NAD <sup>+</sup> cleavage activity by animal and plant TIR domains in cell death pathways. Science, 2019, 365, 793-799.	6.0	357

#	Article	IF	CITATIONS
897	Synthesis, biological evaluation and molecular modeling of novel selective COX-2 inhibitors: sulfide, sulfoxide, and sulfone derivatives of 1,5-diarylpyrrol-3-substituted scaffold. Bioorganic and Medicinal Chemistry, 2019, 27, 115045.	1.4	21
898	Production of metabolites of the anti-cancer drug noscapine using a P450BM3 mutant library. Biotechnology Reports (Amsterdam, Netherlands), 2019, 24, e00372.	2.1	12
899	4D- quantitative structure–activity relationship modeling: making a comeback. Expert Opinion on Drug Discovery, 2019, 14, 1227-1235.	2.5	23
900	Pharmacoinformatics-based identification of potential bioactive compounds against Ebola virus protein VP24. Computers in Biology and Medicine, 2019, 113, 103414.	3.9	32
901	Inclusion of enclosed hydration effects in the binding free energy estimation of dopamine D3 receptor complexes. PLoS ONE, 2019, 14, e0222902.	1.1	9
902	Discovery of novel West Nile Virus protease inhibitor based on isobenzonafuranone and triazolic derivatives of eugenol and indan-1,3-dione scaffolds. PLoS ONE, 2019, 14, e0223017.	1.1	15
903	Novel inhibitors of leukocyte transendothelial migration. Bioorganic Chemistry, 2019, 92, 103250.	2.0	31
904	Structure-activity relationship study of NPP1 inhibitors based on uracil-N1-(methoxy)ethyl-Î <sup>2</sup> -phosphate scaffold. European Journal of Medicinal Chemistry, 2019, 184, 111754.	2.6	8
905	Investigation of Phospholipase $\hat{Cl^3}$ 1 Interaction with SLP76 Using Molecular Modeling Methods for Identifying Novel Inhibitors. International Journal of Molecular Sciences, 2019, 20, 4721.	1.8	5
906	Potent and highly selective dualâ€targeting monoamine oxidaseâ€B inhibitors: Fluorinated chalcones of morpholine versus imidazole. Archiv Der Pharmazie, 2019, 352, e1800309.	2.1	44
907	An IRAK1–PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy. Nature Cell Biology, 2019, 21, 203-213.	4.6	38
908	Benzylamides and piperazinoarylamides of ibuprofen as fatty acid amide hydrolase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 562-576.	2.5	6
909	Molecular Basis of Action of a Small-Molecule Positive Allosteric Modulator Agonist at the Type 1 Cholecystokinin Holoreceptor. Molecular Pharmacology, 2019, 95, 245-259.	1.0	5
910	Novel Approach for the Search for Chemical Scaffolds with Activity at Both Acetylcholinesterase and the $\hat{1}\pm7$ Nicotinic Acetylcholine Receptor: A Perspective on Scaffolds with Dual Activity for the Treatment of Neurodegenerative Disorders. Molecules, 2019, 24, 446.	1.7	13
911	Synthesis and structure-activity relationship of elastase inhibiting novel ethylated thiazole-triazole acetamide hybrids: Mechanistic insights through kinetics and computational contemplations. Bioorganic Chemistry, 2019, 86, 197-209.	2.0	18
912	Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT <sub>1A</sub> Receptor-Biased Agonists with Robust Antidepressant-like Activity. Journal of Medicinal Chemistry, 2019. 62. 2750-2771.	2.9	21
913	Establishing Drug Discovery and Identification of Hit Series for the Anti-apoptotic Proteins, Bcl-2 and Mcl-1. ACS Omega, 2019, 4, 8892-8906.	1.6	35
914	Targeting the neuronal calcium sensor DREAM with small-molecules for Huntington's disease treatment. Scientific Reports, 2019, 9, 7260.	1.6	15

#	Article	IF	CITATIONS
915	The search of potential inhibitors of the AcrAB–TolC system of multidrug-resistant Escherichia coli: an in silico approach. Applied Microbiology and Biotechnology, 2019, 103, 6309-6318.	1.7	26
916	Teratogenic jervine increases the activity of doxorubicin in MCF-7/ADR cells by inhibiting ABCB1. Biomedicine and Pharmacotherapy, 2019, 117, 109059.	2.5	7
917	An explorative study on <i>Staphylococcus aureus</i> MurE inhibitor: induced fit docking, binding free energy calculation, and molecular dynamics. Journal of Receptor and Signal Transduction Research, 2019, 39, 45-54.	1.3	5
918	Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia. Nature Communications, 2019, 10, 2691.	5.8	93
919	Discovery and characterization of trypanocidal cysteine protease inhibitors from the †malaria boxâ€. European Journal of Medicinal Chemistry, 2019, 179, 765-778.	2.6	19
920	Induction of cell cycle arrest and apoptosis by copper complex Cu(SBCM) <sub>2</sub> towards oestrogen-receptor positive MCF-7 breast cancer cells. RSC Advances, 2019, 9, 18359-18370.	1.7	31
921	Ligand discrimination during virtual screening of the CB1 cannabinoid receptor crystal structures following cross-docking and microsecond molecular dynamics simulations. RSC Advances, 2019, 9, 15949-15956.	1.7	10
922	Synthesis and biological evaluation of indole-2-carbohydrazides and thiazolidinyl-indole-2-carboxamides as potent tubulin polymerization inhibitors. Computational Biology and Chemistry, 2019, 80, 512-523.	1.1	11
923	Molecular Basis for Ligand Modulation of a Mammalian Voltage-Gated Ca2+ Channel. Cell, 2019, 177, 1495-1506.e12.	13.5	172
924	Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity. PLoS ONE, 2019, 14, e0217789.	1.1	30
925	A Machine Learning Approach for the Discovery of Ligand-Specific Functional Mechanisms of GPCRs. Molecules, 2019, 24, 2097.	1.7	35
926	Application of Free Energy Perturbation (FEP+) to Understanding Ligand Selectivity: A Case Study to Assess Selectivity Between Pairs of Phosphodiesterases (PDE's). Journal of Chemical Information and Modeling, 2019, 59, 2729-2740.	2.5	20
927	Hierarchical-Clustering, Scaffold-Mining Exercises and Dynamics Simulations for Effectual Inhibitors Against Lipid-A Biosynthesis of Helicobacter pylori. Cellular and Molecular Bioengineering, 2019, 12, 255-274.	1.0	10
928	Understanding the Binding Mechanism of a Pyrazino[1,2â€a]indole Derivative with Calf Thymus DNA. ChemistrySelect, 2019, 4, 5214-5221.	0.7	8
929	Importance of protein dynamics in the structure-based drug discovery of class A G protein-coupled receptors (GPCRs). Current Opinion in Structural Biology, 2019, 55, 147-153.	2.6	33
930	Molecular interaction of silicon quantum dot micelles with plasma proteins: hemoglobin and thrombin. RSC Advances, 2019, 9, 14928-14936.	1.7	11
931	Discovery of potential lumazine synthase antagonists for pathogens involved in bacterial meningitis: In silico study. Informatics in Medicine Unlocked, 2019, 15, 100187.	1.9	10
932	Pyridinylimidazoles as dual glycogen synthase kinase $3\hat{l}^2/p38\hat{l}\pm$ mitogen-activated protein kinase inhibitors. European Journal of Medicinal Chemistry, 2019, 175, 309-329.	2.6	26

#	Article	IF	CITATIONS
933	Computational modeling of the olfactory receptor Olfr73 suggests a molecular basis for low potency of olfactory receptor-activating compounds. Communications Biology, 2019, 2, 141.	2.0	25
934	Fluoro-benzimidazole derivatives to cure Alzheimer's disease: In-silico studies, synthesis, structure-activity relationship and in vivo evaluation for β secretase enzyme inhibition. Bioorganic Chemistry, 2019, 88, 102936.	2.0	12
935	Evaluation of caffeine as inhibitor against collagenase, elastase and tyrosinase using <i>in silico</i> and <i>in vitro</i> approach. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 927-936.	2.5	53
936	Importance of Incorporating Protein Flexibility in Molecule Modeling: A Theoretical Study on Type I1/2 NIK Inhibitors. Frontiers in Pharmacology, 2019, 10, 345.	1.6	11
937	The compromise of virtual screening and its impact on drug discovery. Expert Opinion on Drug Discovery, 2019, 14, 619-637.	2.5	59
938	Dual 5-HT <sub>6</sub> and D <sub>3</sub> Receptor Antagonists in a Group of 1 <i>H</i> Chemical Neuroscience, 2019, 10, 3183-3196.	1.7	24
939	Fusicoccane Diterpenes from Hypoestes forsskaolii as Heat Shock Protein 90 (Hsp90) Modulators. Journal of Natural Products, 2019, 82, 539-549.	1.5	24
940	Development of Covalent Ligands for G Protein-Coupled Receptors: A Case for the Human Adenosine A <sub>3</sub> Receptor. Journal of Medicinal Chemistry, 2019, 62, 3539-3552.	2.9	31
941	Can multiscale simulations unravel the function of metallo-enzymes to improve knowledge-based drug discovery?. Future Medicinal Chemistry, 2019, 11, 771-791.	1.1	9
942	Difluoromethylene at the $\hat{I}^3$ -Lactam $\hat{I}$ ±-Position Improves 11-Deoxy-8-aza-PGE <sub>1</sub> Series EP <sub>4</sub> Receptor Binding and Activity: 11-Deoxy-10,10-difluoro-8-aza-PGE <sub>1</sub> Analog (KMN-159) as a Potent EP <sub>4</sub> Agonist. Journal of Medicinal Chemistry, 2019, 62, 4731-4741.	2.9	23
943	Evaluating the performance of MM/PBSA for binding affinity prediction using class A GPCR crystal structures. Journal of Computer-Aided Molecular Design, 2019, 33, 487-496.	1.3	15
944	Potent and selective EGFR inhibitors based on 5-aryl-7H-pyrrolopyrimidin-4-amines. Bioorganic Chemistry, 2019, 88, 102918.	2.0	10
945	Haptic-Assisted Interactive Molecular Docking Incorporating Receptor Flexibility. Journal of Chemical Information and Modeling, 2019, 59, 2900-2912.	2.5	15
946	G-protein-coupled receptors function as logic gates for nanoparticle binding using systems and synthetic biology approach. Journal of Materials Research, 2019, 34, 1854-1867.	1.2	3
947	Exploration of N5-CAIR Mutase Novel Inhibitors from <i>Pyrococcus horikoshii</i> Computational Study. Journal of Computational Biology, 2019, 26, 457-472.	0.8	2
948	Quantum chemical calculation and binding modes of H1R; a combined study of molecular docking and DFT for suggesting therapeutically potent H1R antagonist. In Silico Pharmacology, 2019, 7, 1.	1.8	8
949	Substrate and inhibitor binding to the serotonin transporter: Insights from computational, crystallographic, and functional studies. Neuropharmacology, 2019, 161, 107548.	2.0	15
950	Structure of Outward-Facing PglK and Molecular Dynamics of Lipid-Linked Oligosaccharide Recognition and Translocation. Structure, 2019, 27, 669-678.e5.	1.6	29

#	Article	IF	CITATIONS
951	Roles of computational modelling in understanding p53 structure, biology, and its therapeutic targeting. Journal of Molecular Cell Biology, 2019, 11, 306-316.	1.5	25
952	Rational design of allosteric modulators of the aromatase enzyme: AnÂunprecedented therapeutic strategy to fight breast cancer. European Journal of Medicinal Chemistry, 2019, 168, 253-262.	2.6	33
953	Selective Inhibition of Human Monoamine Oxidase B by Acacetin 7-Methyl Ether Isolated from Turnera diffusa (Damiana). Molecules, 2019, 24, 810.	1.7	36
954	Molecular features of steroid-binding antidins and their use for assaying serum progesterone. PLoS ONE, 2019, 14, e0212339.	1.1	2
955	Computational prediction methods to simulate structure and binding sites of coumarin with olfactory receptor 5P3. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2019, 82, 1199-1206.	1.1	0
956	Synthesis and Pharmacological Evaluation of Triazolopyrimidinone Derivatives as Noncompetitive, Intracellular Antagonists for CC Chemokine Receptors 2 and 5. Journal of Medicinal Chemistry, 2019, 62, 11035-11053.	2.9	11
957	Calculation of absolute binding free energies between the hERG channel and structurally diverse drugs. Scientific Reports, 2019, 9, 16586.	1.6	30
958	Mechanism of Small Molecules Inhibiting Activator Protein-1 DNA Binding Probed with Induced Fit Docking and Metadynamics Simulations. Journal of Chemical Information and Modeling, 2019, 59, 5276-5280.	2.5	10
959	Specific Residues in a Purine Transporter Are Critical for Dimerization, ER Exit, and Function. Genetics, 2019, 213, 1357-1372.	1.2	9
960	Discovery of Ganoderma lucidum triterpenoids as potential inhibitors against Dengue virus NS2B-NS3 protease. Scientific Reports, 2019, 9, 19059.	1.6	75
961	Structural Basis for the Interaction and Processing of $\hat{l}^2$ -Lactam Antibiotics by I,d-Transpeptidase 3 (LdtMt3) from Mycobacterium tuberculosis. ACS Infectious Diseases, 2019, 5, 260-271.	1.8	8
962	Modified rivaroxaban microparticles for solid state properties improvement based on drug-protein/polymer supramolecular interactions. Powder Technology, 2019, 344, 819-829.	2.1	11
963	Exploring the Binding Interaction Mechanism of Taxol in $\hat{l}^2$ -Tubulin and Bovine Serum Albumin: A Biophysical Approach. Molecular Pharmaceutics, 2019, 16, 669-681.	2.3	33
964	Structural insights into ligand binding features of dual FABP4/5 inhibitors by molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics, 2019, 37, 4790-4800.	2.0	9
965	Activation of atypical protein kinase C by sphingosine 1-phosphate revealed by an aPKC-specific activity reporter. Science Signaling, 2019, 12, .	1.6	41
966	Computation-guided analysis of paroxetine binding to hSERT reveals functionally important structural elements and dynamics. Neuropharmacology, 2019, 161, 107411.	2.0	21
967	Comparative Binding Analysis of <i>N</i> -Acetylneuraminic Acid in Bovine Serum Albumin and Human α-1 Acid Glycoprotein. Journal of Chemical Information and Modeling, 2019, 59, 326-338.	2.5	26
968	Optimization of a 1,3,4-oxadiazole series for inhibition of Ca2+/calmodulin-stimulated activity of adenylyl cyclases 1 and 8 for the treatment of chronic pain. European Journal of Medicinal Chemistry, 2019, 162, 568-585.	2.6	22

#	Article	IF	CITATIONS
969	Enzymatic synthesis of non-natural trisaccharides and galactosides; Insights of their interaction with galectins as a function of their structure. Carbohydrate Research, 2019, 472, 1-15.	1.1	3
970	Cross-talk between allosteric and orthosteric binding sites of $\hat{l}^3$ -amino butyric acid type A receptors (GABA <sub>A</sub> -Rs): A computational study revealing the structural basis of selectivity. Journal of Biomolecular Structure and Dynamics, 2019, 37, 3065-3080.	2.0	5
971	Biological evaluation of isoflavonoids from Genista halacsyi using estrogen-target cells: Activities of glucosides compared to aglycones. PLoS ONE, 2019, 14, e0210247.	1.1	10
972	Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters. Psychopharmacology, 2019, 236, 939-952.	1.5	42
973	An in silico approach to discover the best molecular modeling strategy for designing novelCDK4 inhibitors. Chemical Biology and Drug Design, 2019, 93, 556-569.	1.5	2
974	Ginsenosides Act As Positive Modulators of P2X4 Receptors. Molecular Pharmacology, 2019, 95, 210-221.	1.0	23
975	Ligand binding to human prostaglandin E receptor EP4 at the lipid-bilayer interface. Nature Chemical Biology, 2019, 15, 18-26.	3.9	85
976	Identification of Selective Acyl Sulfonamide–Cycloalkylether Inhibitors of the Voltage-Gated Sodium Channel (Na <sub>V</sub> ) 1.7 with Potent Analgesic Activity. Journal of Medicinal Chemistry, 2019, 62, 908-927.	2.9	25
977	Rationalization of stereoselectivity in enzyme reactions. Wiley Interdisciplinary Reviews: Computational Molecular Science, 2019, 9, e1403.	6.2	5
978	Reliability of Docking-Based Virtual Screening for GPCR Ligands with Homology Modeled Structures: A Case Study of the Angiotensin II Type I Receptor. ACS Chemical Neuroscience, 2019, 10, 677-689.	1.7	23
979	<i>In silico</i> development of new acetylcholinesterase inhibitors. Journal of Biomolecular Structure and Dynamics, 2019, 37, 1007-1021.	2.0	15
980	The dynamic properties of angiotensin II type 1 receptor inverse agonists in solution and in the receptor site. Arabian Journal of Chemistry, 2019, 12, 5062-5078.	2.3	19
981	Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist. Journal of Biomolecular Structure and Dynamics, 2020, 38, 32-47.	2.0	23
982	Characterization of medicinal plant-associated biocontrol Bacillus subtilis (SSL2) by liquid chromatography-mass spectrometry and evaluation of compounds by in silico and in vitro methods. Journal of Biomolecular Structure and Dynamics, 2020, 38, 500-510.	2.0	5
983	Binding and stability of indirubin-3-monoxime in the GSK3β enzyme: a molecular dynamics simulation and binding free energy study. Journal of Biomolecular Structure and Dynamics, 2020, 38, 957-974.	2.0	10
984	Purpurin modulates Tau-derived VQIVYK fibrillization and ameliorates Alzheimer's disease-like symptoms in animal model. Cellular and Molecular Life Sciences, 2020, 77, 2795-2813.	2.4	46
985	Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R). Journal of Medicinal Chemistry, 2020, 63, 2292-2307.	2.9	21
986	Exploring the potent inhibitors and binding modes of phospholipase A2 through in silico investigation. Journal of Biomolecular Structure and Dynamics, 2020, 38, 4221-4231.	2.0	27

#	Article	IF	CITATIONS
987	Synthesis and biological evaluation of $1,2,4$ -triazolidine- $3$ -thiones as potent acetylcholinesterase inhibitors: in vitro and in silico analysis through kinetics, chemoinformatics and computational approaches. Molecular Diversity, 2020, 24, 1185-1203.	2.1	11
988	Design, synthesis, in silico and in vitro evaluation of novel diphenyl ether derivatives as potential antitubercular agents. Molecular Diversity, 2020, 24, 1265-1279.	2.1	3
989	Combinatorial inhibition of Angiotensin converting enzyme, Neutral endopeptidase and Aminopeptidase N by N-methylated peptides alleviates blood pressure and fibrosis in rat model of dexamethasone-induced hypertension. Peptides, 2020, 123, 170180.	1,2	9
990	Inhibition of SARS-CoV 3CL protease by flavonoids. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 145-151.	2.5	508
991	Superior inhibition of influenza virus hemagglutinin-mediated fusion by indole-substituted spirothiazolidinones. Bioorganic and Medicinal Chemistry, 2020, 28, 115130.	1.4	20
992	Designing Antiviral Substances Targeting the Ebola Virus Viral Protein 24., 2020, , 147-177.		1
993	Virtual screening-driven discovery of dual 5-HT6/5-HT2A receptor ligands with pro-cognitive properties. European Journal of Medicinal Chemistry, 2020, 185, 111857.	2.6	26
994	Characterisation of the binding of dihydro-alpha-lipoic acid to fibrinogen and the effects on fibrinogen oxidation and fibrin formation. International Journal of Biological Macromolecules, 2020, 147, 319-325.	3.6	9
995	In silico analysis of alternative splicing on drug-target gene interactions. Scientific Reports, 2020, 10, 134.	1.6	11
996	Ranolazine may exert its beneficial effects by increasing myocardial adenosine levels. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H189-H202.	1.5	13
997	Design and synthesis of cyanamides as potent and selective N-acylethanolamine acid amidase inhibitors. Bioorganic and Medicinal Chemistry, 2020, 28, 115195.	1.4	17
998	Benzodioxaneâ€Benzamides as Antibacterial Agents: Computational and SAR Studies to Evaluate the Influence of the 7â€Substitution in FtsZ Interaction. ChemMedChem, 2020, 15, 195-209.	1.6	16
999	Steroid sulfatase inhibiting lanostane triterpenes – Structure activity relationship and in silico insights. Bioorganic Chemistry, 2020, 95, 103495.	2.0	11
1000	Identification of novel flavonoid inhibitor of Catechol-O-Methyltransferase enzyme by molecular screening, quantum mechanics/molecular mechanics and molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics, 2020, 38, 5307-5319.	2.0	8
1001	Towards discovery of new leishmanicidal scaffolds able to inhibit <i>Leishmania</i> GSK-3. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 199-210.	2.5	12
1002	Computational and In Vitro Investigation of (-)-Epicatechin and Proanthocyanidin B2 as Inhibitors of Human Matrix Metalloproteinase 1. Biomolecules, 2020, 10, 1379.	1.8	13
1003	Exploring the SARS-CoV-2 Proteome in the Search of Potential Inhibitors via Structure-Based Pharmacophore Modeling/Docking Approach. Computation, 2020, 8, 77.	1.0	30
1004	Discovery of a stable tripeptide targeting the N-domain of CRF1 receptor. Amino Acids, 2020, 52, 1337-1351.	1.2	0

#	Article	IF	CITATIONS
1005	Structure based pharmacophore modelling approach for the design of azaindole derivatives as DprE1 inhibitors for tuberculosis. Journal of Molecular Graphics and Modelling, 2020, 101, 107718.	1.3	15
1006	Evidence for a Stereoselective Mechanism for Bitopic Activity by Extended-Length Antagonists of the D <sub>3</sub> Dopamine Receptor. ACS Chemical Neuroscience, 2020, 11, 3309-3320.	1.7	13
1007	Potential therapeutic effect of turmeric contents against SARS-CoV-2 compared with experimental COVID-19 therapies: in silico study. Journal of Biomolecular Structure and Dynamics, 2022, 40, 2024-2037.	2.0	27
1008	Regioisomerization of Antimalarial Drug WR99210 Explains the Inactivity of a Commercial Stock. Antimicrobial Agents and Chemotherapy, 2020, 65, .	1.4	3
1009	Setup and Validation of a Reliable Docking Protocol for the Development of Neuroprotective Agents by Targeting the Sigma-1 Receptor (S1R). International Journal of Molecular Sciences, 2020, 21, 7708.	1.8	6
1010	In Silico Molecular Study of Tryptophan Bitterness. Molecules, 2020, 25, 4623.	1.7	8
1011	Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2–P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach. Journal of Molecular Graphics and Modelling, 2020, 101, 107730.	1.3	21
1012	Adenosine Receptor Ligands: Coumarin–Chalcone Hybrids as Modulating Agents on the Activity of hARs. Molecules, 2020, 25, 4306.	1.7	8
1013	Enhancement of glioblastoma multiforme therapy through a novel Quercetin-Losartan hybrid. Free Radical Biology and Medicine, 2020, 160, 391-402.	1.3	16
1014	Polyamines and its analogue modulates amyloid fibrillation in lysozyme: A comparative investigation. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129557.	1.1	7
1015	Computational studies of potent covalent inhibitors on wild type or T790M/L858R mutant epidermal growth factor receptor. European Journal of Pharmaceutical Sciences, 2020, 152, 105463.	1.9	6
1016	Structure-based discovery of small molecule APC-Asef interaction inhibitors: In silico approaches and molecular dynamics simulations. Journal of Molecular Modeling, 2020, 26, 207.	0.8	5
1017	Design and synthesis of pinane oxime derivatives as novel anti-influenza agents. Bioorganic Chemistry, 2020, 102, 104106.	2.0	5
1018	Design, synthesis, and biological evaluation of 5-((8-methoxy-2-methylquinolin-4-yl)amino)-1H-indole-2-carbohydrazide derivatives as novel Nur77 modulators. European Journal of Medicinal Chemistry, 2020, 204, 112608.	2.6	16
1019	A study of Rose Bengal against a 2-keto-3-deoxy-d-manno-octulosonate cytidylyltransferase as an antibiotic candidate. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 1414-1421.	2.5	3
1020	Selective Interactions of O-Methylated Flavonoid Natural Products with Human Monoamine Oxidase-A and -B. Molecules, 2020, 25, 5358.	1.7	10
1021	Photoswitchable Azo- and Diazocine-Functionalized Derivatives of the VEGFR-2 Inhibitor Axitinib. International Journal of Molecular Sciences, 2020, 21, 8961.	1.8	27
1022	Structure-activity relationship studies and bioactivity evaluation of 1,2,3-triazole containing analogues as a selective sphingosine kinase-2 inhibitors. European Journal of Medicinal Chemistry, 2020, 206, 112713.	2.6	8

#	Article	IF	CITATIONS
1023	Synthesis, computational studies and enzyme inhibitory kinetics of benzothiazole-linked thioureas as mushroom tyrosinase inhibitors. Journal of Biomolecular Structure and Dynamics, 2021, 39, 7035-7043.	2.0	11
1024	Structure-based evolution of a promiscuous inhibitor to a selective stabilizer of protein–protein interactions. Nature Communications, 2020, 11, 3954.	5.8	35
1025	In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection. Viruses, 2020, 12, 805.	1.5	13
1026	A comparative study of the binding modes of SLC-0111 and its analogues in the hCA II and hCA IX active sites using QM/MM, molecular docking, MM-GBSA and MD approaches. Biophysical Chemistry, 2020, 265, 106439.	1.5	9
1027	Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 1539-1544.	2.5	113
1028	Cinnamic acid derivatives as chemosensitising agents against DOX-treated lung cancer cells – Involvement of carbonyl reductase 1. European Journal of Pharmaceutical Sciences, 2020, 154, 105511.	1.9	14
1029	Pharmacology and Molecular Mechanisms of Clinically Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for the Treatment of Endocrine-Resistant Breast Cancer. Molecular Pharmacology, 2020, 98, 364-381.	1.0	17
1030	MovableType Software for Fast Free Energy-Based Virtual Screening: Protocol Development, Deployment, Validation, and Assessment. Journal of Chemical Information and Modeling, 2020, 60, 5437-5456.	2.5	7
1031	Design, Synthesis, and Pharmacological Characterization of a Neutral, Non-Prodrug Thrombin Inhibitor with Good Oral Pharmacokinetics. Journal of Medicinal Chemistry, 2020, 63, 12574-12594.	2.9	15
1032	ATP modulates SLC7A5 (LAT1) synergistically with cholesterol. Scientific Reports, 2020, 10, 16738.	1.6	21
1033	In-silico strategies for identification of potent inhibitor for MMP-1 to prevent metastasis of breast cancer. Journal of Biomolecular Structure and Dynamics, 2020, 39, 1-20.	2.0	8
1034	Characterizing the binding and function of TARP î³8-selective AMPA receptor modulators. Journal of Biological Chemistry, 2020, 295, 14565-14577.	1.6	19
1035	Synthesis, biological evaluation, and <i>in silico</i> studies of novel chalcone- and pyrazoline-based 1,3,5-triazines as potential anticancer agents. RSC Advances, 2020, 10, 34114-34129.	1.7	11
1036	Screening of Heteroaromatic Scaffolds against Cystathionine Beta-Synthase Enables Identification of Substituted Pyrazolo[3,4-c]Pyridines as Potent and Selective Orthosteric Inhibitors. Molecules, 2020, 25, 3739.	1.7	2
1037	Alchemical Binding Free Energy Calculations in AMBER20: Advances and Best Practices for Drug Discovery. Journal of Chemical Information and Modeling, 2020, 60, 5595-5623.	2.5	177
1038	Structural and functional characterization of C0021158, a high-affinity monoclonal antibody that inhibits Arginase 2 function via a novel non-competitive mechanism of action. MAbs, 2020, 12, 1801230.	2.6	2
1039	Insight into glycogen synthase kinase- $3\hat{l}^2$ inhibitory activity of phyto-constituents from Melissa officinalis: in silico studies. In Silico Pharmacology, 2020, 8, 2.	1.8	31
1040	Antiangiogenic Activity and in Silico Cereblon Binding Analysis of Novel Thalidomide Analogs. Molecules, 2020, 25, 5683.	1.7	11

#	Article	IF	CITATIONS
1041	Synthesis and discovery of ï‰-3 polyunsaturated fatty acid- alkanolamine (PUFA-AA) derivatives as anti-inflammatory agents targeting Nur77. Bioorganic Chemistry, 2020, 105, 104456.	2.0	12
1042	Azasteroid Alkylators as Dual Inhibitors of AKT and ERK Signaling for the Treatment of Ovarian Carcinoma. Cancers, 2020, 12, 1263.	1.7	4
1043	Fluorophoreâ€Labeled Cyclic Nucleotides as Potent Agonists of Cyclic Nucleotideâ€Regulated Ion Channels. ChemBioChem, 2020, 21, 2311-2320.	1.3	2
1044	Higher Accuracy Achieved for Protein–Ligand Binding Pose Prediction by Elastic Network Model-Based Ensemble Docking. Journal of Chemical Information and Modeling, 2020, 60, 2939-2950.	2.5	13
1045	Inhibition of glutathione and s-allyl glutathione on pancreatic lipase: Analysis through in vitro kinetics, fluorescence spectroscopy and in silico docking. International Journal of Biological Macromolecules, 2020, 160, 623-631.	3.6	12
1046	Bioisosteric Replacement of Arylamide-Linked Spine Residues with $\langle i \rangle N \langle  i \rangle$ -Acylhydrazones and Selenophenes as a Design Strategy to Novel Dibenzosuberone Derivatives as Type I 1/2 p381± MAP Kinase Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 7347-7354.	2.9	14
1047	The effect of multiple simulation parameters on MM/PBSA performance for binding affinity prediction of CB1 cannabinoid receptor agonists and antagonists. Chemical Biology and Drug Design, 2020, 96, 1244-1254.	1.5	5
1048	A New Family of Jumonji C Domain-Containing KDM Inhibitors Inspired by Natural Product Purpurogallin. Frontiers in Chemistry, 2020, 8, 312.	1.8	17
1049	Synthesis and Structure–Activity Relationships of 5′-Aryl-14-alkoxypyridomorphinans: Identification of a μ Opioid Receptor Agonist/Î′ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects. Journal of Medicinal Chemistry, 2020, 63, 7663-7694.	2.9	21
1050	Synthesis, α-glucosidase inhibition and in silico studies of some 4-(5-fluoro-2-substituted-1H-benzimidazol-6-yl)morpholine derivatives. Bioorganic Chemistry, 2020, 101, 104002.	2.0	14
1051	Rigorous Free Energy Simulations in Virtual Screening. Journal of Chemical Information and Modeling, 2020, 60, 4153-4169.	2.5	114
1052	The Atypical Protein Kinase C Small Molecule Inhibitor ζ-Stat, and Its Effects on Invasion Through Decreases in PKC-ζ Protein Expression. Frontiers in Oncology, 2020, 10, 209.	1.3	9
1053	The mechanism of a high-affinity allosteric inhibitor of the serotonin transporter. Nature Communications, 2020, 11, 1491.	5.8	30
1054	Targeting Orthosteric and Allosteric Pockets of Aromatase via Dual-Mode Novel Azole Inhibitors. ACS Medicinal Chemistry Letters, 2020, 11, 732-739.	1.3	18
1055	Synthesis and Structure-Activity Relationship Studies of Hydrazide-Hydrazones as Inhibitors of Laccase from Trametes versicolor. Molecules, 2020, 25, 1255.	1.7	12
1056	Molecular Target Validation of Aspartate Transcarbamoylase from <i>Plasmodium falciparum</i> by Torin 2. ACS Infectious Diseases, 2020, 6, 986-999.	1.8	7
1057	Novel Furan-2-yl-1 <i>H</i> -pyrazoles Possess Inhibitory Activity against $\hat{l}_{\pm}$ -Synuclein Aggregation. ACS Chemical Neuroscience, 2020, 11, 2303-2315.	1.7	9
1058	Structure-based identification of small molecules against influenza A virus endonuclease: an in silico and in vitro approach. Pathogens and Disease, 2020, 78, .	0.8	2

#	Article	IF	Citations
1059	Modulation of estrogen-related receptors subtype selectivity: Conversion of an ERRÎ $^2$ Î $^3$ selective agonist to ERRÎ $^2$ Î $^3$ pan agonists. Bioorganic Chemistry, 2020, 102, 104079.	2.0	10
1060	Design of antitumor drugs targeting c-kit receptor by a new mixed ligand-structure based method. Journal of Molecular Graphics and Modelling, 2020, 100, 107666.	1.3	6
1061	Directed Computational Evolution of Quorum-Quenching Lactonases from the Amidohydrolase Superfamily. Structure, 2020, 28, 635-642.e3.	1.6	5
1062	Design and pharmacological profile of a novel covalent partial agonist for the adenosine A1 receptor. Biochemical Pharmacology, 2020, 180, 114144.	2.0	10
1063	Pharmacophore-enabled virtual screening, molecular docking and molecular dynamics studies for identification of potent and selective histone deacetylase 8 inhibitors. Computers in Biology and Medicine, 2020, 123, 103850.	3.9	9
1064	Simulative structure and binding sites of lyral with olfactory receptor 10J5 using computational prediction methods. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2020, 83, 1-8.	1.1	2
1065	Dual Binding to Orthosteric and Allosteric Sites Enhances the Anticancer Activity of a TRAP1-Targeting Drug. Journal of Medicinal Chemistry, 2020, 63, 2930-2940.	2.9	16
1066	<i>In Silico</i> Investigation of Bitter Hop-Derived Compounds and Their Cognate Bitter Taste Receptors. Journal of Agricultural and Food Chemistry, 2020, 68, 10414-10423.	2.4	16
1067	Identification and Repurposing of Trisubstituted Harmine Derivatives as Novel Inhibitors of Mycobacterium tuberculosis Phosphoserine Phosphatase. Molecules, 2020, 25, 415.	1.7	9
1068	Deciphering the enzymatic target of a new family of antischistosomal agents bearing a quinazoline scaffold using complementary computational tools. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 511-523.	2.5	2
1069	A Pilot Study of All-Computational Drug Design Protocol–From Structure Prediction to Interaction Analysis. Frontiers in Chemistry, 2020, 8, 81.	1.8	10
1070	The small molecule GAT1508 activates brain-specific GIRK1/2 channel heteromers and facilitates conditioned fear extinction in rodents. Journal of Biological Chemistry, 2020, 295, 3614-3634.	1.6	20
1071	Hops compounds modulatory effects and 6-prenylnaringenin dual mode of action on GABAA receptors. European Journal of Pharmacology, 2020, 873, 172962.	1.7	12
1072	Design, Synthesis, and Molecular Modeling Studies of Novel Coumarin Carboxamide Derivatives as eEF-2K Inhibitors. Journal of Chemical Information and Modeling, 2020, 60, 1766-1778.	2.5	17
1073	Structural, molecular, functional and immunological characterization of Wuchereria bancrofti-galectin. International Journal of Biological Macromolecules, 2020, 150, 206-217.	3.6	3
1074	Design, synthesis, and pharmacological evaluation of novel and selective COX-2 inhibitors based on bumetanide scaffold. Bioorganic Chemistry, 2020, 100, 103878.	2.0	11
1075	Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D <sub>3</sub> Dopamine Receptor Agonist. Journal of Medicinal Chemistry, 2020, 63, 5526-5567.	2.9	15
1076	Synthesis, inÂvitro evaluation and molecular docking of a new class of indolylpropyl benzamidopiperazines as dual AChE and SERT ligands for Alzheimer's disease. European Journal of Medicinal Chemistry, 2020, 198, 112368.	2.6	18

#	Article	IF	CITATIONS
1077	Computational Investigations on the Binding Mode of Ligands for the Cannabinoid-Activated G Protein-Coupled Receptor GPR18. Biomolecules, 2020, 10, 686.	1.8	13
1078	Theoretical study of the adiponectin receptors: binding site characterization and molecular dynamics of possible ligands for drug design. SN Applied Sciences, 2020, 2, 1.	1.5	8
1079	Discovery and optimization of novel phenyldiazepine and pyridodiazepine based Aurora kinase inhibitors. Bioorganic Chemistry, 2020, 99, 103800.	2.0	3
1080	Identification of mitochondrial toxicants by combined in silico and in vitro studies – A structure-based view on the adverse outcome pathway. Computational Toxicology, 2020, 14, 100123.	1.8	13
1081	Truncated (N)-Methanocarba Nucleosides as Partial Agonists at Mouse and Human A <sub>3</sub> Adenosine Receptors: Affinity Enhancement by <i>N</i> > <sup>6</sup> -(2-Phenylethyl) Substitution. Journal of Medicinal Chemistry, 2020, 63, 4334-4348.	2.9	17
1082	How Computational Chemistry and Drug Delivery Techniques Can Support the Development of New Anticancer Drugs. Molecules, 2020, 25, 1756.	1.7	23
1083	Multiscale Molecular Modeling in G Protein-Coupled Receptor (GPCR)-Ligand Studies. Biomolecules, 2020, 10, 631.	1.8	8
1084	Computational Insights into Molecular Activation and Positive Cooperative Mechanisms of FFAR1 Modulators. Journal of Chemical Information and Modeling, 2020, 60, 3214-3230.	2.5	9
1085	Structural and functional evidence for citicoline binding and modulation of 20S proteasome activity: Novel insights into its pro-proteostatic effect. Biochemical Pharmacology, 2020, 177, 113977.	2.0	13
1086	Integrating Ligand and Target-Driven Based Virtual Screening Approaches With in vitro Human Cell Line Models and Time-Resolved Fluorescence Resonance Energy Transfer Assay to Identify Novel Hit Compounds Against BCL-2. Frontiers in Chemistry, 2020, 8, 167.	1.8	17
1087	Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus. Viruses, 2020, 12, 367.	1.5	27
1088	A Photoswitchable Inhibitor of the Human Serotonin Transporter. ACS Chemical Neuroscience, 2020, 11, 1231-1237.	1.7	14
1089	Virtual screening by 2-D fingerprints, shape and docking for discovering new chemotypes of activator protein-1 inhibitors. Journal of Biomolecular Structure and Dynamics, 2021, 39, 2455-2462.	2.0	0
1090	Structure-based screening and validation of bioactive compounds as Zika virus methyltransferase (MTase) inhibitors through first-principle density functional theory, classical molecular simulation and QM/MM affinity estimation. Journal of Biomolecular Structure and Dynamics, 2021, 39, 2338-2351.	2.0	30
1091	Investigating into the molecular interactions of flavonoids targeting NS2B-NS3 protease from ZIKA virus through <i>in-silico</i> approaches. Journal of Biomolecular Structure and Dynamics, 2021, 39, 272-284.	2.0	26
1092	Anti-dengue infectivity evaluation of bioflavonoid from <i>Azadirachta indica</i> by dengue virus serine protease inhibition. Journal of Biomolecular Structure and Dynamics, 2021, 39, 1417-1430.	2.0	38
1093	Discovery of new small-molecule cyclin-dependent kinase 6 inhibitors through computational approaches. Molecular Diversity, 2021, 25, 367-382.	2.1	8
1094	GWOVina: A grey wolf optimization approach to rigid and flexible receptor docking. Chemical Biology and Drug Design, 2021, 97, 97-110.	1.5	18

#	Article	IF	CITATIONS
1095	Design and synthesis of novel fluorescently labeled analogs of vemurafenib targeting MKK4. European Journal of Medicinal Chemistry, 2021, 209, 112901.	2.6	5
1096	Rationally designed N-phenylsulfonylindoles as a tool for the analysis of the non-basic 5-HT6R ligands binding mode. European Journal of Medicinal Chemistry, 2021, 209, 112916.	2.6	2
1097	Synthesis, characterization, biological activity and molecular docking studies of novel schiff bases derived from thiosemicarbazide: Biochemical and computational approach. Journal of Molecular Structure, 2021, 1231, 129666.	1.8	27
1098	In vitro and in silico evaluation of the inhibitory effect of a curcumin-based oxovanadium (IV) complex on alkaline phosphatase activity and bacterial biofilm formation. Applied Microbiology and Biotechnology, 2021, 105, 147-168.	1.7	16
1099	Novel potent (dihydro)benzofuranyl piperazines as human histamine receptor ligands – Functional characterization and modeling studies on H3 and H4 receptors. Bioorganic and Medicinal Chemistry, 2021, 30, 115924.	1.4	5
1100	Identification of a druggable protein–protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1. Journal of Biological Chemistry, 2021, 296, 100098.	1.6	20
1101	Discovery of Amoebicidal Compounds by Combining Computational and Experimental Approaches. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	2
1102	Mining Natural Products for Macrocycles to Drug Difficult Targets. Journal of Medicinal Chemistry, 2021, 64, 1054-1072.	2.9	25
1103	The latest automated docking technologies for novel drug discovery. Expert Opinion on Drug Discovery, 2021, 16, 625-645.	2.5	29
1104	Structure-activity relationship (SAR) studies of N-(3-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine (SRI-22819) as NF-Ò¡B activators for the treatment of ALS. European Journal of Medicinal Chemistry, 2021, 210, 112952.	2.6	2
1105	Analysis of plant-derived phytochemicals as anti-cancer agents targeting cyclin dependent kinase-2, human topoisomerase lla and vascular endothelial growth factor receptor-2. Journal of Receptor and Signal Transduction Research, 2021, 41, 217-233.	1.3	8
1106	Negative Image-Based Screening: Rigid Docking Using Cavity Information. Methods in Molecular Biology, 2021, 2266, 125-140.	0.4	1
1107	Advances in structure-based drug design. , 2021, , 55-103.		9
1108	Structure-Based Virtual Screening: Theory, Challenges and Guidelines. , 2021, , .		0
1109	Biaryl sulfonamides as <i>cisoid</i> azosteres for photopharmacology. Chemical Communications, 2021, 57, 4126-4129.	2.2	9
1110	Inhibition of $\langle scp \rangle d \langle scp \rangle -\langle i \rangle glycero \langle i \rangle -\hat{l}^2 -\langle scp \rangle d \langle scp \rangle -\langle i \rangle manno \langle i \rangle -heptose 1-phosphate adenylyltransferase from \langle i \rangle Burkholderia pseudomallei \langle i \rangle by epigallocatechin gallate and myricetin. Biochemical Journal, 2021, 478, 235-245.$	1.7	4
1111	Bitter Sensing <i>TAS2R50</i> Mediates the <i>trans</i> -Resveratrol-Induced Anti-inflammatory Effect on Interleukin 6 Release in HGF-1 Cells in Culture. Journal of Agricultural and Food Chemistry, 2021, 69, 13339-13349.	2.4	20
1112	Aspects of Protein Structure, Function, and Dynamics in Rational Drug Designing., 2021,, 35-57.		1

#	Article	IF	CITATIONS
1113	Discovery and Biological Evaluation of $\langle i \rangle N \langle  i \rangle$ -Methyl-pyrrolo[2,3- $\langle i \rangle b \langle  i \rangle$ ] pyridine-5-carboxamide Derivatives as JAK1-Selective Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 958-979.	2.9	12
1114	Structure-Based Design of Potent Selective Nanomolar Type-II Inhibitors of Glycogen Synthase Kinase- $3\hat{l}^2$ . Journal of Medicinal Chemistry, 2021, 64, 1497-1509.	2.9	9
1115	A study of inhibitors of d-glycero- $\hat{l}^2$ -d-manno-heptose-1-phosphate adenylyltransferase from Burkholderia pseudomallei as a potential antibiotic target. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 776-784.	2.5	3
1117	New insights about the serine/threonine protein kinase substrates from Mycobacterium tuberculosis using molecular docking, quantum similarity analysis and DFT calculations. F1000Research, 0, 10, 66.	0.8	0
1118	Structure-based identification of inhibitors disrupting the CD2–CD58 interactions. Journal of Computer-Aided Molecular Design, 2021, 35, 337-353.	1.3	1
1119	Computational identification of potential lead molecules targeting rho receptor of <i>Neisseria gonorrhoeae</i> . Journal of Biomolecular Structure and Dynamics, 2022, 40, 6415-6425.	2.0	2
1120	Identification of theÂmost potent acetylcholinesterase inhibitors from plants for possible treatment of Alzheimer's disease: a computational approach. Egyptian Journal of Medical Human Genetics, 2021, 22, .	0.5	15
1121	Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors. Cancer Research, 2021, 81, 2220-2233.	0.4	19
1122	Trends in application of advancing computational approaches in GPCR ligand discovery. Experimental Biology and Medicine, 2021, 246, 1011-1024.	1.1	5
1123	βâ€sheet breakers with consecutive phenylalanines: Insights into mechanism of dissolution of βâ€amyloid fibrils. Proteins: Structure, Function and Bioinformatics, 2021, 89, 762-780.	1.5	4
1124	Force Field Optimization Guided by Small Molecule Crystal Lattice Data Enables Consistent Sub-Angstrom Protein–Ligand Docking. Journal of Chemical Theory and Computation, 2021, 17, 2000-2010.	2.3	52
1125	Functional alterations by a subgroup of neonicotinoid pesticides in human dopaminergic neurons. Archives of Toxicology, 2021, 95, 2081-2107.	1.9	32
1126	Probing biased activation of mu-opioid receptor by the biased agonist PZM21 using all atom molecular dynamics simulation. Life Sciences, 2021, 269, 119026.	2.0	13
1127	Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth <i>In Vivo</i> . ACS Pharmacology and Translational Science, 2021, 4, 926-940.	2.5	5
1129	Crystal Structure and Subsequent Ligand Design of a Nonriboside Partial Agonist Bound to the Adenosine A <sub>2A</sub> Receptor. Journal of Medicinal Chemistry, 2021, 64, 3827-3842.	2.9	29
1130	Reliable and Accurate Solution to the Induced Fit Docking Problem for Protein–Ligand Binding. Journal of Chemical Theory and Computation, 2021, 17, 2630-2639.	2.3	60
1131	Design, synthesis and biological evaluation of 2-substituted-6-[(4-substituted-1-piperidyl)methyl]-1H-benzimidazoles as inhibitors of ebola virus infection. European Journal of Medicinal Chemistry, 2021, 214, 113211.	2.6	9
1132	Phenothiazine as novel human superoxide dismutase modulators: discovery, optimization, and biological evaluation. Journal of Biomolecular Structure and Dynamics, 2022, 40, 7070-7083.	2.0	1

#	Article	IF	CITATIONS
1133	Bioactive Triterpenes of Protium heptaphyllum Gum Resin Extract Display Cholesterol-Lowering Potential. International Journal of Molecular Sciences, 2021, 22, 2664.	1.8	22
1135	Binding Sites for Oligosaccharide Repeats from Lactic Acid Bacteria Exopolysaccharides on Bovine β-Lactoglobulin Identified by NMR Spectroscopy. ACS Omega, 2021, 6, 9039-9052.	1.6	7
1136	Optimization of sulfobutyl-ether-β-cyclodextrin levels in oral formulations to enhance progesterone bioavailability. International Journal of Pharmaceutics, 2021, 596, 120212.	2.6	19
1137	Therapeutic inhibition of keratinocyte TRPV3 sensory channel by local anesthetic dyclonine. ELife, 2021, 10, .	2.8	14
1138	Novel Aryl-Substituted Pyrimidones as Inhibitors of 3-Mercaptopyruvate Sulfurtransferase with Antiproliferative Efficacy in Colon Cancer. Journal of Medicinal Chemistry, 2021, 64, 6221-6240.	2.9	14
1139	Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors. Bioorganic and Medicinal Chemistry, 2021, 35, 116085.	1.4	9
1140	Binding mechanism of naringenin with monoamine oxidase – B enzyme: QM/MM and molecular dynamics perspective. Heliyon, 2021, 7, e06684.	1.4	11
1141	Targeting Chikungunya Virus Replication by Benzoannulene Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 4762-4786.	2.9	6
1142	The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors. Scientific Reports, 2021, 11, 9283.	1.6	48
1143	In Silico Identification of Small Molecules as New Cdc25 Inhibitors through the Correlation between Chemosensitivity and Protein Expression Pattern. International Journal of Molecular Sciences, 2021, 22, 3714.	1.8	12
1144	Computational Design and Development of Benzodioxane-Benzamides as Potent Inhibitors of FtsZ by Exploring the Hydrophobic Subpocket. Antibiotics, 2021, 10, 442.	1.5	10
1145	Design and Structure–Activity Relationships of Isothiocyanates as Potent and Selective <i>N</i> -Acylethanolamine-Hydrolyzing Acid Amidase Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 5956-5972.	2.9	4
1149	Computational Identification of a Putative Allosteric Binding Pocket in TMPRSS2. Frontiers in Molecular Biosciences, 2021, 8, 666626.	1.6	3
1150	A Study of 3CLpros as Promising Targets against SARS-CoV and SARS-CoV-2. Microorganisms, 2021, 9, 756.	1.6	6
1151	Docking Paradigm in Drug Design. Current Topics in Medicinal Chemistry, 2021, 21, 507-546.	1.0	23
1152	Identification of small molecule allosteric modulators of 5,10-methylenetetrahydrofolate reductase (MTHFR) by targeting its unique regulatory domain. Biochimie, 2021, 183, 100-107.	1.3	8
1153	Expanding the boundaries of ligand–target modeling by exascale calculations. Wiley Interdisciplinary Reviews: Computational Molecular Science, 2021, 11, e1535.	6.2	13
1154	Molecular mechanism of mitoquinol mesylate in mitigating the progression of hepatocellular carcinomaâ€"in silico and in vivo studies. Journal of Cellular Biochemistry, 2021, 122, 1157-1172.	1.2	2

#	Article	IF	CITATIONS
1155	E-pharmacophore based screening to identify potential HIV-1 gp120 and CD4 interaction blockers for wild and mutant types. SAR and QSAR in Environmental Research, 2021, 32, 353-377.	1.0	3
1156	Exploring the antidiabetic potential of compounds isolated from Anacardium occidentale using computational aproach: ligand-based virtual screening. In Silico Pharmacology, 2021, 9, 25.	1.8	8
1157	Novel bisubstrate uridine-peptide analogues bearing a pyrophosphate bioisostere as inhibitors of human O-GlcNAc transferase. Bioorganic Chemistry, 2021, 110, 104738.	2.0	2
1158	Synthetic Strategies towards Imidazopyridinones and 7â€Azaoxindoles and their Evaluation as Antibacterial Agents. European Journal of Organic Chemistry, 2021, 2021, 2701-2712.	1.2	2
1159	Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy. Journal of Medicinal Chemistry, 2021, 64, 7507-7532.	2.9	18
1160	Carbonyl reduction pathway in hepatic in vitro metabolism of anthracyclines: Impact of structure on biotransformation rate. Toxicology Letters, 2021, 342, 50-57.	0.4	4
1161	Diterpenoids from Zhumeria majdae roots as potential heat shock protein 90 (HSP90) modulators. Phytochemistry, 2021, 185, 112685.	1.4	5
1162	Structure based virtual screening: Fast and slow. Wiley Interdisciplinary Reviews: Computational Molecular Science, 2022, 12, e1544.	6.2	25
1163	Evaluation of potential anti-RNA-dependent RNA polymerase (RdRP) drugs against the newly emerged model of COVID-19 RdRP using computational methods. Biophysical Chemistry, 2021, 272, 106564.	1.5	49
1164	Exploring the 2′-Hydroxy-Chalcone Framework for the Development of Dual Antioxidant and Soybean Lipoxygenase Inhibitory Agents. Molecules, 2021, 26, 2777.	1.7	20
1165	Tetrahydroquinoline/4,5â€Dihydroisoxazole Molecular Hybrids as Inhibitors of Breast Cancer Resistance Protein (BCRP/ABCG2). ChemMedChem, 2021, 16, 2686-2694.	1.6	6
1166	Rational design of allosteric modulators: Challenges and successes. Wiley Interdisciplinary Reviews: Computational Molecular Science, 2021, 11, e1529.	6.2	39
1167	Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists. Journal of Medicinal Chemistry, 2021, 64, 8806-8825.	2.9	12
1168	Molecular docking-aided identification of small molecule inhibitors targeting $\hat{l}^2$ -catenin-TCF4 interaction. IScience, 2021, 24, 102544.	1.9	6
1169	Potent and Subtype-Selective Dopamine D <sub>2</sub> Receptor Biased Partial Agonists Discovered via an Ugi-Based Approach. Journal of Medicinal Chemistry, 2021, 64, 8710-8726.	2.9	3
1170	Structural basis for the binding of a selective inverse agonist AF64394 with the human G-protein coupled receptor 3 (GPR3). Journal of Biomolecular Structure and Dynamics, 2022, 40, 10181-10190.	2.0	4
1171	Evaluation of 3―and 4â€Phenoxybenzamides as Selective Inhibitors of the Monoâ€ADPâ€Ribosyltransferase PARP10. ChemistryOpen, 2021, 10, 939-948.	0.9	4
1172	Off-Target-Based Design of Selective HIV-1 PROTEASE Inhibitors. International Journal of Molecular Sciences, 2021, 22, 6070.	1.8	5

#	Article	IF	CITATIONS
1173	Determinants for $\hat{l}\pm4\hat{l}^22$ vs. $\hat{l}\pm3\hat{l}^24$ Subtype Selectivity of Pyrrolidine-Based nAChRs Ligands: A Computational Perspective with Focus on Recent cryo-EM Receptor Structures. Molecules, 2021, 26, 3603.	1.7	7
1174	Computational Modeling of C-Terminal Tails to Predict the Calcium-Dependent Secretion of Endoplasmic Reticulum Resident Proteins. Frontiers in Chemistry, 2021, 9, 689608.	1.8	5
1175	Potency boost of a <i>Mycobacterium tuberculosis</i> dihydrofolate reductase inhibitor by multienzyme F <sub>420</sub> H <sub>2</sub> -dependent reduction. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	9
1176	New benzimidazolequinones as trypanosomicidal agents. Bioorganic Chemistry, 2021, 111, 104823.	2.0	12
1177	To Probe the Binding Interactions between Two FDA Approved Migraine Drugs (Ubrogepant and) Tj ETQq0 0 0 rg Simulations. ACS Chemical Neuroscience, 2021, 12, 2629-2642.	gBT /Overlo 1.7	ock 10 Tf 50 7
1178	Spectroscopic and Molecular Docking Study of the Interaction between Neutral Re(I) Tetrazolate Complexes and Bovine Serum Albumin. Chemistry - A European Journal, 2021, 27, 11406-11417.	1.7	9
1181	Exploring aromatic cage flexibility of the histone methyllysine reader protein Spindlin1 and its impact on binding mode prediction: an in silico study. Journal of Computer-Aided Molecular Design, 2021, 35, 695-706.	1.3	1
1182	Structure-Based Design of Selective Salt-Inducible Kinase Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 8142-8160.	2.9	28
1183	Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids. Bioorganic and Medicinal Chemistry, 2021, 41, 116215.	1.4	7
1184	Immunoproteasome and Non-Covalent Inhibition: Exploration by Advanced Molecular Dynamics and Docking Methods. Molecules, 2021, 26, 4046.	1.7	3
1185	A Novel Cardenolide Glycoside Isolated from Xysmalobium undulatum Reduces Levels of the Alzheimer's Disease-Associated β-Amyloid Peptides Aβ42 In Vitro. Pharmaceuticals, 2021, 14, 743.	1.7	2
1186	Molecular docking studies of 1,3,4 -thiadiazoles as myeloperoxidase inhibitors. Journal of Pharmaceutical and Biological Sciences, 2021, 9, 63-69.	0.2	0
1187	Switching Lysophosphatidylserine G Protein-Coupled Receptor Agonists to Antagonists by Acylation of the Hydrophilic Serine Amine. Journal of Medicinal Chemistry, 2021, 64, 10059-10101.	2.9	5
1188	Synthetic fluorescent MYC probe: Inhibitor binding site elucidation and development of a high-throughput screening assay. Bioorganic and Medicinal Chemistry, 2021, 42, 116246.	1.4	1
1190	Antiproliferative Properties and G-Quadruplex-Binding of Symmetrical Naphtho[1,2-b:8,7-b']dithiophene Derivatives. Molecules, 2021, 26, 4309.	1.7	0
1191	Midkine Interaction with Chondroitin Sulfate Model Synthetic Tetrasaccharides and Their Mimetics: The Role of Aromatic Interactions. Chemistry - A European Journal, 2021, 27, 12395-12409.	1.7	7
1192	Synthesis, SAR study, and bioactivity evaluation of a series of Quinoline-Indole-Schiff base derivatives: Compound 10E as a new Nur77 exporter and autophagic death inducer. Bioorganic Chemistry, 2021, 113, 105008.	2.0	7
1193	Unraveling the binding mechanism of an Oxovanadium(IV) – Curcumin complex on albumin, DNA and DNA gyrase by in vitro and in silico studies and evaluation of its hemocompatibility. Journal of Inorganic Biochemistry, 2021, 221, 111402.	1.5	6

#	Article	IF	CITATIONS
1194	Identification of Quinolinones as Antivirals against Venezuelan Equine Encephalitis Virus. Antimicrobial Agents and Chemotherapy, 2021, 65, e0024421.	1.4	5
1195	VIRTUAL SCREENING STATEGIES IN DRUG DISCOVERY – A BRIEF OVERVIEW. Science and Technology, 2021, 59, 415.	0.1	1
1196	Tuning the activity of known drugs via the introduction of halogen atoms, a case study of SERT ligands – Fluoxetine and fluvoxamine. European Journal of Medicinal Chemistry, 2021, 220, 113533.	2.6	16
1197	Near-physiological-temperature serial crystallography reveals conformations of SARS-CoV-2 main protease active site for improved drug repurposing. Structure, 2021, 29, 1382-1396.e6.	1.6	28
1198	Subtypeâ€selective positive modulation of K Ca 2 channels depends on the HA/HB helices. British Journal of Pharmacology, 2021, , .	2.7	9
1199	Structure-Based Optimization of Quinazolines as Cruzain and <i>Tbr</i> CATL Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 13054-13071.	2.9	19
1200	The Interaction of Hemin, a Porphyrin Derivative, with the Purified Rat Brain 2-Oxoglutarate Carrier. Biomolecules, 2021, 11, 1175.	1.8	3
1201	Identification of lead compounds from large natural product library targeting 3C-like protease of SARS-CoV-2 using E-pharmacophore modelling, QSAR and molecular dynamics simulation. In Silico Pharmacology, 2021, 9, 49.	1.8	8
1202	Preliminary modelling as the first stage of targeted organic synthesis. Russian Chemical Reviews, 2021, 90, 831-867.	2.5	3
1203	Structural studies of codeinone reductase reveal novel insights into aldo-keto reductase function in benzylisoquinoline alkaloid biosynthesis. Journal of Biological Chemistry, 2021, 297, 101211.	1.6	4
1204	Curcumin and Its New Derivatives: Correlation between Cytotoxicity against Breast Cancer Cell Lines, Degradation of PTP1B Phosphatase and ROS Generation. International Journal of Molecular Sciences, 2021, 22, 10368.	1.8	8
1205	In quest of small-molecules as potent non-competitive inhibitors against influenza. Bioorganic Chemistry, 2021, 114, 105139.	2.0	5
1206	Molecular Determinants and Pharmacological Analysis for a Class of Competitive Non-transported Bicyclic Inhibitors of the Betaine/GABA Transporter BGT1. Frontiers in Chemistry, 2021, 9, 736457.	1.8	5
1207	Molecular investigation of artificial and natural sweeteners as potential anti-inflammatory agents. Journal of Biomolecular Structure and Dynamics, 2022, 40, 12608-12620.	2.0	7
1208	Discovery and SAR Evolution of Pyrazole Azabicyclo[3.2.1]octane Sulfonamides as a Novel Class of Non-Covalent N-Acylethanolamine-Hydrolyzing Acid Amidase (NAAA) Inhibitors for Oral Administration. Journal of Medicinal Chemistry, 2021, 64, 13327-13355.	2.9	6
1209	Antimalarial Inhibitors Targeting Epigenetics or Mitochondria in Plasmodium falciparum: Recent Survey upon Synthesis and Biological Evaluation of Potential Drugs against Malaria. Molecules, 2021, 26, 5711.	1.7	5
1210	Evaluation of the IKK $\hat{I}^2$ Binding of Indicaxanthin by Induced-Fit Docking, Binding Pose Metadynamics, and Molecular Dynamics. Frontiers in Pharmacology, 2021, 12, 701568.	1.6	24
1211	A Cornflower Extract Containing N-Feruloylserotonin Reduces Inflammation in Human Skin by Neutralizing CCL17 and CCL22 and Inhibiting COX-2 and 5-LOX. Mediators of Inflammation, 2021, 2021, 1-13.	1.4	5

#	Article	IF	CITATIONS
1212	Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants. Journal of Virology, 2021, 95, e0143721.	1.5	24
1213	Probe Confined Dynamic Mapping for G Protein-Coupled Receptor Allosteric Site Prediction. ACS Central Science, 2021, 7, 1847-1862.	5.3	15
1215	DD04107-Derived neuronal exocytosis inhibitor peptides: Evidences for synaptotagmin-1 as a putative target. Bioorganic Chemistry, 2021, 115, 105231.	2.0	2
1216	Cholinesterases, carbonic anhydrase inhibitory properties and in silico studies of novel substituted benzylamines derived from dihydrochalcones. Computational Biology and Chemistry, 2021, 94, 107565.	1.1	23
1217	HTS-based discovery and optimization of novel positive allosteric modulators of the $\hat{l}\pm7$ nicotinic acetylcholine receptor. European Journal of Medicinal Chemistry, 2021, 222, 113560.	2.6	1
1218	Discovery of novel hit compounds as potential HDAC1 inhibitors: The case of ligand- and structure-based virtual screening. Computers in Biology and Medicine, 2021, 137, 104808.	3.9	22
1219	Synthesis, structure-activity relationships and molecular docking studies of phenyldiazenyl sulfonamides as aromatase inhibitors. European Journal of Medicinal Chemistry, 2021, 224, 113737.	2.6	14
1220	Synthesis, in vitro cytotoxic, anti-Mycobacterium tuberculosis and molecular docking studies of 4-pyridylamino- and 4-(ethynylpyridine)quinazolines. Journal of Molecular Structure, 2021, 1243, 130824.	1.8	6
1221	Insights into the binding interaction mechanism of 12,12-dihydrochromeno[2,3-c]isoquinolin-5-amine in bovine serum albumin and prostaglandin H2 synthase-1: A biophysical approach. Journal of Molecular Structure, 2021, 1245, 131131.	1.8	5
1222	Structure-activity relationships of agonists for the orphan G protein-coupled receptor GPR27. European Journal of Medicinal Chemistry, 2021, 225, 113777.	2.6	9
1223	Best Practices for Docking-Based Virtual Screening. , 2021, , 75-98.		8
1224	Conserved sequence motifs in human TMTC1, TMTC2, TMTC3, and TMTC4, new O-mannosyltransferases from the GT-C/PMT clan, are rationalized as ligand binding sites. Biology Direct, 2021, 16, 4.	1.9	9
1225	Pyrimidone inhibitors targeting Chikungunya Virus nsP3 macrodomain by fragment-based drug design. PLoS ONE, 2021, 16, e0245013.	1.1	16
1226	Identification of imidazo[4,5-c]pyridin-2-one derivatives as novel Src family kinase inhibitors against glioblastoma. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 1539-1550.	2.5	3
1227	Molecular docking analysis: Basic technique to predict drug-receptor interactions., 2021,, 131-155.		14
1228	<i>N</i> -Aryl iminochromenes inhibit cyclooxygenase enzymes <i>via</i> i\i∈–i€ stacking interactions and present a novel class of anti-inflammatory drugs. RSC Advances, 2021, 11, 29385-29393.	1.7	4
1229	Beneficent and Maleficent Effects of Cations on Bufadienolide Binding to Na <sup>+</sup> ,K <sup>+</sup> -ATPase. Journal of Chemical Information and Modeling, 2021, 61, 976-986.	2.5	2
1230	Virus Disinfection from Environmental Water Sources Using Living Engineered Biofilm Materials. Advanced Science, 2020, 7, 1903558.	5.6	28

#	Article	IF	CITATIONS
1231	Binding Free Energy Calculation Using Quantum Mechanics Aimed for Drug Lead Optimization. Methods in Molecular Biology, 2020, 2114, 257-268.	0.4	26
1232	Molecular Docking to Flexible Targets. Methods in Molecular Biology, 2015, 1215, 445-469.	0.4	18
1233	Structure-Based Computational Approaches for Small-Molecule Modulation of Protein-Protein Interactions. Methods in Molecular Biology, 2015, 1278, 77-92.	0.4	5
1234	Binding Site Druggability Assessment in Fragment-Based Drug Design. Methods in Molecular Biology, 2015, 1289, 13-21.	0.4	7
1235	Protein-protein interactions: analysis and prediction. , 2008, , 353-410.		1
1236	Modeling of Membrane Proteins. Springer Series on Bio- and Neurosystems, 2019, , 371-451.	0.2	5
1237	3D Motifs. , 2017, , 361-392.		7
1238	Molecular docking and dynamics simulations studies of OmpATb identifies four potential novel natural product-derived anti-Mycobacterium tuberculosis compounds. Computers in Biology and Medicine, 2020, 122, 103811.	3.9	6
1239	Density functional theory and molecular dynamics simulation support Ganoderma lucidum triterpenoids as broad range antagonist of matrix metalloproteinases. Journal of Molecular Liquids, 2020, 311, 113322.	2.3	13
1240	Numerous Compounds Orchestrate Coffee's Bitterness. Journal of Agricultural and Food Chemistry, 2020, 68, 6692-6700.	2.4	21
1241	CHAPTER 4. Current Status and Future Direction of Fragment-Based Drug Discovery: A Computational Chemistry Perspective. RSC Drug Discovery Series, 2015, , 73-100.	0.2	2
1242	Pharmacophore-based Virtual Screening in Drug Discovery. , 2008, , 76-119.		10
1243	At the Root of <i>T2R</i> Gene Evolution: Recognition Profiles of Coelacanth and Zebrafish Bitter Receptors. Genome Biology and Evolution, 2021, 13, .	1.1	17
1249	Crystal structure of type II NADH:quinone oxidoreductase from <i>Caldalkalibacillus thermarum</i> with an improved resolution of 2.15â€Ã Acta Crystallographica Section F, Structural Biology Communications, 2017, 73, 541-549.	0.4	10
1250	Predicting Molecular Interactions in Structural Proteomics. , 2009, , 185-209.		3
1252	The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors. PLoS Computational Biology, 2018, 14, e1005948.	1.5	19
1253	Identification of Ecdysone Hormone Receptor Agonists as a Therapeutic Approach for Treating Filarial Infections. PLoS Neglected Tropical Diseases, 2016, 10, e0004772.	1.3	16
1254	Binding-Site Assessment by Virtual Fragment Screening. PLoS ONE, 2010, 5, e10109.	1.1	56

#	Article	IF	CITATIONS
1255	Development of a Unique Small Molecule Modulator of CXCR4. PLoS ONE, 2012, 7, e34038.	1.1	104
1256	In Silico Assessment of Potential Druggable Pockets on the Surface of $\hat{l}\pm 1$ -Antitrypsin Conformers. PLoS ONE, 2012, 7, e36612.	1.1	39
1257	Identification of the Substrate Recognition and Transport Pathway in a Eukaryotic Member of the Nucleobase-Ascorbate Transporter (NAT) Family. PLoS ONE, 2012, 7, e41939.	1.1	42
1258	Allosteric Regulation of Serine Protease HtrA2 through Novel Non-Canonical Substrate Binding Pocket. PLoS ONE, 2013, 8, e55416.	1.1	31
1259	A High Throughput Screen Identifies Potent and Selective Inhibitors to Human Epithelial 15-Lipoxygenase-2. PLoS ONE, 2014, 9, e104094.	1.1	18
1260	Anticancer Activities of Pterostilbene-Isothiocyanate Conjugate in Breast Cancer Cells: Involvement of PPARÎ <sup>3</sup> . PLoS ONE, 2014, 9, e104592.	1.1	23
1261	Biochemical and Structural Characterization of Mycobacterial Aspartyl-tRNA Synthetase AspS, a Promising TB Drug Target. PLoS ONE, 2014, 9, e113568.	1.1	31
1262	Molecular Probing of the HPV-16 E6 Protein Alpha Helix Binding Groove with Small Molecule Inhibitors. PLoS ONE, 2016, 11, e0149845.	1.1	19
1263	QM/MM simulations provide insight into the mechanism of bioluminescence triggering in ctenophore photoproteins. PLoS ONE, 2017, 12, e0182317.	1.1	7
1264	Design and synthesis of constrained bicyclic molecules as candidate inhibitors of influenza A neuraminidase. PLoS ONE, 2018, 13, e0193623.	1.1	6
1265	Supercomputer Modeling of Dual-Site Acetylcholinesterase (AChE) Inhibition. Supercomputing Frontiers and Innovations, 2018, 5, .	0.5	2
1266	Isolation of Compounds from <i>Sargassum wightii </i> by GCMS and the Molecular Docking against Anti-Inflammatory Marker COX2. International Letters of Chemistry, Physics and Astronomy, 0, 63, 1-12.	0.0	9
1267	Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit. Oncotarget, 2017, 8, 37568-37583.	0.8	60
1268	Discovery of novel frizzled-7 inhibitors by targeting the receptor's transmembrane domain. Oncotarget, 2017, 8, 91459-91470.	0.8	26
1269	The In Silico Drug Discovery Toolbox: Applications in Lead Discovery and Optimization. Current Medicinal Chemistry, 2019, 26, 3838-3873.	1.2	47
1270	Molecular Docking: Challenges, Advances and its Use in Drug Discovery Perspective. Current Drug Targets, 2019, 20, 501-521.	1.0	246
1271	Revisiting De Novo Drug Design: Receptor Based Pharmacophore Screening. Current Topics in Medicinal Chemistry, 2014, 14, 1890-1898.	1.0	14
1272	Application of Computational Techniques to Unravel Structure-Function Relationship and their Role in Therapeutic Development. Current Topics in Medicinal Chemistry, 2018, 18, 1769-1791.	1.0	5

#	Article	IF	CITATIONS
1273	In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease. Current Neuropharmacology, 2018, 16, 786-848.	1.4	18
1274	Discovery of Traditional Chinese Medicine Derived Compounds as Wild Type and Mutant Plasmodium falciparum Dihydrofolate Reductase Inhibitors: Induced Fit Docking and ADME Studies. Current Drug Discovery Technologies, 2021, 18, 554-569.	0.6	20
1275	Molecular Modeling of an Orphan GPR18 Receptor. Letters in Drug Design and Discovery, 2019, 16, 1167-1174.	0.4	6
1277	Design, synthesis, antifungal activity, and QM/MM docking study of two azole derivatives with indole ring. Journal of Research in Pharmacy, 2020, 24, 681-692.	0.1	3
1278	Protein-Ligand Docking Methodologies and Its Application in Drug Discovery., 2017,, 891-914.		1
1279	Molecular dynamics of sialic acid analogues and their interaction with influenza hemagglutinin. Indian Journal of Pharmaceutical Sciences, 2010, 72, 449.	1.0	2
1280	Molecular Modeling Studies of Interaction Between Plasmid DNA (pBR322) and Dendritic Antioxidants. Journal of Cancer Science & Therapy, 2011, 03, .	1.7	3
1281	Virtual Screening Strategies in Drug Design. Revista Virtual De Quimica, 2012, 4, .	0.1	16
1282	Active compound from the leaves of vitex negundo L. shows anti-inflammatory activity with evidence of inhibition for secretory phospholipase A2 through molecular docking. Bioinformation, 2011, 7, 199-206.	0.2	29
1283	The molecular basis for an allosteric inhibition of K+-flux gating in K2P channels. ELife, 2019, 8, .	2.8	20
1284	A chemical probe of CARM1 alters epigenetic plasticity against breast cancer cell invasion. ELife, 2019, 8, .	2.8	32
1285	Distinct inactive conformations of the dopamine D2 and D3 receptors correspond to different extents of inverse agonism. ELife, 2020, 9, .	2.8	31
1286	GRID-independent molecular descriptor analysis and molecular docking studies to mimic the binding hypothesis of $\hat{I}^3$ -aminobutyric acid transporter 1 (GAT1) inhibitors. PeerJ, 2019, 7, e6283.	0.9	3
1287	Structure–activity relationships of valine, <i>tert</i> -leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA. RSC Medicinal Chemistry, 2022, 13, 156-174.	1.7	11
1288	Design and Synthesis of Hsp90 Inhibitors with Bâ€Raf and PDHK1 Multiâ€Target Activity. ChemistryOpen, 2021, 10, 1177-1185.	0.9	5
1289	Structure-based docking, pharmacokinetic evaluation, and molecular dynamics-guided evaluation of traditional formulation against SARS-CoV-2 spike protein receptor bind domain and ACE2 receptor complex. Chemical Papers, 2022, 76, 1063-1083.	1.0	9
1290	Selected Class of Enamides Bearing Nitro Functionality as Dual-Acting with Highly Selective Monoamine Oxidase-B and BACE1 Inhibitors. Molecules, 2021, 26, 6004.	1.7	7
1291	Probing the intermolecular interactions, binding affinity, charge density distribution and dynamics of silibinin in dual targets AChE and BACE1: QTAIM and molecular dynamics perspective. Journal of Biomolecular Structure and Dynamics, 2022, 40, 12880-12894.	2.0	5

#	ARTICLE	IF	CITATIONS
1292	NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity?. ACS Chemical Neuroscience, 2021, 12, 4020-4036.	1.7	7
1293	Targeting cryptic-orthosteric site of PD-L1 for inhibitor identification using structure-guided approach. Archives of Biochemistry and Biophysics, 2021, 713, 109059.	1.4	14
1294	Carbon-silicon switch led to the discovery of novel synthetic cannabinoids with therapeutic effects in a mouse model of multiple sclerosis. European Journal of Medicinal Chemistry, 2021, 226, 113878.	2.6	2
1298	Computational Studies and Molecular Dynamics of the Potent Biochemical and Molecular Markers in Relevance to Oral Cancer. The Open Nutraceuticals Journal, 2012, 5, 213-218.	0.2	1
1300	Protein-Ligand Docking Methodologies and Its Application in Drug Discovery. Advances in Medical Technologies and Clinical Practice Book Series, 2016, , 196-219.	0.3	0
1301	Recent Advancements in Docking Methodologies. Advances in Medical Technologies and Clinical Practice Book Series, 2016, , 267-294.	0.3	0
1302	Recent Advancements in Docking Methodologies. , 2017, , 848-875.		0
1303	E-pharmacophore screening and induced fit docking of phytocompounds against human dihydroorotate dehydrogenase. International Journal of Pharma and Bio Sciences, 2017, 8, .	0.1	0
1304	Evolutionary Analysis Provides Insight into the Origin and Adaptation of HCV. SSRN Electronic Journal, $0,  ,  .$	0.4	0
1309	Evalution and Molecular Docking of Benzimidazole and its Derivatives as a Potent Antibacterial Agent. Biomedical and Pharmacology Journal, 2019, 12, 1835-1847.	0.2	1
1312	A new porphyrin as selective substrate-based inhibitor of breast cancer resistance protein (BCRP/ABCG2). Chemico-Biological Interactions, 2022, 351, 109718.	1.7	4
1313	Inside and Out of the Pore: Comparing Interactions and Molecular Dynamics of Influenza A M2 Viroporin Complexes in Standard Lipid Bilayers. Journal of Chemical Information and Modeling, 2021, 61, 5550-5568.	2.5	5
1316	<scp>CIFDock</scp> : A novel <scp>CHARMM</scp> â€based flexible receptor–flexible ligand docking protocol. Journal of Computational Chemistry, 2022, 43, 84-95.	1.5	4
1324	Insight into Mechanism of Action of Anticancer Benzazoles. Current Topics in Medicinal Chemistry, 2020, 20, 2056-2069.	1.0	1
1328	Flavanone glycosides as acetylcholinesterase inhibitors: computational and experimental evidence. Indian Journal of Pharmaceutical Sciences, 2014, 76, 567-70.	1.0	15
1329	Synthesis, Kinetics, Binding Conformations and Structure-activity Relationship of Potent Tyrosinase Inhibitors: Aralkylated 2-aminothiazole-ethyltriazole Hybrids. Iranian Journal of Pharmaceutical Research, 2021, 20, 206-228.	0.3	0
1330	Identification of a Novel Delta Opioid Receptor Agonist Chemotype with Potential Negative Allosteric Modulator Capabilities. Molecules, 2021, 26, 7236.	1.7	5
1331	Network-based identification of miRNAs and transcription factors and in silico drug screening targeting l´-secretase involved in Alzheimer's disease. Heliyon, 2021, 7, e08502.	1.4	4

#	Article	IF	Citations
1332	A3 adenosine receptor agonists containing dopamine moieties for enhanced interspecies affinity. European Journal of Medicinal Chemistry, 2022, 228, 113983.	2.6	4
1333	Development of a DHA-Losartan hybrid as a potent inhibitor of multiple pathway-induced platelet aggregation. Journal of Biomolecular Structure and Dynamics, 2022, 40, 13889-13900.	2.0	0
1335	Novel methyllycaconitine analogues selective for the $\hat{l}\pm4\hat{l}^22$ over $\hat{l}\pm7$ nicotinic acetylcholine receptors. Bioorganic and Medicinal Chemistry, 2021, 51, 116516.	1.4	2
1336	Synthesis, structural, vibrational, molecular docking and nonlinear optical studies of (E)-N′-(2,3-dimethoxybenzylidene)-4-fluorobenzohydrazide. Journal of Molecular Structure, 2022, 1254, 132375.	1.8	2
1338	Roles of hydrophilic residues in GABA binding site of GABA-II receptor explain the addition/inhibition effects of competitive ligands. Neurochemistry International, 2022, 153, 105258.	1.9	3
1339	Class I histone deacetylases (HDAC1–3) are histone lysine delactylases. Science Advances, 2022, 8, eabi6696.	4.7	141
1340	Phenolic Profile, Antioxidant and Enzyme Inhibition Properties of the Chilean Endemic Plant Ovidia pillopillo (Gay) Meissner (Thymelaeaceae). Metabolites, 2022, 12, 90.	1.3	4
1342	In Silico, In Vitro, and In Vivo Analysis of Tanshinone IIA and Cryptotanshinone from Salvia miltiorrhiza as Modulators of Cyclooxygenase-2/mPGES-1/Endothelial Prostaglandin EP3 Pathway. Biomolecules, 2022, 12, 99.	1.8	2
1344	Synthesis and Characterization of 5-(2-Fluoro-4-[ <sup>11</sup> C]methoxyphenyl)-2,2-dimethyl-3,4-dihydro-2 <i>H</i> pyrano[2,3- <i>b</i> pyridir as a PET Imaging Ligand for Metabotropic Glutamate Receptor 2. Journal of Medicinal Chemistry, 2022, 65, 2593-2609.	ne-7-carbox 2.9	kamide
1345	G protein-coupled receptor interaction prediction based on deep transfer learning. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2022, PP, 1-1.	1.9	1
1346	Pharmacological Effect of GABA Analogues on GABA-ϱ2 Receptors and Their Subtype Selectivity. Life, 2022, 12, 127.	1.1	2
1347	Repurposing of approved drugs and nutraceuticals to identify potential inhibitors of SARS-COV-2's entry into human host cells: a structural analysis using induced-fit docking, MMGBSA and molecular dynamics simulation approach. Molecular Simulation, 2022, 48, 367-386.	0.9	3
1348	Improved cyclobutyl nabilone analogs as potent CB1 receptor agonists. European Journal of Medicinal Chemistry, 2022, 230, 114027.	2.6	1
1349	Design and synthesis of adamantyl-substituted flavonoid derivatives as anti-inflammatory Nur77 modulators: Compound B7 targets Nur77 and improves LPS-induced inflammation in vitro and in vivo. Bioorganic Chemistry, 2022, 120, 105645.	2.0	7
1350	Optimized POCl3-assisted synthesis of 2-amino-1,3,4-thiadiazole/1,3,4-oxadiazole derivatives as anti-influenza agents. Arabian Journal of Chemistry, 2022, 15, 103712.	2.3	11
1351	Design and synthesis of 6-amino-quinoxaline-alkynyl as potential aromatase (CYP19A1) inhibitors. Journal of Molecular Structure, 2022, 1255, 132473.	1.8	5
1352	Some Antioxidant Properties of Components from the Flower of <i>Ochna integerrima</i> and Their Beneficial Effects on HaCaT Keratinocytes and <i>in Silico</i> Analysis on Tyrosinase. Chemistry and Biodiversity, 2022, 19, .	1.0	3
1353	Discovery of Novel Acetylcholinesterase Inhibitors by Virtual Screening, In Vitro Screening, and Molecular Dynamics Simulations. Journal of Chemical Information and Modeling, 2022, 62, 1550-1572.	2.5	5

#	Article	IF	CITATIONS
1354	7-Acetoxyhorminone from Salvia multicaulis Vahl. as Promising Inhibitor of 3-Hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) Reductase. Pharmaceuticals, 2022, 15, 198.	1.7	2
1355	Structure-based design of a novel third-generation antipsychotic drug lead with potential antidepressant properties. Nature Neuroscience, 2022, 25, 39-49.	7.1	30
1356	Identification of potential biological targets of oxindole scaffolds via in silico repositioning strategies. F1000Research, 0, 11, 217.	0.8	0
1357	Identification of potential biological targets of oxindole scaffolds via in silico repositioning strategies. F1000Research, 0, 11, 217.	0.8	0
1358	Hypothesis-Driven, Structure-Based Design in Photopharmacology: The Case of eDHFR Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 4798-4817.	2.9	10
1359	Binding and Activation of Serotonergic G-Protein Coupled Receptors by the Multimodal Antidepressant Vortioxetine. ACS Chemical Neuroscience, 2022, 13, 1129-1142.	1.7	1
1360	Development and Biological Characterization of a Novel Selective TrkA Agonist with Neuroprotective Properties against Amyloid Toxicity. Biomedicines, 2022, 10, 614.	1.4	7
1361	Discovery of P2Y <sub>2</sub> Receptor Antagonist Scaffolds through Virtual High-Throughput Screening. Journal of Chemical Information and Modeling, 2022, 62, 1538-1549.	2.5	6
1362	Synthesis and Biological Evaluation of 1-(2-(6-Methoxynaphthalen-2-yl)-6-methylnicotinoyl)-4-Substituted Semicarbazides/Thiosemicarbazides as Anti-Tumor Nur77 Modulators. Molecules, 2022, 27, 1698.	1.7	2
1363	Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells. Biomedicines, 2022, 10, 601.	1.4	17
1365	Versatile Synthesis of <i>rac</i> ―and <i>meso</i> â€Hydroxymethyl Cyclohexenoids Containing Phenyl Groups: αâ€Î²â€Glucosidase Activities, Inhibition Kinetics and Molecular Docking Studies. European Journal of Organic Chemistry, 2022, 2022, .	1.2	0
1366	Novel derivatives of arabinogalactan, pullulan & lactobionic acid for targeting asialoglycoprotein receptor: Biomolecular interaction, synthesis & evaluation. International Journal of Biological Macromolecules, 2022, 207, 683-699.	3.6	8
1367	<i>GlycoGrip</i> : Cell Surface-Inspired Universal Sensor for Betacoronaviruses. ACS Central Science, 2022, 8, 22-42.	5.3	31
1368	Leveraging nonstructural data to predict structures and affinities of protein–ligand complexes. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	17
1369	Novel 1,3,5-Triazinyl Aminobenzenesulfonamides Incorporating Aminoalcohol, Aminochalcone and Aminostilbene Structural Motifs as Potent Anti-VRE Agents, and Carbonic Anhydrases I, II, VII, IX, and XII Inhibitors. International Journal of Molecular Sciences, 2022, 23, 231.	1.8	5
1370	Identification of Potential Inhibitors for Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) Angiotensin-converting Enzyme 2 and the Main Protease from Anatolian Traditional Plants. Letters in Drug Design and Discovery, 2022, 19, 996-1006.	0.4	7
1371	Structure–Activity Studies of 3,9-Diazaspiro[5.5]undecane-Based γ-Aminobutyric Acid Type A Receptor Antagonists with Immunomodulatory Effect. Journal of Medicinal Chemistry, 2021, 64, 17795-17812.	2.9	4
1372	Synthesis of Anti-Inflammatory Spirostene-Pyrazole Conjugates by a Consecutive Multicomponent Reaction of Diosgenin with Oxalyl Chloride, Arylalkynes and Hydrazines or Hydrazones. Molecules, 2022, 27, 162.	1.7	0

#	Article	IF	CITATIONS
1373	Discovery of a Positive Allosteric Modulator of Cholecystokinin Action at CCK1R in Normal and Elevated Cholesterol. Frontiers in Endocrinology, 2021, 12, 789957.	1.5	3
1374	Synthesis, Molecular Docking and Antiplasmodial Activities of New Tetrahydro-β-Carbolines. International Journal of Molecular Sciences, 2021, 22, 13569.	1.8	3
1375	Docking, Binding Free Energy Calculations and In Vitro Characterization of Pyrazine Linked 2-Aminobenzamides as Novel Class I Histone Deacetylase (HDAC) Inhibitors. Molecules, 2022, 27, 2526.	1.7	5
1376	Target Hopping from Protein Kinases to PXR: Identification of Small-Molecule Protein Kinase Inhibitors as Selective Modulators of Pregnane X Receptor from TÃ $\frac{1}{4}$ KIC Library. Cells, 2022, 11, 1299.	1.8	3
1377	Synthesis of Novel Glycolipid Mimetics of Heparan Sulfate and Their Application in Colorectal Cancer Treatment in a Mouse Model. Chemistry - an Asian Journal, 2022, 17, .	1.7	8
1378	Putative Synthetic Cannabinoids MEPIRAPIM, 5F-BEPIRAPIM (NNL-2), and Their Analogues Are T-Type Calcium Channel (Ca <sub>V</sub> 3) Inhibitors. ACS Chemical Neuroscience, 2022, 13, 1395-1409.	1.7	4
1379	Identification of a Vitamin-D Receptor Antagonist, MeTC7, which Inhibits the Growth of Xenograft and Transgenic Tumors <i>In Vivo</i> . Journal of Medicinal Chemistry, 2022, 65, 6039-6055.	2.9	3
1380	Resorcinol Derivatives as Novel Aldose Reductase Inhibitors: In Silico and In Vitro Evaluation. Letters in Drug Design and Discovery, 2022, 19, .	0.4	0
1381	Defining Steric Requirements at CB <sub>1</sub> and CB <sub>2</sub> Cannabinoid Receptors Using Synthetic Cannabinoid Receptor Agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1, PX-2, NNL-1, and Their Analogues. ACS Chemical Neuroscience, 2022, 13, 1281-1295.	1.7	6
1382	Computational Insights and In Vitro Validation of Antibacterial Potential of Shikimate Pathway-Derived Phenolic Acids as NorA Efflux Pump Inhibitors. Molecules, 2022, 27, 2601.	1.7	8
1383	Tapping into the antitubercular potential of 2,5-dimethylpyrroles: A structure-activity relationship interrogation. European Journal of Medicinal Chemistry, 2022, 237, 114404.	2.6	10
1406	Overlapping synthetic peptides as a tool to map protein-protein interactions in FSH as a model system of nonadditive interactions. Biochimica Et Biophysica Acta - General Subjects, 2022, 1866, 130153.	1.1	1
1407	Novel CRBN-Recruiting Proteolysis-Targeting Chimeras as Degraders of Stimulator of Interferon Genes with In Vivo Anti-Inflammatory Efficacy. Journal of Medicinal Chemistry, 2022, 65, 6593-6611.	2.9	26
1408	Determination of key residues in MRGPRX2 to enhance pseudo-allergic reactions induced by fluoroquinolones. Scientific Reports, 2022, 12, 6650.	1.6	1
1410	Molecular Simulations and Drug Discovery of Adenosine Receptors. Molecules, 2022, 27, 2054.	1.7	6
1411	Computational-Based Discovery of the Anti-Cancer Activities of Pyrrole-Based Compounds Targeting the Colchicine-Binding Site of Tubulin. Molecules, 2022, 27, 2873.	1.7	5
1412	Rational Discovery of Antiviral Whey Protein-Derived Small Peptides Targeting the SARS-CoV-2 Main Protease. Biomedicines, 2022, 10, 1067.	1.4	7
1413	Substituted Purines as High-Affinity Histamine H3 Receptor Ligands. Pharmaceuticals, 2022, 15, 573.	1.7	3

#	Article	IF	CITATIONS
1414	A novel small-molecule selective activator of homomeric GIRK4 channels. Journal of Biological Chemistry, 2022, 298, 102009.	1.6	11
1415	Design, Semisynthesis, and Estrogenic Activity of Lignan Derivatives from Natural Dibenzylbutyrolactones. Pharmaceuticals, 2022, 15, 585.	1.7	2
1416	Conjugates of Lupane Triterpenoids with Arylpyrimidines: Synthesis and Anti-inflammatory Activity. Steroids, 2022, 184, 109042.	0.8	3
1417	In Vitro and In Silico Evaluation of Cholinesterase Inhibition by Alkaloids Obtained from Branches of Abuta panurensis Eichler. Molecules, 2022, 27, 3138.	1.7	3
1418	A comprehensive evaluation of the potential binding poses of fentanyl and its analogs at the $\hat{A}\mu$ -opioid receptor. Computational and Structural Biotechnology Journal, 2022, 20, 2309-2321.	1.9	8
1419	Phosphatidylinositol Phosphates Modulate Interactions between the StarD4 Sterol Trafficking Protein and Lipid Membranes. Journal of Biological Chemistry, 2022, , 102058.	1.6	9
1420	Synthesis, Screening and Characterization of Novel Potent Arp2/3 Inhibitory Compounds Analogous to CK-666. Frontiers in Pharmacology, $0,13,.$	1.6	4
1422	Design and synthesis of chromone-based monoamine oxidase B inhibitors with improved drug-like properties. European Journal of Medicinal Chemistry, 2022, 239, 114507.	2.6	6
1423	Understanding the complete bioluminescence cycle from a multiscale computational perspective: A review. Journal of Photochemistry and Photobiology C: Photochemistry Reviews, 2022, 52, 100537.	5.6	9
1425	Fast, Routine Free Energy of Binding Estimation Using MovableType. ACS Symposium Series, 0, , 247-265.	0.5	1
1426	Using PD-L1 full-length structure, enhanced induced fit docking and molecular dynamics simulations for structural insights into inhibition of PD-1/PD-L1 interaction by small-molecule ligands. Molecular Simulation, 2022, 48, 1269-1283.	0.9	2
1427	Multitarget, Selective Compound Design Yields Potent Inhibitors of a Kinetoplastid Pteridine Reductase 1. Journal of Medicinal Chemistry, 2022, 65, 9011-9033.	2.9	8
1428	Design and Synthesis of Hepatitis B Virus (HBV) Capsid Assembly Modulators and Evaluation of Their Activity in Mammalian Cell Model. Pharmaceuticals, 2022, 15, 773.	1.7	5
1429	Development of a Novel Class of Pyridazinone Derivatives as Selective MAO-B Inhibitors. Molecules, 2022, 27, 3801.	1.7	10
1430	UHPLC-MS Metabolomic Fingerprinting, Antioxidant, and Enzyme Inhibition Activities of Himantormia lugubris from Antarctica. Metabolites, 2022, 12, 560.	1.3	10
1431	Computational discovery of small drug-like compounds as potential inhibitors of PD-1/PD-L1 interactions. Journal of Biomolecular Structure and Dynamics, $0$ , , $1$ -17.	2.0	1
1432	Nudix hydrolase 18 catalyzes the hydrolysis of active triphosphate metabolites of the antivirals remdesivir, ribavirin, and molnupiravir. Journal of Biological Chemistry, 2022, 298, 102169.	1.6	3
1433	Design, synthesis, and biological evaluation of (E)-N′-substitute-4-((4-pyridylpyrimidin-2-yl)amino)benzohydrazide derivatives as novel potential CDK9 inhibitors. Arabian Journal of Chemistry, 2022, 15, 104039.	2.3	4

#	Article	IF	CITATIONS
1434	Lack of interaction of the fluorosurfactant C6O4 with human renal transporters: In vitro/in silico analysis. Toxicology, 2022, 476, 153257.	2.0	3
1435	Identification of the Inhibition Effects of Some Natural Antiproliferative Agents on CA-I, CA-II, and AChE Activities Isolated from Human Erythrocytes by Kinetic and Molecular Docking Studies. Russian Journal of Bioorganic Chemistry, 2022, 48, 720-730.	0.3	3
1436	Design, Synthesis, and Characterization of [ <sup>18</sup> F]mG2P026 as a High-Contrast PET Imaging Ligand for Metabotropic Glutamate Receptor 2. Journal of Medicinal Chemistry, 2022, 65, 9939-9954.	2.9	3
1437	Inhibitor induced conformational changes in SARS-COV-2 papain-like protease. Scientific Reports, 2022, 12, .	1.6	5
1438	Cytotoxic Effects on Breast Cancer Cell Lines of Chalcones Derived from a Natural Precursor and Their Molecular Docking Analysis. Molecules, 2022, 27, 4387.	1.7	6
1439	Palladium(II) Complexes of Substituted Salicylaldehydes: Synthesis, Characterization and Investigation of Their Biological Profile. Pharmaceuticals, 2022, 15, 886.	1.7	8
1440	Allosteric inhibitors of the main protease of SARS-CoV-2. Antiviral Research, 2022, 205, 105381.	1.9	23
1441	A Cancer Cell–Intrinsic GOT2–PPARδ Axis Suppresses Antitumor Immunity. Cancer Discovery, 2022, 12, 2414-2433.	7.7	20
1442	Molecular docking and dynamics based approach for the identification of kinase inhibitors targeting PI3Kα against non-small cell lung cancer: a computational study. RSC Advances, 2022, 12, 21452-21467.	1.7	18
1443	Modulation of KV4.3-KChIP2 Channels by IQM-266: Role of DPP6 and KCNE2. International Journal of Molecular Sciences, 2022, 23, 9170.	1.8	1
1444	A new era for the design of TRPV1 antagonists and agonists with the use of structural information and molecular docking of capsaicin-like compounds. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 2169-2178.	2.5	4
1445	Structure-Based Identification of Naphthoquinones and Derivatives as Novel Inhibitors of Main Protease M <sup>pro</sup> and Papain-like Protease PL <sup>pro</sup> of SARS-CoV-2. Journal of Chemical Information and Modeling, 2022, 62, 6553-6573.	2.5	19
1446	Potentiation of Drug Toxicity through Virus Latency Reversal Promotes Preferential Elimination of HIV Infected Cells. Advanced Therapeutics, 2022, 5, .	1.6	0
1447	Novel 2-aminopyrimidine Schiff bases as possible GABA-AT inhibitors: molecular docking, MAOS, and pharmacological screening. Medicinal Chemistry Research, 0, , .	1.1	0
1448	Induced-Fit Docking Enables Accurate Free Energy Perturbation Calculations in Homology Models. Journal of Chemical Theory and Computation, 2022, 18, 5710-5724.	2.3	9
1449	Modeling receptor flexibility in the structure-based design of KRASG12C inhibitors. Journal of Computer-Aided Molecular Design, 0, , .	1.3	5
1450	The structure and characterization of human cytochrome P450 8B1 supports future drug design for nonalcoholic fatty liver disease and diabetes. Journal of Biological Chemistry, 2022, 298, 102344.	1.6	7
1451	Upacicalcet Is a Novel Secondary Hyperparathyroidism Drug that Targets the Amino Acid Binding Site of Calcium-Sensing Receptor. Molecular Pharmacology, 2022, 102, 183-195.	1.0	6

#	Article	IF	Citations
1452	Beyond Retigabine: Design, Synthesis, and Pharmacological Characterization of a Potent and Chemically Stable Neuronal Kv7 Channel Activator with Anticonvulsant Activity. Journal of Medicinal Chemistry, 2022, 65, 11340-11364.	2.9	7
1453	Larvicidal, acetylcholinesterase inhibitory activities of four essential oils and their constituents against Aedes albopictus, and nanoemulsion preparation. Journal of Pest Science, 2023, 96, 961-971.	1.9	6
1454	Identification of potent ABL inhibitors from coumestrol: an integrative <i>in silico</i> approach. Journal of Computational Biophysics and Chemistry, 0, , .	1.0	1
1455	Anticancer therapeutic potential of phosphorylated galactosylated chitosan against N-nitrosodiethyl amine-induced hepatocarcinogenesis. Archives of Biochemistry and Biophysics, 2022, 728, 109375.	1.4	5
1456	Synthesis, characterization, anti-tuberculosis activity and molecular modeling studies of thiourea derivatives bearing aminoguanidine moiety. Journal of Molecular Structure, 2022, 1270, 133899.	1.8	9
1458	Molecular Screening and Toxicity Estimation of 260,000 Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) through Machine Learning. Journal of Chemical Information and Modeling, 2022, 62, 4569-4578.	2.5	11
1460	2-Arylmelatonin analogues: Probing the 2-phenyl binding pocket of melatonin MT1 and MT2 receptors. European Journal of Medicinal Chemistry, 2022, 243, 114762.	2.6	1
1461	Virtual screening techniques in pharmaceutical research. , 2022, , 89-128.		0
1462	Druggable sites/pockets of theÂp53-DNAJA1 protein–protein interaction: In silico modeling and in vitro/in vivo validation. Methods in Enzymology, 2022, , 83-107.	0.4	0
1463	Structure–Activity Relationship Development Efforts towards Peripherally Selective Analogs of the Cannabinoid Receptor Partial Agonist BAY 59-3074. Molecules, 2022, 27, 5672.	1.7	1
1464	Unprecedented Combination of Polyketide Natural Product Fragments Identifies the New Hedgehog Signaling Pathway Inhibitor Grismonone. Chemistry - A European Journal, 2022, 28, .	1.7	11
1465	Proposed Mechanism for Emodin as Agent for Methicillin Resistant Staphylococcus Aureus: In Vitro Testing and In Silico Study. Current Issues in Molecular Biology, 2022, 44, 4490-4499.	1.0	0
1466	Novel 5-Nitrofuran-Tagged Imidazo-Fused Azines and Azoles Amenable by the Groebke–Blackburn–Bienaymé Multicomponent Reaction: Activity Profile against ESKAPE Pathogens and Mycobacteria. Biomedicines, 2022, 10, 2203.	1.4	2
1467	Structural basis for strychnine activation of human bitter taste receptor TAS2R46. Science, 2022, 377, 1298-1304.	6.0	23
1468	Assessment of Al-Based Protein Structure Prediction for the NLRP3 Target. Molecules, 2022, 27, 5797.	1.7	6
1470	High-resolution structures of a siderophore-producing cyclization domain from Yersinia pestis offer a refined proposal of substrate binding. Journal of Biological Chemistry, 2022, 298, 102454.	1.6	4
1471	Pharmacological characterization of novel synthetic opioids: Isotonitazene, metonitazene, and piperidylthiambutene as potent $\hat{l}\frac{1}{4}$ -opioid receptor agonists. Neuropharmacology, 2022, 221, 109263.	2.0	11
1472	Data Science-Driven Analysis of Substrate-Permissive Diketopiperazine Reverse Prenyltransferase NotF: Applications in Protein Engineering and Cascade Biocatalytic Synthesis of (â°')-Eurotiumin A. Journal of the American Chemical Society, 2022, 144, 19326-19336.	6.6	10

#	Article	IF	Citations
1473	Bee-safe peptidomimetic acaricides achieved by comparative genomics. Scientific Reports, 2022, 12, .	1.6	6
1474	Promising SARS-CoV-2 main protease inhibitor ligand-binding modes evaluated using LB-PaCS-MD/FMO. Scientific Reports, 2022, 12, .	1.6	15
1476	A novel KPC-113 variant conferring carbapenem and ceftazidime-avibactam resistance in a multidrug-resistant Pseudomonas aeruginosa isolate. Clinical Microbiology and Infection, 2023, 29, 387.e7-387.e14.	2.8	5
1477	Resistor: An algorithm for predicting resistance mutations via Pareto optimization over multistate protein design and mutational signatures. Cell Systems, 2022, 13, 830-843.e3.	2.9	5
1478	Dual-Reporter System for Real-Time Monitoring of SARS-CoV-2 Main Protease Activity in Live Cells Enables Identification of an Allosteric Inhibition Path. ACS Bio & Med Chem Au, 2022, 2, 627-641.	1.7	1
1479	Definition of the Acceptor Substrate Binding Specificity in Plant Xyloglucan Endotransglycosylases Using Computational Chemistry. International Journal of Molecular Sciences, 2022, 23, 11838.	1.8	2
1480	Identification and characterization of alternative sites and molecular probes for SARS-CoV-2 target proteins. Frontiers in Chemistry, 0, $10$ , .	1.8	0
1481	Binding versus Enzymatic Processing of $\hat{l}\mu$ -Trimethyllysine Dioxygenase Substrate Analogues. ACS Medicinal Chemistry Letters, 2022, 13, 1723-1729.	1.3	0
1482	Discovery of 4-methyl-3-(pyridin-2-ylamino)benzamide derivatives as C-Abl inhibitors with potential neuroprotective effect. Bioorganic and Medicinal Chemistry, 2022, 74, 117069.	1.4	1
1483	X-ray crystalographic data, absolute configuration, and anticholinesterase effect of dihydromyricitrin 3-O-rhamnoside. Scientific Reports, 2022, 12, .	1.6	1
1485	Discovery and Optimization of Indoline-Based Compounds as Dual 5-LOX/sEH Inhibitors: <i>In Vitro</i> and <i>In Vivo</i> Anti-Inflammatory Characterization. Journal of Medicinal Chemistry, 2022, 65, 14456-14480.	2.9	11
1486	Discovery of 5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole-2-carboxamide derivatives as novel anti-cancer agents targeting Nur77. European Journal of Medicinal Chemistry, 2022, 244, 114849.	2.6	4
1487	Carbapenem antibiotic inhibiting a mammalian serine protease: structure of the acylaminoacyl peptidase–meropenem complex. Chemical Science, 0, , .	3.7	0
1488	In Silico Approach for the Evaluation of the Potential Antiviral Activity of Extra Virgin Olive Oil (EVOO) Bioactive Constituents Oleuropein and Oleocanthal on Spike Therapeutic Drug Target of SARS-CoV-2. Molecules, 2022, 27, 7572.	1.7	3
1489	Structure–Activity Studies of 1 <i>H</i> -lmidazo[4,5- <i>c</i> ]quinolin-4-amine Derivatives as A <sub>3</sub> Adenosine Receptor Positive Allosteric Modulators. Journal of Medicinal Chemistry, 2022, 65, 15238-15262.	2.9	6
1491	Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR. Journal of Enzyme Inhibition and Medicinal Chemistry, 2023, 38, 239-245.	2.5	2
1492	Computational drug discovery under RNA times. QRB Discovery, 2022, 3, .	0.6	6
1493	Design, synthesis, and bioevaluation of imidazo [1,2–a] pyrazine derivatives as tubulin polymerization inhibitors with potent anticancer activities. Bioorganic and Medicinal Chemistry, 2022, 76, 117098.	1.4	4

#	Article	IF	CITATIONS
1494	Replacing the oxidationâ€sensitive triaminoaryl chemotype of problematic K <sub>V</sub> 7 channel openers: Exploration of a nicotinamide scaffold. Archiv Der Pharmazie, 0, , .	2.1	3
1495	Isolation of Compounds from <i>Sargassum wightii </i> by GCMS and the Molecular Docking against Anti-Inflammatory Marker COX2. International Letters of Chemistry, Physics and Astronomy, 0, 63, 1-12.	0.0	1
1496	Synthesis, molecular structure investigation, biological evaluation and docking studies of novel spirothiazolidinones. Results in Chemistry, 2023, 5, 100726.	0.9	4
1497	Design, synthesis, biological evaluation and crystal structure determination of dual modulators of carbonic anhydrases and estrogen receptors. European Journal of Medicinal Chemistry, 2023, 246, 115011.	2.6	3
1498	Design and synthesis of 2-(2,2-diarylethyl)-cyclamine derivatives as M3 receptor antagonists and functional evaluation on COPD. Bioorganic Chemistry, 2023, 131, 106308.	2.0	0
1505	Novel 6-Aminoquinazolinone Derivatives as Potential Cross GT1-4 HCV NS5B Inhibitors. Viruses, 2022, 14, 2767.	1.5	2
1506	Combining computational and experimental evidence on the activity of antimalarial drugs on <scp>papainâ€like</scp> protease of <scp>SARSâ€CoV</scp> â€2: A repurposing study. Chemical Biology and Drug Design, 2023, 101, 809-818.	1.5	3
1507	Allosteric Modulators of Dopamine D2 Receptors for Fine-Tuning of Dopaminergic Neurotransmission in CNS Diseases: Overview, Pharmacology, Structural Aspects and Synthesis. Molecules, 2023, 28, 178.	1.7	7
1508	The slow but steady rise of binding free energy calculations in drug discovery. Journal of Computer-Aided Molecular Design, 2023, 37, 67-74.	1.3	7
1509	Leucine 434 is essential for docosahexaenoic acid–induced augmentation of L-glutamate transporter current. Journal of Biological Chemistry, 2023, 299, 102793.	1.6	1
1510	Comprehensive Characterization of a Systematic Library of Alkyl and Alicyclic Synthetic Cannabinoids Related to CUMYL-PICA, CUMYL-BUTICA, CUMYL-CBMICA, and CUMYL-PINACA. ACS Chemical Neuroscience, 0, , .	1.7	0
1511	Improved docking of peptides and small molecules in iMOLSDOCK. Journal of Molecular Modeling, 2023, 29, .	0.8	2
1512	Structure-Based Design, Synthesis, and Biological Evaluation of the Cage–Amide Derived Orthopox Virus Replication Inhibitors. Viruses, 2023, 15, 29.	1.5	3
1513	The Impact of Software Used and the Type of Target Protein on Molecular Docking Accuracy. Molecules, 2022, 27, 9041.	1.7	5
1514	The Development of Pharmacophore Models for the Search of New Natural Inhibitors of SARS-CoV-2 Spike RBD–ACE2 Binding Interface. Molecules, 2022, 27, 8938.	1.7	0
1515	In silico and in vitro studies confirm Ondansetron as a novel acetylcholinesterase and butyrylcholinesterase inhibitor. Scientific Reports, 2023, 13, .	1.6	3
1516	Structural Elucidation of Relevant Gibberellic Acid Impurities and <i>In Silico</i> Investigation of Their Interaction with Soluble Gibberellin Receptor GID1. ACS Omega, 2023, 8, 1957-1966.	1.6	1
1517	Identifying Dopamine D3 Receptor Ligands through Virtual Screening and Exploring the Binding Modes of Hit Compounds. Molecules, 2023, 28, 527.	1.7	4

#	Article	IF	Citations
1518	Inhibition of Cancer Cell Proliferation and Bacterial Growth by Silver(I) Complexes Bearing a CH3-Substituted Thiadiazole-Based Thioamide. Molecules, 2023, 28, 336.	1.7	2
1519	Discovery of inhibitors against SARS-CoV-2 main protease using fragment-based drug design. Chemico-Biological Interactions, 2023, 371, 110352.	1.7	3
1520	Triterpenic Acid Amides as Potential Inhibitors of the SARS-CoV-2 Main Protease. Molecules, 2023, 28, 303.	1.7	3
1521	A Guide to In Silico Drug Design. Pharmaceutics, 2023, 15, 49.	2.0	22
1522	Identification and Characterization of ML321: A Novel and Highly Selective D <sub>2</sub> Dopamine Receptor Antagonist with Efficacy in Animal Models That Predict Atypical Antipsychotic Activity. ACS Pharmacology and Translational Science, 2023, 6, 151-170.	2.5	1
1523	Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase. Nutrients, 2023, 15, 577.	1.7	5
1524	Sodium-Dependent Neutral Amino Acid Transporter 2 Can Serve as a Tertiary Carrier for <scp>I</scp> -Type Amino Acid Transporter 1-Utilizing Prodrugs. Molecular Pharmaceutics, 2023, 20, 1331-1346.	2.3	2
1525	Modeling the Orthosteric Binding Site of the G Protein-Coupled Odorant Receptor OR5K1. Journal of Chemical Information and Modeling, 2023, 63, 2014-2029.	2.5	10
1526	A new robust classifier to detect hot-spots and null-spots in protein–protein interface: validation of binding pocket and identification of inhibitors in in vitro and in vivo models. , 2023, , 247-263.		0
1527	Impact of the Substitution Pattern at the Basic Center and Geometry of the Amine Fragment on 5-HT6 and D3R Affinity in the 1H-Pyrrolo[3,2-c]quinoline Series. Molecules, 2023, 28, 1096.	1.7	1
1529	Novel 1,4-Dihydropyridine Derivatives as Mineralocorticoid Receptor Antagonists. International Journal of Molecular Sciences, 2023, 24, 2439.	1.8	1
1530	Targeting pleckstrin-2/Akt signaling reduces proliferation in myeloproliferative neoplasm models. Journal of Clinical Investigation, 2023, 133, .	3.9	2
1531	Multi-state Model-Based Identification of Cryptic Allosteric Sites on Human Serotonin Transporter. ACS Chemical Neuroscience, 2023, 14, 1686-1694.	1.7	6
1532	Heteroaromatic salvinorin A analogue (P-3Âl) elicits antinociceptive and anxiolytic-like effects. Fìtoterapìâ, 2023, 167, 105488.	1.1	0
1533	Binding preference at the $\hat{1}$ /4-opioid receptor underlies distinct pharmacology of cyclopropyl versus valeryl analogs of fentanyl. Neuropharmacology, 2023, 227, 109442.	2.0	7
1534	Pharmacological characterization of novel small molecule agonists and antagonists for the orphan receptor GPR139. European Journal of Pharmacology, 2023, 943, 175553.	1.7	2
1535	Sub-pocket-focused designing of tacrine derivatives as potential acetylcholinesterase inhibitors. Computers in Biology and Medicine, 2023, 155, 106666.	3.9	4
1536	Synthesis of conjugates of (aR,7S)-colchicine with monoterpenoids and investigation of their biological activity. Russian Chemical Bulletin, 2023, 72, 248-262.	0.4	4

#	Article	IF	CITATIONS
1537	A Novel CMY Variant Confers Transferable High-Level Resistance to Ceftazidime-Avibactam in Multidrug-Resistant Escherichiacoli. Microbiology Spectrum, 2023, 11, .	1.2	2
1538	Designed for Circularity: Chemically Recyclable and Enzymatically Degradable Biorenewable Schiff Base Polyester-Imines. ACS Sustainable Chemistry and Engineering, 2023, 11, 3451-3465.	3.2	2
1539	Nano–bio interaction between human immunoglobulin G and nontoxic, near-infrared emitting water-borne silicon quantum dot micelles. RSC Advances, 2023, 13, 6051-6064.	1.7	1
1540	Human Glucosylceramide Synthase at Work as Provided by " <i>In Silico</i> àê•Molecular Docking, Molecular Dynamics, and Metadynamics. ACS Omega, 2023, 8, 8755-8765.	1.6	1
1541	A novel chemical attack on Notch-mediated transcription by targeting the NACK ATPase. Molecular Therapy - Oncolytics, 2023, 28, 307-320.	2.0	1
1542	Modified Akuamma Alkaloids with Increased Potency at the Mu-opioid Receptor. Journal of Medicinal Chemistry, 2023, 66, 3312-3326.	2.9	0
1543	Dual PTP1B/TC-PTP Inhibitors: Biological Evaluation of 3-(Hydroxymethyl)cinnoline-4(1H)-Ones. International Journal of Molecular Sciences, 2023, 24, 4498.	1.8	0
1544	Off-target activity of NBOMes and NBOMe analogs at the $\hat{A}\mu$ opioid receptor. Archives of Toxicology, 2023, 97, 1367-1384.	1.9	1
1545	Allosteric inhibition of $\langle scp \rangle$ TEM $\langle scp \rangle$ â $\in$ 1 $\hat{I}^2$ lactamase: Microsecond molecular dynamics simulations provide mechanistic insights. Protein Science, 2023, 32, .	3.1	2
1546	Exploration of LPS2 agonist binding modes using the combination of a new hydrophobic scaffold and homology modeling. European Journal of Medicinal Chemistry, 2023, 252, 115271.	2.6	0
1547	Chemical Constituents of the Mushroom Dictyophora indusiata and Their Anti-Inflammatory Activities. Molecules, 2023, 28, 2760.	1.7	3
1548	Expanding the Library of 1,2,4-Oxadiazole Derivatives: Discovery of New Farnesoid X Receptor (FXR) Antagonists/Pregnane X Receptor (PXR) Agonists. Molecules, 2023, 28, 2840.	1.7	1
1549	Calculations of the binding free energies of the Comprehensive <i>in vitro</i> Proarrhythmia Assay (CiPA) reference drugs to cardiac ion channels. Biophysics and Physicobiology, 2023, 20, n/a.	0.5	0
1551	Perspective for Discovery of Small Molecule IL-6 Inhibitors through Study of Structure–Activity Relationships and Molecular Docking. Journal of Medicinal Chemistry, 2023, 66, 4417-4433.	2.9	11
1552	Allosteric modulation of a human odorant receptor. Current Biology, 2023, 33, 1523-1534.e4.	1.8	3
1553	Mitigating hERG Liability of Tollâ€Like Receptor 9 and 7 Antagonists through Structureâ€Based Design. ChemMedChem, 2023, 18, .	1.6	3
1554	Potent FOXO3a Activators from Biologically Active Compound Library for Cancer Therapeutics: AnÂinÂsilico Approach. Applied Biochemistry and Biotechnology, 0, , .	1.4	1
1555	SARS-CoV-2 evolved variants optimize binding to cellular glycocalyx. Cell Reports Physical Science, 2023, 4, 101346.	2.8	12

#	Article	IF	CITATIONS
1556	Selective PPAR-Delta/PPAR-Gamma Activation Improves Cognition in a Model of Alzheimer's Disease. Cells, 2023, 12, 1116.	1.8	5
1557	Tuning the Biological Activity of PI3Kδ Inhibitor by the Introduction of a Fluorine Atom Using the Computational Workflow. Molecules, 2023, 28, 3531.	1.7	1
1558	Characterization of Potent ABCG2 Inhibitor Derived from Chromone: From the Mechanism of Inhibition to Human Extracellular Vesicles for Drug Delivery. Pharmaceutics, 2023, 15, 1259.	2.0	0
1559	Benzenesulfonamide derivatives as <i>Vibrio cholerae</i> carbonic anhydrases inhibitors: a computational-aided insight in the structural rigidity-activity relationships. Journal of Enzyme Inhibition and Medicinal Chemistry, 2023, 38, .	2.5	6
1588	SBDD and Its Challenges. Challenges and Advances in Computational Chemistry and Physics, 2023, , 1-24.	0.6	0
1610	In Silico Insights Toward the Exploration of Adenosine Receptors Ligand Recognition. Topics in Medicinal Chemistry, 2023, , 275-315.	0.4	О